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ABSTRACT  
Colorectal cancer (CRC) is the second most prevalent cancer. Although not typically 
considered a hormonally responsive malignancy, oestrogens are linked to disease 
risk and survival. Here, it is hypothesised that oestrogen synthesis, via steroid 
sulphatase (STS) and 17-hydroxysteroid dehydrogenases (HSD17), is promoted 
in CRC leading to oestrogen-driven tumour proliferation. To identify potential novel 
treatment targets oestrogen metabolism was characterised in CRC. Oestrogen 
metabolism was characterised in CRC cell lines and human colon tissue using 
Western blotting, qRT-PCR, STS activity assay and proliferation assays. A mass 
spectrometry method to quantify oestrogen metabolites was developed and 
validated for cell culture medium. 
 
CRC exhibited increased STS activity indicating increased intratumoural oestrogen 
availability. In CRC a drive towards potent oestradiol production through decreased 
HSD17β2 expression (oxidative enzyme) and increased HSD17β7 and 12 
expression (reductive enzymes) was seen. STS over-expression increased 
proliferation in CRC cell line HCT116, which was at least in part mediated through 
G protein-coupled oestrogen receptor action. Additionally, STS activity was 
regulated in vitro and in vivo by the inflammatory modulator TNFα.  
 
This thesis demonstrates that increased STS activity and oestrogen synthesis in 
CRC increases tumour proliferation via GPER. Thus, multiple novel targets have 
been identified to impede CRC proliferation.  
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2 
 
1.1 COLON ANATOMY AND PHYSIOLOGY 
The gastrointestinal (GI) system is a long tube open at both ends with the lumen of 
the GI tract an extension of the external environment. It is divided into specialised 
structures such as the oral cavity, stomach, small intestine, large intestine and anus. 
Together they enable food to enter, be broken down both mechanically and 
chemically, facilitate nutrient absorption and allow waste to be expelled, with the 
whole system influenced by various hormones (Kapit et al., 2000), such as ghrelin, 
leptin and motilin. 
 
The focus here is the colon, the main component of the large intestine. The colon’s 
primary function is to absorb water and electrolytes. Prior to entering the large bowel 
liquid chime enters the colon from the small intestine and as it progresses through 
to the rectum by peristalsis water is reabsorbed, it becomes solid and is expelled as 
waste. Additionally, bacteria in the colon ferment soluble fibre, help produce short 
chain fatty acids, regulate blood cholesterol and vitamin K (Kapit et al., 2000). 
   
The colon is commonly divided into four sections; ascending, transverse, 
descending and sigmoid as shown in Figure 1.1. The ascending colon begins at the 
caecum ascending along the right hand side of the body where it meets the 
transverse colon. The transverse colon sits across the top of the abdomen leading 
to the descending colon situated on the left hand side which connects to the 
sigmoid; named due to its ‘S’ shape and which in turn becomes the rectum (Kapit 
et al., 2000, Kapoor, 2013). 
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Figure 1.1 Basic colon anatomy. The ascending colon is on the right hand side of 
the abdomen and begins at the caecum. It links with the transverse colon which 
crosses the top of the abdomen and joins to the descending colon on the left hand 
side. The descending colon then becomes the sigmoid colon and rectum. Drawing 
kindly provided by Christina Wingfield (Kapit and Elson, Taylor). 
 
The colon wall layers are shown in Figure 1.2 and are: 
 The mucosa: the innermost layer consisting of a smooth columnar epithelial 
cell layer, mucus glands to lubricate the passage of faeces, (typically taking 
1-3 days), connective tissue and a thin smooth muscle layer.  
 The submucosa: contains blood vessels, nerves and connective tissue.  
 The muscularis: a circular band of muscle and a longitudinal muscle layer 
important for peristalsis.  
 The serosa: the outermost layer consists of connective tissue and squamous 
epithelial cells (Kapit and Elson, Taylor). 
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Figure 1.2 Layers of the colon wall. The innermost layer is the mucosa followed by 
the submucosa which contains blood vessels, nerves and connective tissue. The 
muscle layers or muscularis consist of a circular band of muscle and a longitudinal 
muscle layer. The outermost layer is the serosa. Drawing kindly provided by 
Christina Wingfield (Kapit and Elson, Taylor). 
 
1.2 COLORECTAL CANCER 
1.2.1 Incidence 
Colorectal cancer (CRC) is the third most common cancer in both men and women 
in England, and is the second leading cause of cancer death in Europe (Office for 
National Statistics, 2016). Incidence has been increasing for both sexes and is more 
pronounced in men. However, a combination of earlier detection and new 
treatments has led to a steady fall in mortality (Figure 1.3). The year 2010 saw 58 
and 38 new cases per 100,000 men and women, respectively. General population 
lifetime risk is estimated at 1 in 14 for men and 1 in 19 for women. As with many 
cancers, risk increases with age. In 2010 71% of new cases in men and 74% in 
women were in those 65 and over (Ferlay et al., 2013, Ait Ouakrim et al., 2015, 
Office for National Statistics, 2016). 
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Figure 1.3 Bowel cancer incidence and mortality rates, by sex, England, 
1971−2010. Age-standardised rates per 100,000 population, standardised using the 
European Standard Population. Incidence has been increasing but mortality rates 
falling (Office for National Statistics, 2016).  
 
The majority (95%) of CRCs are adenocarcinomas arising from mucus producing 
epithelial cells. Other CRC types include, squamous cells, carcinoid and sarcomas 
(Cancer Research UK, 2015b). CRC is staged like most cancers using the TNM 
system; Tumour, Nodes and Metastases. This standardised method of staging 
informs of tumour size relating to layers of the bowel wall (Figure 1.2), whether it 
has spread to lymph nodes and metastasised. CRC can then be grouped into stages 
(Table 1.1) assisting with treatment decisions and predicting outcome (Cancer 
Research UK, 2015a). TNM is the most widely used system, particularly in clinical 
practice, however Dukes’ classification, described by British pathologist Cuthbert 
Dukes in 1932 (Dukes, 1932), is sometimes used as an alternative (Table 1.2).  
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Table 1.1Stages of colorectal cancer using TNM method (Cancer Research UK, 
2015a). 
Stage Description 
0 Cancer is confined to bowel inner lining 
I Cancer has infiltrated into muscle layer of bowel wall. T1/2, N0, M0 
IIa Cancer has grown to the outer lining. T3, N0, M0 
IIb 
Cancer has grown out of bowel wall and into surrounding structures. 
T4, N0, M0 
IIIa 
Tumour is in the inner or muscle layer of the colon and has spread to 
local lymph nodes. T1/2, N1, M0 
IIIb 
Tumour has grown through to the outer lining of the bowel wall, into 
surrounding structures and to local lymph nodes. T3/4, N1, M0 
IIIc Any size of tumour with spread to more local lymph nodes. T, N2, M0 
IV Spread to other parts of the body. T, N, M1 
 
Table 1.2 TNM staging compared to Dukes’ staging (National Institute for Health 
Care and Excellence, 2015). 
Stage T N M Dukes’ Stage 
0 Tin-situ N0 M0  
I 
T1 N0 M0 A 
T2 N0 M0 B1 
II 
T3 N0 M0 B2 
T4 N0 M0 B2 
III 
T1 or T2 N1 or N2 M0 C1 
T3 or T4 N1 or N2 M0 C2 
IV Any T Any N MI D 
 
In addition to stage, CRC is graded out of three, relating to tumour cell 
differentiation; one being low grade well differentiated cells and three poorly 
differentiated. The percentage of CRC diagnosed at each stage for men and women 
is shown in Table 1.3. Unfortunately, CRC is frequently diagnosed later and 
prognosis declines with delayed diagnosis.  
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Table 1.3 Percentage of colorectal cancer diagnosed at each disease stage and 
Five-Year Relative Survival (%) by Stage, Adults Aged 15-99, Former Anglia Cancer 
Network, 2002-2006. (Cancer Research, 2014) 
Stage at 
Diagnosis 
Number of cases 
(%) 
Five year survival (%) 
Men Women 
Stage I 14.6 94.6 100.2 
Stage II 22.2 83.5 85.9 
Stage III 23.7 62.6 62.7 
Stage IV 21.7 6.9 8.1 
Stage Not Known 17.7 18.7 15.1 
All Stages  58.2 61.1 
 
1.2.2 Signs and Symptoms 
CRC does not usually cause symptoms in the early stages and so it is often 
diagnosed late (Table 1.3). Symptoms include a change in bowel habit, blood in 
faeces and abdominal pain. These are not CRC specific and often occur with benign 
conditions such as dietary changes and haemorrhoids. CRC is also associated with 
unintentional weight loss and, due to bleeding from the tumour, iron deficiency 
anaemia. NICE have age related guidelines for anyone presenting with these 
symptoms including when to undertake a faecal occult blood test (FOB) (National 
Institute for Health and Care Excellence, 2015b). The NHS began a screening 
programme in 2006 aimed at detecting early non-symptomatic CRC when survival 
is higher. Men and women aged 60-74 are offered FOB screening every two years 
and is performed by the patient in their own home making it inexpensive and 
convenient. If positive further more detailed investigations such as colonoscopy are 
undertaken. In the UK screening was only fully implemented from 2009 and so the 
long-term impact on diagnosis and survival is currently unknown. However, an early 
meta-analysis showed FOB screening reduced mortality by 16% (Towler et al., 
1998). Also, a multi-centre randomised control trial showed a single flexi-test in 55-
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64 year olds reduced risk of dying and developing CRC by 43% and 33%, 
respectively (Atkin et al., 2010). Additional earlier screening with a one-off flexible 
sigmoidoscopy at age 55 is expected to be fully implemented by December 2016 
(Public Health England, 2015). 
 
1.2.3 Aetiology 
Non-modifiable CRC risk factors include advancing age, male gender, inflammatory 
bowel disease (IBD), family history and heritable syndromes. However, there are 
amendable lifestyle factors such as diet, obesity, physical activity, smoking and 
alcohol which can affect lifetime CRC risk. These are discussed in more detail 
below. 
 
1.2.3.1 Family History and Genetic Mutations 
CRC is predominantly sporadic, but significant proportions, up to 35%, have a 
hereditary component. Approximately 5% of CRCs are due to dominantly inherited 
syndromes, such as familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC or Lynch syndrome) (Short et al., 2015). A 
family history of CRC increases the risk of developing the disease, particularly if a 
first degree relative is diagnosed before the age of 50, reflecting complex 
interactions of inherited genetic susceptibility, shared behaviours and environment 
(Winawer et al., 1996).  
 
FAP is a germline mutation in the adenomatous polyposis (APC) gene causing 
multiple benign colonic polyps, which unless removed inevitably leads to CRC by 
Chapter 1  General Introduction 
9 
 
40-50 years old (Bussey, 1987, InSiGHT, 2016). It is estimated that FAP is 
responsible for 1% of CRCs (Cruz-Correa and Giardiello, 2003). Currently patients 
are offered annual colonoscopies and due to improved survival advised to have a 
colectomy between ages 16-20 (The Association of Colproctology of Great Britain 
and Ireland, 2007, Heiskanen et al., 2000). However, patients are at continued risk 
of upper GI complications and so require follow-up (Vasen et al., 2008).  
 
HNPCC arises from germline mutations in mismatch repair genes and accounts for 
1-3% of CRCs. Patients are offered regular colonoscopies to screen for early 
colorectal disease. However, they also have increased risk of uterine, ovarian, 
stomach, pancreas, biliary and bladder cancer (Vasen et al., 2008, Jarvinen et al., 
2000).  
 
In 1990 Fearon and Vogelstein described CRC as an accumulation of genetic 
mutations. Activation of oncogenes and inactivation of tumour suppressor genes 
progresses normal mucosa to adenoma and then cancer in a stepwise fashion 
(Fearon and Vogelstein, 1990). This model, known as the chromosomal instability 
(CIN) or adenoma-carcinoma sequence is still used today. Acquisition of genomic 
instability is a key factor in CRC and three distinct pathways have been described; 
chromosomal instability (CIN, the most common), microsatellite instability (MSI) and 
CpG island methylator phenotype (CIMP) pathways (Pino and Chung, 2010). The 
predictable progression of sporadic CRC shares many genetic abnormalities with 
inherited conditions; 30- 70% of sporadic CRCs have inactivation of tumour 
suppressor APC. Typically there are inactivation of proto-oncogenes (e.g. Kras) and 
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inactivation of at least three tumour suppressor genes, e.g. APC, loss of p53 and 
loss of heterozygosity on the long arm of chromosome 18  (Armaghany et al., 2012) 
(Figure 1.4).  
 
Figure 1.4 Colon cancer chromosomal instability pathway with progression from 
normal epithelium to adenoma, carcinoma and metastasis by accumulation of 
genetic mutations. Adapted from Davies, R. J., et al. (Davies et al., 2005). This 
successive sequence has been estimated at approximately 15 years (Kozuka et al., 
1975).  
 
1.2.3.2 Inflammatory Bowel Disease 
Ulcerative colitis (UC) and Crohn’s disease (CD) are inflammatory bowel diseases 
(IBD). They are relapsing and remitting disorders characterised by chronic 
inflammation within the GI tract. UC affects the intestinal mucosa of the large bowel 
in an uninterrupted pattern. Whereas CD is transmural and frequently discontinuous 
impacting on any part of the GI tract from mouth to anus (Baumgart and Sandborn, 
2007).  
 
IBD increases the risk of CRC, though the relative risk varies between studies 
(Rosenqvist et al., 1959, Macdougall, 1964, Farraye et al., 2010, Triantafillidis et al., 
2009).  Crohn and Rosenberg described IBD related CRC in 1925 (Crohn and 
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Rosenberg, 1925) with risk affected by disease severity, part of bowel affected and 
length of disease; CRC is rarely found within 7 years of colitis (Mattar et al., 2011). 
The current presumption is CRC risk is higher in IBD due to chronic inflammation 
leading to tissue damage and increasing cell turnover, multiplying the potential for 
DNA damage and DNA repair errors (Barral et al., 2015). NICE have guidelines for 
screening patients with IBD. Colonoscopy with chromoscopy is offered after 10 
years since symptoms began. Based on the findings of this test, such as 
extensiveness of disease and amount of inflammation seen, patients are grouped 
into low, intermediate or high risk of developing CRC. This risk stratification guides 
when to offer the next colonoscopy with low risk at 5 years, intermediate 3 years 
and high risk after 1 year (National Institute for Health and Care Excellence, 2011b). 
 
As discussed in section 1.2.3.1 and Figure 1.4 the majority of sporadic CRCs involve 
activation of oncogenes such as Kras and inactivation of tumour suppressor genes 
like APC and p53. Although these genes are still involved in IBD associated CRC, 
the timing differs. For example, in IBD associated CRC loss of APC occurs less 
frequently and often transpires later. Conversely, p53 mutations emerge earlier and 
are more common (Xie and Itzkowitz, 2008).  
 
1.2.3.3 Modifiable Factors 
There are many lifestyle factors, particularly associated with Western lifestyle, which 
raise CRC risk. Some of which are discussed below. 
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Smoking and alcohol are associated with a multitude of diseases, including CRC 
(Zisman et al., 2006). Alcohol risk may in part be related to the frequently lower 
levels of folic acid found in heavy alcohol users (Giovannucci et al., 1995, 
Giovannucci et al., 1998). Folate is important for DNA methylation, synthesis and 
repair with low dietary intake associated with increased colorectal adenoma thus 
deficiency is thought to enhance carcinogenesis (Giovannucci et al., 1993). A recent 
meta-analysis study concluded folate supplementation had no effect on CRC risk 
(Qin et al., 2015). However, there is a difference between supplementation and 
deficiency. Supplementation may not reduce risk but that is not to say deficiency 
does not increase risk. Folate deficiency in alcohol users may not be comparable to 
other populations and could be increased due to other confounding variables. 
 
Diets high in red and processed meats are also associated with CRC (Larsson and 
Wolk, 2006). In contrast vegetarian and pescovegetarian diets have been linked 
with a lower incidence of CRC (Gilsing et al., 2015, Orlich et al., 2015). Obesity, 
particularly visceral abdominal fat (Giorgino et al., 2005, Krotkiewski et al., 1983), 
physical inactivity (Koivisto et al., 1986, Regensteiner et al., 1991) and a diet high 
in sugar and low in fibre (Riccardi and Rivellese, 1991) increase the risk of 
hyperinsulinaemia and type II diabetes, which are also associated with CRC 
(Peeters et al., 2015, Kramer et al., 2012). Additionally, obesity is pro-inflammatory 
with lymphocytes and macrophages within adipose tissue secreting inflammatory 
cytokines such as tumour necrosis factor (TNF)α and IL-6 (Flores et al., 2015). 
Thus, obesity could be considered an inflammatory condition like IBD and in mice 
obesity induced TNFα contributes to CRC growth (Flores et al., 2012). Both obesity 
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and IBD are more prevalent in Western societies and associated with higher CRC 
risk (Burisch et al., 2014, Cordain et al., 2005, Molodecky et al., 2012). Typically 
IBD is associated with malnutrition and low body mass index (BMI). However, a US 
study found obesity was still an issue in almost a third of patients and a combination 
of obesity and IBD was associated with less severe disease rather than 
exacerbating symptoms (Flores et al., 2015). However, with active disease 
associated with low BMI and malnutrition, obesity likely reflects well controlled 
disease. The frequency of CRC between obese and non-obese IBD patients has 
yet to be assessed.  
 
1.2.4 Treatment 
Once diagnosed, CRC treatment will be guided by disease stage (Table 1.1), patient 
fitness and patient choice. Treatment involves many health care professionals such 
as surgeons, oncologists, gastroenterologists, specialist nurses, physiotherapists, 
pathologists, radiologists and pharmacists and so the treatment plan is a collective 
decision of a multidisciplinary team (MDT) (National Institute for Health and Care 
Excellence, 2014). In the UK treatment is guided by NICE which aims to improve 
outcomes of NHS users by producing evidence based guidelines and developing 
quality standards. The treatment described below is taken from NICE guidelines last 
updated in 2011: Colorectal cancer: the diagnosis and management of colorectal 
cancer (National Institute for Health and Care Excellence, 2011a). 
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1.2.4.1 Surgery 
Surgery is the mainstay of CRC treatment. It can be potentially curative in early 
disease and in advanced disease can palliate symptoms, such as stenting an 
obstructed bowel. Surgical intervention usually involves removing the part of the 
bowel affected with clear margins of normal tissue, local lymph node removal and 
total mesenteric excision. Occasionally isolated metastasis, such as in a liver lobe, 
can be surgically removed and possibly lead to ‘cure’ (National Institute for Health 
and Care Excellence, 2011a). 
 
Surgery type depends on tumour location, but commonly the bowel is removed 
either through a laparotomy incision or performed laparoscopically. Left, transverse, 
right or sigmoid colectomies relate to the different anatomical segments of the 
bowel. Depending on length removed the two remaining ends may be joined 
together in an anastomosis or alternatively a stoma opening in the abdominal wall 
which can sometimes be reversed at a later date. Typically, a left sided stoma 
comes from the colon (colostomy) and the right side from the ileum (ileostomy). 
Each stoma has specific management needs, e.g. electrolyte and water loss 
resulting in dehydration is more common with an ileostomy.  
 
1.2.4.2 Chemotherapy, Radiotherapy and Biological Therapy 
Chemotherapy and radiotherapy can be given before or after surgery to increase 
chance of cure, prolong life or palliate symptoms. Radiotherapy is less common for 
CRC but is used for rectal cancer. Common chemotherapeutic agents are 
Flourouracil (5-FU), Capecitabine (prodrug, metabolised to 5-FU once ingested), 
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Oxaliplatin, Irinotecan and Raltitrexed (usually only given if 5-FU and folic acid 
contraindicated) with typical combinations of: 
 FOLFOX (folinic acid, fluorouracil and oxaliplatin) followed by irinotecan. 
 FOLFOX followed by FOLFIRI (folinic acid, fluorouracil, irinotecan). 
 XELOX (capecitabine, oxaliplatin) followed by FOLFIRI. 
Biological therapies include monoclonal antibodies Cetuximab and Panitumumab 
(anti-endothelial growth-factor receptor), Bevacizumab (targeting vascular 
endothelial growth-factor (VEGF)), Ramicurimab (VEGF receptor 2) and 
recombinant fusion protein Aflibercept (targeting VEGF). These are sometimes 
used in combination with chemotherapy (National Institute for Health and Care 
Excellence, 2011a). 
 
1.2.5 Resistance and Recurrence 
There have been steady improvements in CRC outcome as shown in Figure 1.5. 
However, some patients are unresponsive to therapy or have disease recurrence. 
Why this happens is unclear and denotes that these patients receive treatment 
which is of little or no benefit. 
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Figure 1.5 Bowel cancer age-standardised ten-year net survival, England and 
Wales(Cancer Research UK, 2014) 
 
Therapy failure should be uncovered by clinical monitoring and radiological 
evidence of tumour recurrence or progression. This leads to treatment adjustments 
thus limiting unnecessary side effects. Along with discovering new treatments, 
predicting who will benefit most from current therapeutics remains an important 
CRC management aim to limit unnecessary therapy, side effects and cost. Current 
predictors include clinicopathological staging (section 1.2.1), which is a good marker 
for overall prognosis. Presently several protein and genetic markers help refine 
treatment, monitor response to therapy and inform on prognosis e.g. BRAF 
mutations, carcinoembryonic antigen (CEA), microsatellite instability (MSI) and 
KRAS (Gangadhar and Schilsky, 2010, National Cancer Institute, 2015, Bork et al., 
2015, Phipps et al., 2013, My Cancer Genome, 2015). A new method has been 
recently described by an international consortium assessing 3443 patients from 
across the world. This method terms four consensus molecular subtypes (CMSs); 
microsatellite instability immune, canonical Wnt signaling metabolic dysregulation 
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and mesenchymal activation, with 87% of patients assigned to one of these groups 
(Guinney et al., 2015). It has been well received with hope it can more accurately 
predict treatment response, outcome and guide drug discovery (Wise, 2015). 
However, clinical trials are still needed to validate this classification method and 
more is still needed to help those who do not respond to current therapeutics. 
 
1.3 STEROID HORMONES AND THE COLON 
Steroid hormones are derived from cholesterol (Figure 1.6) with the majority 
synthesised in the adrenals and gonads. Although the colon is not traditionally 
viewed as a hormonal tissue there are over 50 hormones, genes and numerous 
bioactive peptides that work together to regulate secretion, absorption, digestion, 
motility and mucosal growth, making the gut the largest endocrine organ (Rao JN, 
2010). Steroidogenic enzymes and active steroids have been detected in the 
intestines. Thus, the gut is a source of glucocorticoids; important for bowel 
homeostasis and immunoregulation (Sidler et al., 2011, Cima et al., 2004), and sex 
steroid oestrogen production (Sato et al., 2009); having roles both in normal GI 
physiology and carcinogenesis.  
 
1.3.1 Oestrogens and Colorectal Cancer 
Oestrogen has complex influences on the bowel with varying effects on GI 
physiology. For example oestradiol (E2) increased contractility and GI motility in 
animal models (Bruce and Beshudi, 1981) and shortened the synthesis phase of 
the cell cycle in crypt epithelium in mice (Galand et al., 1967). Also, ovariectomy 
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can lead to colonic crypt atrophy in mice (Hoff et al., 1981) and healthy human 
females have GI motility varying with their menstrual cycle, with oestrogen and 
progesterone contributing to constipation (Bernstein et al., 2014, Oh et al., 2013).  
 
In addition to normal physiology in women oestrogen has been shown to influence 
CRC risk. The associations between oestrogens and CRC have been suggested for 
a number of decades. In 1969 Fraumeni et al. noted that nuns had an increased 
risk of both breast and CRC compared to the general population (Fraumeni et al., 
1969). Nuns are a unique population group as they are nulliparous and so have 
uninterrupted menstrual cycles and so a higher lifetime exposure to oestrogen. The 
New York University Women’s Health study found that women with the highest 
quartile range of circulating oestrone (E1) concentrations had the greatest CRC risk 
(Clendenen et al., 2009). A large study with a cohort of 214,162 post-menopausal 
women examined associations between lifetime endogenous oestrogen and CRC. 
It was shown that reproductive factors such as parity, age of menarche and 
menopause more commonly associated with breast cancer also correlated with 
CRC risk. Therefore, lifetime oestrogen exposure is an important risk factor for 
developing CRC (Zervoudakis et al., 2011).  
 
The Women’s Health Initiative (WHI) launched in 1991 was a major research 
program consisting of clinical trials and an observational study involving 161,808 
post-menopausal women. It was designed to test the effect of Hormone 
Replacement Therapy (HRT, commonly conjugated oestrogens and progesterone), 
diet, calcium and vitamin D on conditions such as cardiovascular disease, fractures, 
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breast cancer and CRC. Their findings showed HRT reduced CRC risk by 40% and 
the combined oral contraceptive pill (OCP) reduced CRC risk by 20% (Rossouw et 
al., 2002, Rossouw et al., 2013, Roehm, 2015). Studies have shown differences 
between HRT formulations (oestrogen-progestin versus oestrogen only therapy) 
and protection against CRC. These findings have not been consistent as to which 
formulation may offer the most protection against CRC, but none appear to have 
found any increase in CRC risk. The reason for these inconsistencies with HRT 
formulations is unclear but may relate to duration of treatment within the study 
(Hildebrand et al., 2009, Johnson et al., 2009, Dinger et al., 2007). However, the 
WHI trial did note women diagnosed with CRC whilst using oestrogen plus progestin 
therapy had higher tumour grades, suggesting HRT had a possible role in CRC 
progression (Chlebowski et al., 2004). HRT may initially offer a protection against 
CRC, but once established promote tumour proliferation. Alternatively, HRT side 
effects may mask/simulate CRC symptoms delaying presentation and diagnosis. 
However, the finding of advanced CRC with HRT treatment in the WHI trial has not 
been replicated and could instead be related to study design (Prentice et al., 2009). 
 
A higher lifetime exposure to endogenous circulating oestrogen as altered by 
reproductive factors appears to increase CRC risk in women. Alternatively, direct 
exposure to exogenous oestrogens, such as HRT, OCP or through diet may interact 
with and potentially alter the local colonic environment and offer, at least initially, a 
protective influence in women. Thus, in women there are differences in effects of 
endogenous and exogenous oestrogen on the gut.  
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Men have a lower lifetime exposure to oestrogen compared to women with the main 
source from adipose tissue and skin. However, men have a higher risk of CRC. 
Younger women with higher circulating oestrogen concentrations also have a more 
favourable prognosis than younger men (Hendifar et al., 2009), indicating a complex 
relationship between endogenous oestrogen and CRC risk. In addition, men have 
higher circulating androgens than women, which may also impact on the differences 
in CRC risk and survival between genders. 
 
Obesity is a growing problem that affects both men and women. Adipose tissue 
contains aromatase, an enzyme that catalyses the synthesis of oestrogens from 
circulating androgens. Adipose tissue also expresses the necessary oxidoreductive 
enzymes (discussed in section 1.7) to alter androgen and oestrogen potency 
(Corbould et al., 1998). Thus, adipose is a source of oestrogen with aromatase 
efficiency and expression increasing with advancing age (Bulun and Simpson, 
1994, Hemsell et al., 1974, Cleland et al., 1985, Siiteri, 1987). In premenopausal 
women the ovaries are the principal source of oestrogens (Kapit et al., 2000) 
however in men and post-menopausal women oestrogens are primarily produced 
via aromatase action in adipose and skin tissue (Hemsell et al., 1974, Cleland et al., 
1985). Obesity, with increased adipose tissue mass as well as age enhances 
oestrogen biosynthesis. Therefore, it may be oestrogenic effects combined with 
associated diet and physical activity factors (section 1.2.3.3) that contribute to the 
risk of CRC in obesity.  
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1.4 OESTROGEN SYNTHESIS AND METABOLISM 
The aromatase and sulphatase pathways produce active oestrogens from 
circulating precursor steroids (Figure 1.6). Within the colon aromatase activity is low 
(English et al., 1999, Foster, 2013, Sato et al., 2009) therefore it is thought that 
oestrogen is primarily produced through steroid sulphatase (STS) action.  
 
Oestrogen sulphates are biologically inactive as they have no significant affinity to 
oestrogen receptors (ER) (Zhu et al., 2006). STS converts circulating sulphated 
oestrogens (E1S and E2S) to active oestrogens such as E1 and E2. The reverse 
reaction is catalysed by oestrogen sulphotransferase (SULT1E1).  
 
E1S is the most abundant oestrogen precursor in the circulation of men, non-
pregnant women and postmenopausal women (2-4 nmol/l in males, 2-5 nmol/l in 
premenopausal females and 0.5-2 pmol/l in postmenopausal females (Mueller et 
al., 2015)). Bound to albumin and with a half-life of up to nine hours, E1S is 
considered a reservoir for biologically active oestrogens E1 and E2 (Reed et al., 
2005, Ruder et al., 1972). Once desulphated, E1 can be further reduced by 17β-
hydroxysteroid dehydrogenase enzymes (HSD17β) to E2, which has the highest 
binding affinity for ERs (Zhu et al., 2006).  
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Figure 1.6 Simplified diagram of oestrogen metabolism showing active oestrogens 
E1 and E2 can be generated through either the aromatase or steroid sulphatase 
(STS) enzyme pathways. Oestrogen sulphotransferase (SULT1E1); 17β 
Hydroxysteroid dehydrogenase type 1, 2 and 3 (HSD17β1, 2, 3 respectively).  
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In relation to CRC, oestrogen enzymes STS, SULT1E1 and HSD17βs and 
oestrogen receptors will now be discussed in more detail. 
 
1.5 STS 
STS, also known as arylsulphatase C, is a member of the sulphatase family, 
catalysing the hydrolysis of sulphate ester bonds from a wide range of substrates. 
STS is the principal enzyme for desulphating steroids from their inactive to active 
forms and so activity can impact on local concentrations of E2, 
dehydroepiandrosterone (DHEA) and testosterone (T) (Secky et al., 2013, Purohit 
et al., 2011). STS is a membrane-bound microsomal enzyme, mainly localised in 
the rough endoplasmic reticulum (Sato et al., 2009, Ghosh, 2007) and is virtually 
ubiquitously expressed in small quantities in human tissues, with placenta and liver 
having the greatest activity (Nardi et al., 2009, Dalla Valle et al., 2007, Reed et al., 
2005, Warren and French, 1965).  
 
The STS gene is located on the short arm of chromosome X and mapped in Xp22.3-
Xpter (Yen et al., 1988, Reed et al., 2005, Suzuki et al., 2011, Nardi et al., 2009). 
STS is synthesised as a membrane-associated precursor with 63 kDa mass and 
asparagine-linked oligosaccharide chains. Endoglucosaminidase H cleaves these 
chains resulting in a final size of 61 kDa with a four day half-life (Conary et al., 1986). 
X-ray crystallography has shown STS to be a monomer with a “mushroom-like” 
shape; two hydrophobic anti-parallel alpha helices protruding from a spherical 
molecule. The hydrophobic tail is implanted in the luminal membrane of the 
endoplasmic reticulum and beside it is a long narrow pocket with the enzyme 
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reaction site at the base. To be desulphated substrates and products have to travel 
through the endoplasmic reticulum membrane (Hernandez-Guzman et al., 2003, 
Nussbaumer and Billich, 2004, Thomas and Potter, 2013). 
 
1.5.1 STS Regulation  
There is limited data on the molecular regulation of STS transcription. The STS 
gene spans over 200 kbp with the regulatory region in the first 100 kbp and coding 
region downstream (Nardi et al., 2009). Measuring STS activity is an important part 
of assessing peripheral oestrogen metabolism as STS can undergo various post-
translational modifications. It holds four potential N-glycosylation sites however 
digestion by endoglycosidase H showed only two (Asn47 and Asn259) are used 
(von Figura et al., 1998, Stein et al., 1989). All four of N-linked sites are glycosylated 
to some extent however only mutations in these two glycosylation sites decreased 
activity (Stengel et al., 2008). Since glycosylation alters STS function there does not 
necessarily need to be a change in mRNA or protein expression to alter activity.  
 
Another STS post translational modification is cysteine (C)75 to form formylglycine 
(FGly) at the active site. This is facilitated by coenzyme FGly-generating enzyme 
(FGE) which is encoded by the gene sulphatase-modifying factor 1 (SUMF1). 
Further hydration forms gem-diol hydroxylformylglycine (Thomas and Potter, 2013, 
Schmidt et al., 1995). Like STS, FGE is also glycosylated and found in the 
endoplasmic reticulum. There is some evidence that FGE is secreted by cells, acting 
in a paracrine manner to influence STS activity in neighbouring cells (Preusser-
Kunze et al., 2005, Zito et al., 2007). Additionally, it is suggested that a paralog of 
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SUMF1, SUMF2, lacks the catalytic domain of SUMF1 but can dimerise with 
SUMF1 inhibiting its action and reducing STS activity (Zito et al., 2005). This adds 
another factor in STS regulation but further research is needed to clarify SUMF2’s 
role. 
 
1.5.2 STS Regulation in Disease 
STS mRNA and activity have been shown to be regulated by products of 
inflammation such as NFκB and TNFα. These components are released with 
metabolic inflammation for example high fat diets, overfeeding and obesity 
(Hotamisligil et al., 1995, Hotamisligil et al., 1993, Shoelson et al., 2003). Liver STS 
expression was induced in mouse models of metabolic disease such as ob/ob mice, 
high fat diet and type 2 diabetes models. In these instances STS overexpression 
appeared beneficial with improved body weight and insulin sensitivity, decreased 
hepatic steatosis and inflammation. In female mice this was thought to be through 
active oestrogen generation as these effects were lost with ovariectomy and in 
males by reduced inflammation in white adipose tissue and skeletal muscle (Jiang 
et al., 2014).  
 
In chronic liver disease STS was induced by inflammatory activated NFκB, 
increasing circulating oestrogens which may contribute to this disease associated 
male feminisation. Also, there appears to be a negative feedback loop with STS 
activated oestrogens attenuating NFκB mediated inflammation (Jiang et al., 2016).  
Human and animal data is also supported by cell line studies. Comparable effects 
have been demonstrated in human MG-63 preosteoblasts with NFκB inducing STS 
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expression (Dias and Selcer, 2016). In addition to metabolic disease, STS was 
induced by IGF-II via a PI3-kinase/Akt-NFκB pathway in prostate cancer PC-3 cells 
(Sung et al., 2013). Whereas, the prostate cancer cell line LNCaP had increased 
STS activity in response to IL-6 and TNFα without alteration in STS mRNA levels 
(Suh et al., 2011). Similar effects have also been shown in the breast cancer cell 
line MCF7 (Newman et al., 2000). Together these data suggests STS is regulated 
as part of the inflammatory response in multiple tissue types.  
 
STS activity augmentation by cytokines IL-6 and TNFα without mRNA changes 
suggests post-translational modifications are involved (Honma et al., 2002, Reed et 
al., 2005, Newman et al., 2000, Suzuki et al., 2011, Purohit et al., 1996, Purohit et 
al., 1997).  Another possibility is these cytokines alter membrane permeability, 
increasing substrate accessibility and thus there is more product available to 
desulphate rather than a true increase in STS activity (Purohit et al., 2002). 
However, neither posttranslational modification nor membrane permeability 
alterations in these conditions have been confirmed.  
 
In addition to inflammation STS expression appears be affected by oestrogens. For 
example in MCF7s STS transcription was up regulated by E2 via direct binding to 
oestrogen receptors (ER) and activation of oestrogen response elements (ERE) in 
the promoter regions (Zaichuk et al., 2007, Secky et al., 2013). Additionally, 
treatment with anti-oestrogen ICI182780 reduced both basal and E2 stimulated 
expression of STS mRNA. Oestrogens also induced ERα degradation in an auto 
regulatory feedback loop which was prevented by pretreatment with proteosomal 
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inhibitor MG132. STS mRNA increased after exposure to E2 and MG132, whereas 
MG132 alone reduced STS mRNA (Zaichuk et al., 2007, Fan et al., 2004). As STS 
provides the mechanism, through desulphation, for active oestrogens it is logical 
that it would be involved in feedback mechanisms to regulate oestrogen 
concentrations within tissues.  
 
Sex steroids have a role in immune function and inflammatory processes (Cutolo et 
al., 2002, Bouman et al., 2005). Epidemiological and immunological evidence 
implies that female sex hormones influence chronic inflammatory disease (Ngo et 
al., 2014). Inflammatory cells, such as macrophages and T cells have been shown 
to express ERα and ERβ (Straub, 2007).  Furthermore, STS is frequently 
dysregulated in cancer and a hallmark of cancer is inflammation (Hanahan and 
Weinberg, 2000). Therefore, it is unsurprising that STS is also regulated by 
inflammatory mediators. However, this has yet to be examined in the colon and is 
explored in more detail in Chapter 7. 
 
1.5.3 STS in Colorectal Cancer 
1.5.3.1 Oestrogens 
Sato and colleagues showed CRC tumours had higher oestrogen concentrations 
compared to normal colonic mucosa with higher total oestrogen and E1 
concentrations associated with reduced survival. Importantly, oestrogen 
concentrations were concordant with STS and SULT1E1 expression rather than 
aromatase (which was expressed at low levels). Additionally, STS and SULT1E1 
ratios correlated with prognosis; tumours negative for STS and positive for 
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SULT1E1 had an improved outlook, whereas those positive for STS and negative 
for SULT1E1 were associated with adverse clinical outcome (Sato et al., 2009). As 
discussed in section 1.5.1 STS can undergo post-translational modification and 
these correlations were using mRNA and protein and did not include any direct 
measurement of enzyme activity.  Also demonstrating oestrogen pathway changes 
in CRC, English and colleagues noted HSD17β2 was frequently reduced with no 
alteration in aromatase (English et al., 1999). Increased E1 from the sulphatase 
pathway together with a fall in HSD17β2 would procure E2, the most active 
oestrogen. Therefore, oestrogens generated through the sulphatase pathway may 
contribute to CRC progression and poor survival. The findings from these two 
groups show the consequences of local oestrogen metabolism and the sulphatase 
pathway in CRC. As these enzymes can be targeted by hormonal therapy they offer 
potentially new CRC treatments. 
 
It is unknown how HRT (usually sulphated oestrogens and progesterone) influences 
the progression from adenoma to carcinoma and metastasis. As discussed in 
section 1.3.1 combination HRT reduces CRC risk by 40%, but women diagnosed 
with CRC while using HRT had higher tumor grades (Rossouw et al., 2002). 
Evidence suggests higher STS expression is a frequent finding in CRC although 
further study would be needed to confirm this. For example STS, SULT1E1 
expression and activity in tumours of HRT users versus non-users has not yet been 
examined.   
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1.5.3.2 Androgens 
Androgens may act similarly to oestrogens in CRC with joint protective and cancer 
promoting effects. STS can desulphate DHEAS, a source of androgens as well as 
oestrogens. However, with minimal aromatase activity in the colon (English et al., 
2001) any DHEAS desulphation would be almost exclusively for androgen 
production. The colon does express cytosolic and nuclear androgen receptors (AR) 
(Marugo et al., 1992, Stebbings et al., 1988) and functional membrane AR have 
also been identified in colon tumors (Gu et al., 2009). The effect of androgens in 
CRC is unclear with some studies showing apoptotic and others anti-apoptotic 
effects. In vitro testosterone induced apoptosis, whereas DHEA enhanced survival 
in serum-deprived Caco-2 CRC cells (Anagnostopoulou et al., 2013). However, in 
vivo testosterone has been found to accelerate cell proliferation in the small 
intestine and induced colon cancer in rats, with CRC growth reduced following 
castration (Tutton and Barkla, 1982). A more recent study supports these findings 
with castration protecting against colonic adenomagenesis (development of 
adenomas), reversed by testosterone supplementation in rats and mice (Amos-
Landgraf et al., 2014). However, there are no definitive studies on whether 
androgens influence CRC progression. 
 
Human studies exploring the effect of androgen treatment on the colon have been 
inconsistent. Higher serum DHEAS concentrations in men are associated with 
slightly lower CRC risk (Alberg et al., 2000). However, a large study of 107,859 
prostate cancer patients assessed CRC incidence and androgen deprivation 
therapy (Gillessen et al., 2010). CRC risk rose with increasing androgen deprivation 
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therapy and duration; highest incidence of CRC with orchidectomy, followed by 
GnRH agonist therapy and no androgen deprivation therapy (Lin and Giovannucci, 
2010).  
 
1.6 SULT1E1 
SULT1E1 is an enzyme that sulphates oestrogens and androgens rendering them 
biologically inactive. Conjugation to sulphate or glucuronide groups at carbon 
position three of the four-carbon ring steroid backbone increases hydrophilic 
properties and facilitates circulatory distribution and excretion. Importantly, these 
sex steroids can then become active again through enzymatic deconjugation, such 
as desulphation by STS. Sulphated oestrogens have a longer half-life than the 
unconjugated forms; the half-life of E1S is 10-12 hours and unconjugated active 
oestrogens 20-30 minutes (Ruder et al., 1972). Therefore, circulating inactive 
steroids act as reservoirs for active oestrogen production, enabling local steroid 
metabolism by peripheral tissues (Reed et al., 2005, McNamara et al., 2013).  
 
Figure 1.7 shows how oestrogens can be inactivated by the addition of sulphate 
from universal sulphuryl group donor 3’-phosphoadenosine-5’-phosphosulphate 
(PAPS). In brief, PAPS synthase (PAPSS) is bifunctional with an NH2-terminal APS 
kinase domain and a COOH-terminal ATP sulphuryl domain. These act in two steps 
with the sequential action of ATP sulphurylase and APS kinase to form PAPS 
(Franzon et al., 1999, Venkatachalam, 2003, Harjes et al., 2005). There are two 
human protein isoforms of the PAPSS enzymes; PAPSS1 and PAPSS2 (77% 
homology) and they do not complement each other (van den Boom et al., 2012, 
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Franzon et al., 1999). In brain and skin PAPSS1 dominates and in liver, cartilage 
and the adrenal glands PAPSS2 is more highly expressed.  
 
 
Figure 1.7 Diagram depicting the two step process of 3’-phospoadenosine 5’-
phosphosulphate (PAPS) synthesis and the subsequent usage of PAPS as a co-
substrate for sulphotransferase reactions. PAPS synthase (PAPSS) catalyses two 
sequential reactions to form the universal sulphate donor, 3’-phospoadenosine 5’-
phosphate (PAP). First the adenosine triphosphate (ATP) sulphyurylase domain 
combines sulphate (SO42-) with ATP to form adenosine 5-phophosulphate (APS) 
and pyrophosphate (Ppi). Secondly, APS combines with ATP, catalysed by the APS 
kinase domain creating PAPS. Sulphotranserases, such as SULT1E1 acting on 
oestrone, can then catalyse the transfer of the sulphate to create oestrone-sulphate 
and PAP. 
 
1.6.1 SULT1E1 Structure and Location 
Sulphotransferases fall into two main groups; cytosolic or membrane bound in the 
Golgi apparatus. SULT1E1 is a cytosolic family member with gene located on 
chromosome 4. It is the principal enzyme for oestrogens, catalysing the 
sulphoconjugation of E1 and E2 at the 3-hydroxyl terminus with great efficiency 
(Coughtrie, 2002, Cole et al., 2010, Meinl and Glatt, 2001, Her et al., 1995). 
SULT1A1 and SULT1A3 are also capable of sulphating oestrogens, but have much 
lower affinities. These are 92.5% identical to each other and approximately 50% 
identical to SULT1E1 (Thomas and Potter, 2013).  
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Human SULT1E1 contains 294 amino acids and forms a dimer of 35 kDa with two 
E1 or E2 bound per subunit (Zhang et al., 1998, Pasqualini, 2009). The crystal 
structure with cofactor (PAPS) complex has been reported (Pedersen et al., 2002) 
and together the substrate and PAPS binding site form an open tube through the 
core of the SULT1E1 protein. Residues of the substrate binding site are largely 
hydrophobic and surround the substrate closely positioning the hydroxyl group so it 
can act as acceptor in the sulphate transfer (Thomas and Potter, 2013). 
 
SULT1E1 is expressed in the liver and small intestine and is the dominant 
sulphotransferase in lung tissue. However, expression is absent in the kidney 
(Riches et al., 2009). SULT1E1’s role may be particularly important during fetal 
development (Duanmu et al., 2006) as ablation in mice caused placental thrombosis 
and fetal loss (Tong et al., 2005).  
 
1.6.2 SULT1E1 Regulation 
Sulphotransferase genes are part of phase two metabolism and so transcriptional 
regulation is complex. Glucocorticoids have been shown to effect oestrogen 
function by glucocorticoid receptor-mediated transcriptional up-regulation of 
SULT1E1 and inactivating oestrogens (Gong et al., 2008). SULTs are also 
subjected to substrate negative feedback. Hence endocrine disruptors instead of 
activating oestrogen receptors (ER) can instead bind to SULT1E1.In the presence 
of STS, inactivating SULT1E1 could lead to increased oestrogen activation (Wang 
and James, 2006, Kester et al., 2002). 
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For sulphotransferase reactions, the sulphate molecule is donated from the 
universal sulphate donor, PAPS (Figure 1.7). As PAPS is exclusively produced by 
PAPSS1 and PAPSS2, supply can be considered a rate limiting step. Thus, 
sulphation is at least in part regulated by PAPSS availability (van den Boom et al., 
2012). Additionally, PAP, the by-product of sulphation inhibits SULT1E1 and 
therefore assists through a negative feedback loop in the regulation of sulphation 
(Gulcan and Duffel, 2011, Zhang et al., 1998). 
 
1.6.3 SULT1E1 in Colorectal Cancer 
SULT1E1 and STS expression have been linked to prognosis in CRC with high 
SULT1E1 expression associated with a more favourable prognosis (Sato et al., 
2009). However, there is little further examination of SULT1E1 in the colon. In more 
traditional hormonal cancers, such as breast and endometrial cancer, common 
single nucleotide polymorphisms (SNPs) in SULT1E1 have been shown to affect 
disease free survival and frequently increase risk. This demonstrates the 
importance of SULT1E1 in tumourigenesis (Choi et al., 2005, Hirata et al., 2008).  
 
PAPSS is important for SULT1E1 action however there have been no studies on 
PAPSS activity and expression in colon cancer. However, overexpression of 
SULT1E1 and PAPSS1 in MCF7 cells, leading to increased oestrogen inactivation 
through sulphation, resulted in growth inhibition by arresting cell cycle and inducing 
apoptosis. Paradoxically, PAPSS1 and 2 expression in breast cancer tissue have 
been found to be increased. This may be an initial adaptive response to protect cells 
from oestrogenic mitogenicity by sulphation inactivation (Xu et al., 2012).  
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1.7 17βHYDROXYSTEROID DEHYDROGENASE 
17βHydroxysteroid dehydrogenases (HSD17β) are responsible for the final step in 
formation of active androgens and oestrogens and have a key role in sex steroid 
biology. There are multiple isoenzymes with variable tissue expression aiding 
oestrogen and androgen intracrine biosysnthesis (Labrie et al., 1997). Nicotinamide 
adenine dinucleotide (NAD(H)) or, its phosphate form, (NADP(H)) are required for 
activity. Reductive actions are important for active sex steroid production, whereas 
oxidation decreases hormone activity (Torn et al., 2003). To date 15 HSD17β 
enzymes have been recorded with type 6 and 9 not identified in humans. All bar 
type 5, (an aldo-keto reductase), are short-chain dehydrogenases/reductases. 
HSD17βs are all similar in size and have highly conserved motifs e.g. Rossmann 
fold. Despite this, homology is actually low with variable cellular localisation (Duax 
et al., 2000, Duax et al., 2005, Lukacik et al., 2006, Day et al., 2008b). Kinetic 
studies have shown these enzymes to be multifunctional, but in vivo the majority 
appear to have substrate and directional preferences. HSD17βs implicated in 
oxidising E2 to E1 or reducing E1 to E2 in the colon are discussed below. 
 
1.7.1 HSD17β Oxidation of Oestradiol to Oestrone 
Oestrogen oxidative activity decreases ER stimulation through reduced affinity and 
is the primary reaction in the normal colon (English et al., 1999). This reaction is 
predominantly via HSD17β2 however additionally HSD17β4 and 8 have been 
considered as in vitro they have demonstrated oestrogen oxidative capability (Day 
et al., 2008a, Luu-The et al., 2006, Aka et al., 2009). Currently in the normal colon 
only expression of HSD17β2 and 4 have been identified (English et al., 2000). 
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1.7.1.1 HSD17β type 2  
The HSD17β2 gene is located on chromosome 16q24 and is 387 amino acids. The 
protein sequence shares approximately 20% sequence identity with HSD17β1, the 
primary reductive enzyme (Labrie et al., 1997). HSD17β2 is microsomal, located on 
colonic epithelium luminal surface and is able to metabolise orally administered 
steroids such as HRT and contraceptives (Puranen et al., 1999). 
 
In 1999 English and colleagues quantified the expression of HSD17β2 and 4 in 
human CRC tissues, with expression reduced compared to normal tissue. They 
predicted this would result in higher local E2 concentrations (English et al., 1999), 
although they did not confirm this (such as through LC-MS/MS analysis) and sample 
size was small including just 10 males and 14 females. It was postulated that an 
increase in the E1/E2 ratio in CRC may be important for CRC progression; E1 being 
protective and E2 detrimental. However, another study with a slightly larger sample 
size of 35 females and 39 males found reduced HSD17β2 expression in CRC, with 
presumed increase in E2 synthesis, was associated with improved survival in 
females (Oduwole et al., 2003). As both E1 and E2 possess binding affinity to 
oestrogen receptors these data are conflicting as to which oestrogen is the more 
protective. However, neither study took into account enzyme activity or other 
oestrogen metabolising enzymes such as STS and SULT1E1. In CRC it is likely 
more complex than one type of oestrogen being “good” and another being “bad”. 
The response may instead reflect the oestrogen receptor status of the tumour 
(section 1.8). Additionally, other potential factors to consider are gender, age, pre 
and post-menopausal, genetics and length of oestrogen exposure. 
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1.7.1.2 HSD17β type 4  
HSD17β4 is peroxisomal and expressed in virtually all tissues including intestine 
(Labrie et al., 1997). It is a 736 amino acid protein with an N-terminal 
dehydrogenase domain and a larger C-terminal domain containing hydratase and 
lipid carrier moieties (Breitling et al., 2001). In vitro it has E2 oxidoreductase activity 
(Adamski et al., 1995), conversely in vivo it is instead involved in peroxisomal fatty 
acid β-oxidation (Breitling et al., 2001, Qin et al., 1997) with mutations causing an 
autosomal-recessive disorder of peroxisomal fatty acid β-oxidation called D-
bifunctional protein (DBP) deficiency (Pierce et al., 2010, McMillan et al., 2012). 
Expression is highest in the liver, heart, prostate and testis with up-regulation 
demonstrated in prostate cancer (Zha et al., 2005). In CRC oxidative oestrogen 
activity has been shown to be reduced with down-regulated HSD17β2 and 4 mRNA 
and protein expression (English et al., 1999). However, the activity of each of these 
enzymes on oestrogen oxidation was not separately determined. In breast tissue 
HSD17β2 and 4 were both expressed, but only HSD17β2 had an effect on 
oestrogen oxidation. Thus, in vivo HSD17β4 may only have a minor role in steroid 
metabolism (Miettinen et al., 1999).  
 
1.7.1.3 HSD17β type 14 
HSD17β14 is a cytosolic enzyme and has so far been identified by Northern blot in 
the brain, liver and placenta. It has been shown to oxidise E2, testosterone and 5-
androstenediol (Lukacik et al., 2007). Breast cancer patients receiving tamoxifen 
treatment and whose tumours expressed HSD17β14 had a more favourable 
outcome (Sivik et al., 2012), possibly by increased oxidation of E2 to E1. Additionally, 
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in vitro transfection of HSD17β14 in breast cancer cell line MCF7 lead to reduced 
E2 concentrations (Jansson et al., 2006). Therefore, HSD17β14 may also be 
important in oestrogen metabolism. However, it is unlikely to play a role in CRC as 
no or low expression was seen by Northern blot in the small intestine, colon, 
pancreas, spleen and gonads (Lukacik et al., 2007). 
 
1.7.2 HSD17β Reduction of Oestrone to Oestradiol 
The uptake and desulphation of circulating E1S, followed by reduction of E1 would 
result in the most potent oestrogen, E2. If oestrogens were implicated in CRC 
proliferation and disease progression then limiting E1 to E2 conversion could 
potentially benefit patients. In humans reduction of E1 to E2 is primarily via 
HSD17β1, the best characterised out of the HSD17βs. However, in the colon 
despite HSD17β1 and three transcripts being detected by RT-PCR they were not 
confirmed by Northern analysis (English et al., 1999, English et al., 2000, English et 
al., 2001). Thus, any reductive reactions must be through an alternative enzyme. 
 
1.7.2.1 HSD17β type 7 
HSD17β7 is a 334 amino acid long membrane associated reductive enzyme and 
approximately 37 kDa. In rodents it was reported to catalyse E1 to E2 and is also a 
prolactin receptor-associated protein (Nokelainen et al., 1998, Krazeisen et al., 
1999). However, sequence and promoter analysis suggested its main role in 
cholesterol biosynthesis, reducing zymosterone to zymosterol (Marijanovic et al., 
2003, Ohnesorg and Adamski, 2006). This was supported by HSD17β7 KO mice; 
they are fertile but do not produce viable foetuses due to severe brain 
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malformations, likely due to the reliability of the brain on in situ cholesterol 
biosynthesis (Shehu et al., 2008). However, HSD17β7 is overexpressed in breast 
carcinoma (Oncomine datasets (Rhodes et al., 2004)) and inhibition of this enzyme 
in MCF7 cells resulted in lower E2 and higher DHT concentrations (measured by 
immunoassay) attenuating proliferation. HSD17β7 inhibition in MCF7 xenograft 
mouse studies resulted in tumour shrinkage, reduced HSD17β7 expression, 
decreased plasma E2 and elevated DHT (Wang et al., 2015). Thus, this suggests 
instead of, or in addition to cholesterol metabolism, HSD17β7 has a role balancing 
E2 and DHT sex steroids. There are currently no published studies on HSD17β7 in 
CRC. 
 
1.7.2.2 HSD17β type 12 
HSD17β12 is an endoplasmic reticulum protein with high homology to HSD17β3. In 
vitro studies have shown it efficiently reduces E1 to E2 (Luu-The et al., 2006, 
Blanchard and Luu-The, 2007), however others have suggested that HSD17β12 is 
not very efficient at this reaction in breast cancer (Day et al., 2008b). A study of 41 
matched breast cancer tissues found HSD17β12 was expressed in 83% of breast 
cancers and expression was higher in cancerous tissue (Song et al., 2006). 
However, in vitro knockdown of HSD17β12 in T47D breast cancer cells by siRNA 
did not impact on E1 to E2 metabolism and in vivo the same group found HSD17β1 
was the better endocrine target in breast cancer (Day et al., 2008a). Thus, the role 
of HSD17β12, at least in breast cancer, is unclear (Aka et al., 2009). Expression 
has been identified in many lipid metabolising tissues such as liver, kidney, heart 
and skeletal muscle, but also in endocrine-related organs such as pancreas, 
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pituitary, adrenal, testis and placenta and GI tract. Therefore, HSD17β12 may be 
involved in both lipid biosynthesis regulation and steroid metabolism (Sakurai et al., 
2006). 
 
1.7.3 HSD17β Inhibitors 
Oestrogen metabolism can be inhibited through its receptors and enzymes STS and 
aromatase, with much success in breast cancer. The advantage of inhibiting 
HSD17βs is that expression patterns vary between tissue types and between 
normal and cancerous cells. This potentially allows for more tumour direct and/or 
tissue specific inhibitors to modify steroid pathways and thus minimise unwanted 
side effects. The current focus is on HSD17β1 inhibitors for breast cancer and 
endometriosis and HSD17β3 inhibitors for prostate cancer (Day et al., 2008b). 
However, HSD17β inhibitors are still under development with none yet reaching 
clinical trials.   
 
1.8 OESTROGEN RECEPTORS 
Currently three main oestrogen receptors have been identified; oestrogen receptor 
alpha (ERα/ ESR1), oestrogen receptor beta (ERβ/ ESR2) and G protein-coupled 
oestrogen receptor (GPER/GPER-30).  
 
1.8.1 Oestrogen Receptor Alpha and Beta 
ERα, located on chromosome 6q25 was identified in 1966. ERβ was then later 
discovered in 1996 and is found on chromosome 14q23-24.1. The most potent 
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oestrogen, E2, has a similar binding affinity for both of these receptors (Kennelly et 
al., 2008). ERs are part of the nuclear hormone receptor family and conventionally 
function as ligand-regulated transcription factors (Edwards, 2005). Whereas nuclear 
ERs mediate the typical genomic action of oestrogen, membrane ERs have rapid, 
non-genomic actions (Li et al., 2015). 
 
Mouse ERα KO are infertile due to behavioural and physiological changes (Lubahn 
et al., 1993, Ogawa et al., 1998, Prossnitz and Hathaway, 2015). Additionally 
multiple organ systems are affected such as impaired bone growth (Vidal et al., 
1999, Vidal et al., 2000), loss of cardiovascular protection (Hodgin et al., 2001) and 
increased adipose tissue associated with glucose intolerance and insulin resistance 
(Heine et al., 2000). ERβ KO mice are also infertile however in females this is due 
to ovulation defects and in males for unknown reasons (Antal et al., 2008). 
 
1.8.1.1 ERα and ERβ in Colorectal Cancer 
In the colon these two ERs appear to have opposing functions; ERα is pro-mitogenic 
(Xu and Thomas, 1994, Di Domenico et al., 1996) and ERβ is pro-apoptotic (Qiu et 
al., 2002, Arai et al., 2000). In normal colon ERβ predominates and is fundamental 
to colonic cell homeostasis (Fang et al., 2012, Fang et al., 2010). ERα colonic 
expression is controversial with studies finding either low (Cavallini et al., 2002) or 
no (Witte et al., 2001) expression in the colon and CRC. However, meta-analysis 
has found that ERβ is decreased in CRC suggesting it is a tumour-suppressor gene 
protecting against CRC when activated by oestrogens (Niv, 2015). 
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ERβ KO mice develop colonic hyperproliferation, loss of differentiation and 
disordered apoptosis (Kennelly et al., 2008) with a fall in ERβ attenuating apoptosis. 
Recent research also proposes a role for micro RNA (miRNA) in CRC progression. 
E2 acting on ERβ has been shown to down-regulate miR-135b with loss of ERβ 
increasing miR-135b expression, which may increase DNA mismatch repair activity 
promoting carcinogenesis (He et al., 2012).  
 
Selective oestrogen receptor downregulators (SERDs), such as Fulvestrant and 
selective oestrogen receptor modulators (SERMs), such as tamoxifen and 
raloxifene, are used with great success in treatment for breast cancer. SERM action 
varies in different tissues e.g. acting as ER antagonists in breast tissue, but agonists 
in bone, protecting against osteoporosis (Howell et al., 2004, National Institute for 
Health and Care Excellence, 2015a, National Institute for Health and Care 
Excellence, 2011c). Effects in the colon are however not well documented. HCT116 
CRC cells treated with raloxifene and an ERβ gene constructed into an adenoviral 
vector had reduced proliferation both in vitro and in vivo as xenografts in mice (Tu 
et al., 2012). However, a treatment recreating the protective effects of ERβ in the 
CRC by upregulating expression would be challenging. A large population study of 
85,411 women showed taking tamoxifen for five years for breast cancer led to a 
moderate increased risk of CRC (Newcomb et al., 1999). CRC develops slowly over 
years (Kozuka et al., 1975, Fearon and Vogelstein, 1990) and so the effects of 
SERMs on the healthy colon, adenoma and carcinoma with loss of ERβ may differ 
and change over time. However, as discussed below, the ultimate effects of SERMs 
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and SERDs in the colon are further complicated by the fact they also function as 
GPER agonists (Prossnitz and Barton, 2014). 
 
1.8.2 G Protein-Coupled Oestrogen Receptor 
GPER shares structural homology with angiotensin II receptors and other 
chemotactic peptide receptors. Originally it was presumed the ligand for GPER was 
a peptide; however now it has been shown that GPER is a Gs-coupled receptor that 
promotes oestrogen dependent activation of adenylyl cyclase (Filardo, 2002, Feng 
and Gregor, 1997). Ligands include E2, tamoxifen (Vivacqua et al., 2012, Vivacqua 
et al., 2006b), genistein (Vivacqua et al., 2006a) and aldosterone (Rigiracciolo et 
al., 2016). 
 
The functional location of GPER is unclear. Immunohistochemical analysis on 
breast cancer cells has detected GPER predominately intracellularly (Filardo et al., 
2006). Contrastingly, GPER has characteristics of a plasma membrane ER and has 
been shown to have a short half-life of less than 30 minutes on the plasma 
membrane (Cheng et al., 2011). Tissues such as uterine epithelia (Gao et al., 2011) 
and myometrium (Maiti et al., 2011) have shown GPER as a plasma membrane 
receptor (Filardo and Thomas, 2012).  
 
GPER maps close to the genetic locus defining familial hyperaldosteronism II on 
short arm chromosome 7, 7p22.3 (Carmeci et al., 1997, Lafferty et al., 2000). It has 
a molecular mass of approximately 44 kDa and lesser amounts near 60 and 80 kDa. 
The identity of these larger masses are unclear, however they are eliminated after 
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removal of N-linked glycan chains with glycosidases and the 44 kDa band shifts to 
38 kDa, which is the estimated molecular weight of the unmodified core protein 
(Filardo and Thomas, 2012, Filardo et al., 2007). This receptor can promote modest 
mitogenic responses as well as homeostatic responses. 17β-oestradiol and the 
GPER selective agonist G1 are linked with proliferative responses in cancer cells 
such as breast (Santolla et al., 2015), endometrium (Vivacqua et al., 2006b), ovary 
(Albanito et al., 2007), testis (Chevalier et al., 2011, Franco et al., 2011) and thyroid 
(Vivacqua et al., 2006a). Contrastingly some studies have found GPER activation 
can inhibit proliferation such as in prostate cancer cell lines PC-3, DU145 and 
LNCaP in vitro and PC-3 xenografts in vivo (Chan et al., 2010). Despite GPER 
showing greatest effects in reproductive tissue, KO mice do not have gross 
reproductive anomalies and instead females have several metabolic deficiencies 
including impaired glucose tolerance and reduced bone growth (Martensson et al., 
2009, Prossnitz and Hathaway, 2015). 
 
1.8.2.1 GPER in the Colon 
GPER expression has been demonstrated in colon myenteric neurons. In functional 
studies intact mice treated with G15 (GPER antagonist) had shortened colon transit 
in proestrus and oestrus. Oestrogen treated ovariectomised mice had higher colon 
transit time than vehicle, but this was inhibited by G15. Within the myenteric plexus 
GPER stimulation with G1 led to nitric oxide production and GPER co-localised with 
neuronal nitric oxide synthase (nNOS) (Li et al., 2015). A supporting study found 
rats treated with oestrogen had increased relaxation responses to electric 
stimulation in isolated colon tissues along with increased nNOS expression in the 
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myenteric plexus (Shah et al., 2001). GPER, through nNOS in colonic myenteric 
neurons may contribute to reduced colon transit time and constipation. 
 
There is little documented about GPER in CRC, however, in more traditional 
hormonal cancers, like breast, endometrial and ovarian cancer GPER has been 
linked to disease progression (Smith et al., 2009, Girgert et al., 2014, Skrzypczak 
et al., 2013, Liu et al., 2014). In breast cancer GPER correlates with tumour size 
and metastasis (Filardo et al., 2006) with an inverse relationship between 
expression and disease free survival in patients treated with tamoxifen (Ignatov et 
al., 2011). Tamoxifen is a GPER agonist and so GPER may contribute to drug 
resistance. In vitro studies on GPER-expressing breast cancer cell lines have 
shown downstream GPER activation includes MAPK, PI3K/Akt and related survival/ 
proliferation pathways stimulating cell growth (Filardo et al., 2002, Filardo et al., 
2000, Pandey et al., 2009).  
 
GPER has been identified in mouse colon myenteric neurons (Li et al., 2015), but 
lacks the characterisation of ERα and ERβ in CRC (section 1.8.1.1) such as 
expression and effect on proliferation.  
 
1.9 HYPOTHESIS AND AIMS 
There is compelling evidence that CRC is hormonally responsive with tumour 
oestrogen metabolism frequently altered and impacting on survival. Reproductive 
factors such as parity, age of menarche and menopause affect CRC risk with higher 
endogenous lifetime oestrogen exposure increasing likelihood (Zervoudakis et al., 
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2011, Fraumeni et al., 1969, Clendenen et al., 2009). Tumours with higher 
oestrogen content, increased STS and reduced SULT1E1 enzyme expression are 
associated with a poorer outcome (Sato et al., 2009). However, the oestrogen 
metabolism pathway has yet to be fully elucidated in CRC or targeted therapeutically 
in CRC. Oestrogen metabolism involves several enzymes e.g. STS, SULT1E1, 
HSD17β1, 2, 7 and 12, PAPSS1 and 2. Previously their role in CRC has been 
examined individually with no information currently on the complexity of their 
interactions. This may explain some of the conflicting results on oestrogen and CRC 
risk reported in the literature. Additionally, which oestrogen receptors are important 
in the colon remains controversial.  
 
Utilising available research tools such as real time PCR, Western Blotting, cell 
culture, activity assays and LC-MS/MS this thesis examines oestrogen metabolism 
in human colon tissue, human colorectal cancer tissue, CRC cell lines and xenograft 
mouse models. This novel and multi-directional approach aims to identify 
therapeutically targetable oestrogenic changes in CRC. The hypotheses are: 
 Active E2 synthesis is promoted in CRC through increased STS activity and 
changes to HSD17β enzyme ratios. 
 E2 enhances tumour proliferation through GPER action.  
 E2 synthesis and GPER can be targeted therapeutically to reduce tumour 
proliferation and extend survival.   
  
 
 
 
 
CHAPTER 2. MATERIALS AND METHODS 
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2.1 CELL CULTURE 
Cell lines (Table 2.1) were grown in 75 cm2 tissue culture flasks  with vented cap 
(T75, Corning Ltd, UK) in media supplemented with 10% fetal bovine serum (FBS, 
Sigma-Aldrich, Poole, UK) and 1% penicillin-streptomycin (10,000 units/ 100 ml, 
Invitrogen, Paisley, UK) at 37oC with 5% CO2. To reflect that the majority of CRCs 
are adenocarcinomas, only CRC cell lines originating from adenocarcinomas were 
chosen and included HCT116 and HT29 cells grown in McCoys 5A (modified) 
Medium with L-Glutamine (Life Technologies, Grand Island, NY, USA), Caco-2 cells 
cultured in Minimum Essential Medium (MEM) plus Earle’s Salts and 5 mM L-
Glutamine (Life Technologies, Grand Island, NY, USA) and Colo205 in RPMI-1640 
medium with 5 mM L-glutamine and NaHCO3 (Sigma-Aldrich, Poole, UK). Cells 
used for positive controls included breast cancer cell lines MCF7 and MDAMB231 
grown in RPMI-1640 medium and placental choriocarcinoma cell line JEG3 cultured 
in DMF-12 media (Life Technologies, Grand Island, NY, USA). All cells were 
adherent except Colo205 cells which grew in part suspension. 
 
MCF7 and HCT116 cells were kindly gifted from Professor C. McCabe and Caco-2 
cells from Dr C. Tselepis (The University of Birmingham). All other cell lines were 
obtained from ATCC. To ensure high quality data all gifted cells were verified 
through DNA Diagnostics Centre with cell markers checked against recommended 
online cell line databases (DNA Diagnostics Centre, 2015). 
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Table 2.1 Summary of ATCC cell line basic characteristics (ATCC, 2016). 
Cell Line Type Gender Description 
HCT116 
(CCL-247) 
Colorectal carcinoma Male 
Adult 
No previous treatment 
 
Colo205 
(CCL-222) 
Colorectal 
adenocarcinoma 
Male 
70 years old 
Dukes’ stage D 
From metastatic site: ascites 
Caucasian 
Previously treated with 5-FU 
 
Caco-2 
(HTB-37) 
Colorectal 
adenocarcinoma 
Male 
72 years old 
Caucasian 
 
HT29 
(HTB-38) 
Colorectal 
adenocarcinoma 
Female 
44 years old 
Caucasian 
p53 mutation 
 
MCF7 
(HTB-22) 
Breast 
adenocarcinoma 
Female 
69 years old 
Caucasian 
From metastatic site: pleural 
effusion 
ER+ 
 
MDA-MB-
231 
(HTB-26) 
Breast 
adenocarcinoma 
Female 
51 years old 
From metastatic site: pleural 
effusion 
Caucasian 
 
Jeg 3 
(HTB-36) 
Placenta 
choriocarcinoma 
Female 
One of six from the Woods strain 
of the Erwin-Turner tumor model 
by Kohler and associates 
 
Cells were reviewed three times per week for media change or if 80% confluent split 
into new T75 flasks with new passage number noted. Passage numbers used were 
50-70 for HCT116 cells, 5-20 for Colo205 cells, 20-40 for Caco-2 cells, 60-90 for 
HT29 cells, 5-20 for MCF7 cells, 5-20 for MDA-MB-231 cells and 8-20 for Jeg3 cells. 
To split cells medium was removed and cells washed twice with phosphate buffered 
saline (PBS, Oxoid, Hampshire, England). To trypsinise 1-3ml of Tryple express 
(Invitrogen, Paisley, UK) was applied and cells incubated at 37oC for 2-5 minutes. 
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Trypsin was deactivated by FBS containing media and cells gently mixed into 
suspension. For seeding 10 µl of cell suspension was pipetted into a 
haemocytometer (Immune Systems Ltd) and cells counted at 100 x magnification. 
The average of three counts was used to calculate number of cells per µl.  
 
2.2 PROTEIN EXTRACTION 
2.2.1 Cells in Culture 
Cells in suspension were pelleted by centrifugation at 450 rcf for 5 minutes. Medium 
was removed and cells washed twice with PBS. Radioimmunoprecipitation assay 
buffer (RIPA Buffer, Sigma-Aldrich, Poole, UK) with protease inhibitor cocktail 
(1:100, Sigma-Aldrich, Poole, UK, 1ml RIPA Buffer per 0.5-5 x 107 cells) was used 
to lyse the cells and protein lysate stored at -80oC in a microcentrifuge tube.  
 
2.2.2 Plated Cells 
For plated cells media was removed and cells gently washed twice with PBS. As 
Colo205 cells grow part in suspension the PBS wash was collected and centrifuged 
to pellet cells as per section 2.2.1. For 6 well plates 250 µl of RIPA Buffer with 
protease inhibitor cocktail was applied to lyse cells and 500 µl for T25 flasks. Plates 
or flasks were frozen at -20oC, thawed at room temperature and scraped to collect 
protein lysate. Lysate was stored in a microcentrifuge tube at -80oC. 
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Protein lysate was clarified by centrifugation at 13, 000 rpm at 4oC for 10 minutes. 
Supernatant was then transferred avoiding cell debris pellet to a clean 
microcentrifuge tube. 
 
2.2.3 Tissue 
Human colon tissue (≤ 30 mg frozen in liquid nitrogen) was weighed and placed on 
dry ice. RIPA buffer (≤ 1 ml) with protease inhibitor cocktail and phosphatase 
inhibitors (Thermo Scientific, UK (both 1:100 dilution)) were used to homogenise 
tissue.   
 
Different methods of homogenisation were tested to balance time, cost and yield. 
However, due to limited tissue availability it was not possible to do a direct 
comparison between the methods: 
1. Homogenised in RIPA using a TissueRuptor device for approximately 40 
seconds.  
2. Crushing tissue with a micro pestle (Sigma-Aldrich, Poole, UK) in RIPA until 
homogenised, freezing at -80oC for 30 minutes and repeating the crushing process  
3. Utilising a Qiagen Tissuelyser II on loan (Qiagen, Manchester, UK). This involved 
a steel bead inserted into the microcentrifuge tube with the tissue and RIPA which 
was then shaken until homogenised. 
 
Micopestle method was mainly employed due to low costs and similar protein yields 
to other trialled methods. Once homogenised the soluble fraction was separated by 
centrifuging at 13,000 rpm for 10 minutes at 4oC. The supernatant was then 
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transferred, avoiding the pelleted cell debris, to a new microcentrifuge tube and 
stored at -80oC. To reduce freeze-thaw mediated degradation supernatant was 
aliquoted and stored at -80oC. 
 
2.2.4 Protein Quantification 
A bicinchoninic acid (BCA) assay (Bio Rad, Hertfordshire, UK) was used as per 
manufacturer’s instructions to quantify concentration of protein harvested from 
tissue or cells. In brief, 4 µl of sample (in duplicate) or pre-prepared standard (0, 
0.125, 0.25, 0.5, 0.75, 1, 1.5 and 2 mg/ml) was pipetted into a 96 well plate. Solution 
B was added to Solution A in a 1:50 dilution and 80µl of combined reagents added 
to each sample. The plate was incubated at 37oC for 30 minutes.  BCA assay utilises 
the reduction of Cu2+ to Cu+ by proteins in alkaline solution. Chelation of copper with 
protein in alkaline solution containing sodium potassium tartrate forms a light-blue 
complex. BCA reacts with the reduced cuprous cation forming a water soluble 
BCA/copper complex and turning the solution purple. This colourimetric change can 
be measured at 560 nm on a Wallac Victor3 1420 multilabel counter and protein 
concentration calculated from the standard curve. 
  
2.3 RNA EXTRACTION 
RNA was extracted from cells using RNeasy® kit (Qiagen, Manchester, UK) as per 
manufacturer’s instructions (see 2.3.3 for details).  
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2.3.1 Cells in Culture 
Cells in suspension from T75 culture flasks (section 2.1) were pelleted by 
centrifugation at 300 rcf for 5 minutes and media removed. RLT Buffer (10 µl β-ME 
(Sigma-Aldrich, Poole, UK)/ 1 ml RLT buffer) was added to the cell pellet and mixed 
by pipetting. The lysate was then homogenised by passing it through a blunt 21 
gauge needle with RNase free-syringe several times and RNA extraction continued 
as described in section 2.3.3. 
 
2.3.2 Tissue 
Human colon tissue (≤ 30 mg frozen in liquid nitrogen) was weighed and placed on 
dry ice. Homogenisation techniques were as described in section 2.2.3 using RLT 
Buffer. Once homogenised lysate was stored at -80oC, or RNA extraction was 
completed as described below. 
 
2.3.3 RNA Extraction 
70% ethanol was added to homogenised lysate and mixed by pipetting. This mix 
was transferred to an RNeasy spin column with collection tube and centrifuged > 
8000 rpm for 15 seconds with flow through discarded. Note on-column DNase 
treatment was not performed. RW1 Buffer was added with further 15 seconds 
centrifugation at > 8000 rpm with flow-through discarded. Twice RPE buffer was 
added followed by centrifugation at > 8000 rpm for 15 seconds and 2 minutes with 
flow-through discarded. Ethanol carry over was reduced by a further 1 minute 
centrifugation at full speed. To elute RNA the column was placed in a new collection 
tube with 40 µl RNase free water and centrifuged at > 8000 rpm for 1 minute. RNA 
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yield and purity was calculated in ng/µl using a NanoDrop Spectrometer (NanoDrop 
Products, Wilmington, DE, USA). Purity was quantified using absorbance at 260 
(nucleic acids) and 280 nm (proteins). A 260/280 nm ratio of around 2.0 is accepted 
for RNA. Additionally 260/230 nm gives information of other contaminants, with a 
good result being 2.0-2.2. RNA was stored at -80oC until reverse transcribed which 
was typically one week. 
 
2.4 REVERSE TRANSCRIPTION 
To synthesise cDNA from cell lines a Tetro cDNA Synthesis Kit (Bioline Reagents 
Ltd, London, UK) was used as per manufacturer’s instructions. Up to 5 µg of RNA 
(extracted as described in section 2.3) was added to a premix containing 4 µl 5x RT 
Buffer, 1 µl Ribosafe Rnase Inhibitor, 1 µl Tetro Reverse Transcriptase (200u/µl), 1 
µl 10 nM dNTP mix, 1 µl Primer Oligo (dT)18 and totalled to 20 µl with DEPC-treated 
water. This was mixed by pipetting and incubated at 45oC for 30 minutes with 
reaction terminated by 5 minute incubation at 85oC before being stored at -20oC. 
 
Maximal cDNA yield was generated from human RNA samples using a more 
sensitive kit, SensiFAST™ (Bioline Reagents Ltd, London, UK). Up to 1 µg of RNA 
was added to 4 µl of 5 x TransAmp Buffer, 1 µl Reverse Transcriptase and totalled 
to 20 µl of Dnase/Rnase free water. This mix was run on an Eppendorf Mastercycler 
Gradient PCR Thermal Cycler using the program 25°C for 10 min (primer 
annealing), 42°C for 15 min (reverse transcription), 85°C for 5 min (inactivation) and 
4°C hold (or chill on ice).  
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2.5 PICOGREEN ASSAY 
Concentration of cDNA was determined using PicoGreen assay (Invitrogen, 
Paisley, UK) as per manufacturer’s instructions. In brief 1 µl of cDNA was added (in 
duplicate) to 99 µl 1x TE Buffer and 100 µl 1x PicoGreen and compared to a 
standard curve as analysed on Wallac Victor3 1420 multilabel counter, (excitation 
~480 nm, emission ~520 nm). PicoGreen is a fluorescent asymmetric cyanine dye 
that on binding to double stranded DNA (dsDNA) forms a luminescent complex 
exhibiting a > 1000 fold increase in fluorescence compared to free dye in solution. 
The amount of fluorescence is proportional to the concentration of dsDNA and so 
cDNA. 
 
2.6 QUANTITATIVE POLYMERASE CHAIN REACTION 
Relative concentrations of specific mRNA were determined using quantitative real-
time PCR. Pre-optimised specific TaqMan™ (Applied Biosystems, Poole, UK) gene 
expression assays were used and are listed in Table 2.2. Genes were validated in 
duplex as shown in Appendix II.  
 
Bound to the 5’ end of the oligonucleotide probe is a fluorescent reporter dye (FAM 
or VIC) and at the 3’ end a quencher (TAMRA). Intact, the proximity of the quencher 
reduces fluorescence emitted from the reporter by fluorescence resonance energy 
transfer (FRET). If the target sequence is present, the probe anneals and is cleaved 
during extension by 5’ nuclease activity of Applied Biosystems hot-start DNA 
polymerase. Subsequently the quencher and reporter dye are separated and the 
emitted fluorescent signal by the reporter dye increases (Figure 2.1). As the PCR 
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reaction cycles, the reporter dye signal intensifies and is detected in real time with 
fluorescence proportional to the amount of amplicon produced; the higher the copy 
number, the sooner fluorescence will appear.  
 
Table 2.2 Table of TaqMan® gene expression assay used. 
Gene Code 
RPLPO 4310879E 
PP1A Hs04194521_s1 
HPRT1 4310890E 
HSD17β1 Hs00166219_g1 
HSD17β2 HS00157993_m1 
HSD17β7 Hs00996127_m1 
HSD17β12 Hs00275054_m1 
STS Hs00165853_m1 
SULT1E1 HS00193690_m1 
PAPSS1 Hs00193745_m1 
PAPSS2 Hs00190682_m1 
GPER Hs00173506_m1 
ERβ HS00230957_m1 
ERα HS00174860_m1 
TNFα Hs01113624_g1 
gapdh 4352932E 
il-6 Mm00446190_m1 
sts Mm04214605_u1 
hsd17β2 Mm00500430_m1 
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Figure 2.1 Principles of real-time PCR. From Real-Time PCR Systems Chemistry 
Guide, PN 4348358 used with permission from Thermo Fisher Scientific (Thermo 
Fisher Scientific, 2005). Representation of how the 5’ nuclease chemistry uses a 
fluorogenic probe to enable detection of a specific PCR product. 
 
Loaded into a 96 well plate was cDNA (minimum 20 ng calculated using PicoGreen), 
mastermix and probes totalling 12 µl. The reaction program was 50oC 2 minutes, 
95oC 10 minutes, followed by 40 cycles of 95oC for 15 seconds then 60oC for 1 
minute. The cycle threshold (Ct) was used for statistical analysis; ΔCt (gene of 
interest Ct minus internal standard gene Ct), with graphical display given in arbitrary 
units (i.e. 1000*(2-ΔCt)). If levels of expression were undetermined an arbitrary Ct of 
42 was used to allow for numerical analysis. 
 
It is recommended to use more than one internal control (Sorby et al., 2010) in real 
time PCR to improve accuracy. However, human tissue sample availability limited 
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the number of real-time PCR reactions performed. GeNorm and Normfinder 
software were used to select a single internal standard control gene for human colon 
tissue samples and cell lines (Appendix II). RPLPO was the most stably expressed 
gene in colon cancer cell lines and on research performed by Dr Rowan Hardy 
(University of Birmingham) GAPDH was most consistently expressed in wild-type 
and mice overexpressing human TNFα (Tg-TNF).  
 
2.7 PROLIFERATION ASSAY 
Two types of proliferation assay were performed in this project and which method 
used is stated for each experiment.  
 
2.7.1 CyQUANT 
Cell proliferation was analysed using CyQUANT® (Life Technologies, Grand Island, 
NY, USA) as per manufacturer’s instructions. CyQUANT® uses a green fluorescent 
dye that when binding to cellular nucleic acids emits fluorescence (480/520 nm). 
The fluorescence emission correlates with cell number.  
 
Cells were seeded at 5000 cells/well in a 96 well plate in replicates of six covering 
4, 24, 48, 72 and 96 hour time points. Four hours gave initial cell count once cells 
had adhered after seeding. After each time point media was completely removed 
and plate stored at -80oC until ready for analysis. To analyse plate buffer and green 
fluorescent dye were added to each well and read on a plate reader (Wallac 
Victor3TM 1420 Multilabel Counter, PerkinElmer) using fluorescence 480/520 nm. 
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The counts at 4 hours were averaged and the percentage change at each 
subsequent time point calculated.  
 
2.7.2 BrdU 
To monitor changes in proliferation in response to oestrogens 5-bromo-
2’deoxyuridine (BrdU) proliferation assay (Roche products Ltd, UK) was performed 
as per manufacturer’s instructions. 
 
The optimal cell seeding density and BrdU incubation was calculated for each cell 
line. Cells were seeded at 1000-10,000 cells per well with BrdU incubation times of 
2, 4 or 6 hours. The optimal results for Caco-2 cells were 4000 cells, HCT116 and 
HT29 500 cells all with 4 hour BrdU incubations. 
 
After treatment (such as E1 1, 10, 100 and 500 nM, E2 1, 10, 100 and 500 nM, with 
SFBS and complete media controls for 48 hours each in 6-8 wells of a 96 well plate), 
100 µM BrdU was added. BrdU is an analog of thymidine and is incorporated into 
the DNA of proliferating cells. After 4 hours media containing BrdU was removed 
and cells fixed and DNA denatured in one-step using FixDenat. After 30 minutes 
this was removed and monoclonal antibody to BrdU containing horseradish 
peroxidase (HRP) added for 90 minutes. This antibody binds to the BrdU in the 
newly synthesised DNA. Anti-BrdU was then removed and cells washed three times 
in PBS. This was a colourimetric assay and when the substrate containing tetra-
methylbenzidine (TMB) was added it catalysed the conversion of HRP on the anti-
BrdU from colourless to blue, measurable on a Wallac plate reader at 405 nm 
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absorbance. Colour would develop over 5-30 minutes, with intensity proportional to 
BrdU incorporation. Even at the higher oestrogen concentrations all cells 
proliferated and on visual observance looked healthy, suggesting no toxic effects at 
these doses.    
 
2.8 STS ASSAY 
This assay has been previously described (Purohit et al., 1995, Duncan et al., 1993) 
and has been adapted for CRC cell lines and tissue. Differences between the STS 
activity assay performed in protein lysate and intact cells are described in sections 
2.8.1 and 2.8.2 respectively.  
 
Conversion of E1S to E1 by STS was measured using [6,7-3H] E1S (4 × 105 dpm, 
Perkin-ElmerLS, Boston, MA, USA) adjusted to a final concentration of 20 μM with 
unlabeled E1S in PBS (protein lysate) or serum free cell media (intact cells). [4-14C] 
E1 (1 × 104 dpm, Perkin-Elmer) was also included in the reaction mixture to monitor 
procedural losses. The dose of E1S was chosen to ensure the reaction was not 
saturated (did not reach total count) and did not have any toxic cellular effects (as 
assessed visually). As the sulphate group is labile, every three months unlabelled 
E1S was purified of any E1 by toluene extraction. In addition a second clean-up 
occurred when making the substrate as 3HE1S also underwent removal of any 3HE1.  
 
After incubation at 37oC, E1 was extracted using liquid-liquid extraction. E1S is 
hydrophilic, whereas E1 is hydrophobic and therefore the two can be separated 
using toluene; 4 mls toluene was added and vortexed for 30 seconds. After this, 1 
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ml of toluene (top layer) was added to 4 mls scintillin (Fisher Scientific, UK) and 
counted on a scintillation spectrophotometer. Reactions were performed in 
duplicate. Positive controls included JEG3 or Caco-2 cells with and without the STS 
inhibitor STX64. A total count of non-toluene extracted substrate was also counted 
and this represented maximum conversion and allowed for calculation of hydrolysed 
E1 concentration. Negative controls were a total count extracted with toluene to 
assess any potential non-enzymic loss of the E1S sulphate group, and a PBS blank 
(background count). The average recovery of 14CE1 varied in intact plated cells, most 
likely due to some SULT1E1 activity. Plated cells in culture would be exposed to the 
necessary co-factors required for SULT1E1 action whereas these would not be 
present in the buffer used for lysed cells. The scintillation spectrophotometer 
software gave an adjusted reading to account for any crossover of 3HE1 and 14CE1. 
 
E1S to E1 conversion was corrected for procedural losses using the percentage of 
14C recovery ((3H count/ 100) x (100- %14C recovery) + 3H count)). The mass of 
E1S hydrolysed was calculated from the 3HE1 counts obtained (corrected for dilution, 
non-enzymatic hydrolysis and recovery of 14CE1 added) and the specific activity of 
the substrate. The results were expressed as nmoles of the product formed/ mg 
protein/ hour. Each batch of experiments included an incubation without any 
enzyme (i.e. tissue/ cell lysate) to monitor non-enzymatic hydrolysis of the substrate 
(blanks).  
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2.8.1 Protein Lysate 
Conversion of E1S to E1 by STS was measured using 60 µg of human colon protein 
lysate. 0.5 ml of unlabelled E1S, 3HE1S, 14CE1 in PBS was added to the protein and 
incubated at 37oC for 4 hours in Pyrex tubes (Scientific Laboratory Supplies, 
Nottingham, UK). Recovery of 14CE1 averaged 97.45 % (96.29, 98.60) in human 
lysate, 91.26% (89.63, 92.90) in mouse colon homogenate, 96.12% ± 3.7 in JEG3 
lysate and 95.86% ± 1.01 in Caco-2 lysate. 
 
2.8.2 Plated Cells 
Cells seeded into 6 well plates (100,000 cells per well) or T25 flasks (250,000 cells 
per well) had media removed and were washed with PBS. 1 ml of unlabelled E1S, 
3HE1S, 14CE1 in serum free media was added and incubated at 37oC overnight (18 
hours). This was a longer assay than protein lysate to take into account transport 
across the cell membrane. To improve accuracy 0.5 ml rather than trying to recover 
all of the original 1 ml was used for analysis. Protein was harvested and quantified 
(sections 2.2.2 and 2.2.4) with results expressed as E1 conversion in pmol/mg/hr. 
Recovery of 14CE1 varied between cell lines probably due to SULT1E1 activity e.g. 
HCT116 14CE1 recovery was 78.96% ± 1.89 and Caco-2 86.44% ± 1.52. 
 
2.9 WESTERN BLOTTING 
Protein (10-25 µg) with equal volume Laemmli sample buffer (Laemmli Buffer (Bio 
Rad, Hertfordshire, UK) with a 1 in 20 dilution of β2-Mercaptoethanol (Sigma-
Aldrich, Poole, UK)) was denatured at 100oC for 5 minutes. Proteins were separated 
on a 10% SDS-PAGE gel (Protogel, Resolving buffer, Stacking buffer (Geneflow 
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Ltd, UK), dH2O, TEMED (Sigma-Aldrich, Poole, UK), 10% Ammonium persulfate 
(Sigma-Aldrich, Poole, UK)). Separated protein was transferred for 1 hour 20 
minutes at 360 mA on to a polyvinylidene fluoride (PVDF) membrane (Millipore (UK) 
Ltd). To prevent non-specific binding membranes were blocked in 5% non-fat milk 
in Tris-buffered saline with 0.1% Tween (TBST, (dH2O, 50 ml 1 M Tris pH 7.6, 0.625 
ml Tween 80 (Sigma) and 20 g NaCl)) for 1 hour at room temperature or overnight 
at 4oC. 
 
Membranes were washed several times in TBST and incubated with primary 
antibody also made in TBST. Membranes were washed again with TBST before 
incubation with corresponding HRP conjugated secondary antibody in TBST. 
Antibodies used and details on incubation length and concentration are shown in 
Table 2.3. 
  
Antigen antibody complexes were visualised using ECL Western blotting detection 
reagent (GE Healthcare Life Sciences, UK) and x-ray film (Kodak) which was 
developed on a Xenograph Compact X4. To allow for detection of multiple proteins 
a mild stripping buffer (Tris, Glycine, SDS, pH 2.2) was applied twice for 10 minutes 
at room temperature, followed by further washes of TBST. The membrane was then 
blocked in 5% non-fat milk again before further antibodies were applied. 
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Table 2.3 Western blot antibodies used with details on incubation length and 
concentration. 
Antibody Antibody 
Type 
Supplier Primary 
Concentration 
Secondary 
Concentration 
β-actin  
(A5441) 
Mouse 
monoclonal 
Sigma 1:5,000 at room 
temperature for 1 
hour 
1:10,000 at room 
temperature for 1 
hour 
HSD17β1 
(ab51045) 
Rabbit 
monoclonal 
Abcam 1:2,000 at 4oC 
over night  
1:5,000 at room 
temperature for 1 
hour 
HSD17β2  
(10978-1-AP) 
Rabbit 
polyclonal 
Proteintech 1:1,000 in 1% 
milk in TBST 
incubated over 
night at 4oC 
1:2,000 in 1% 
milk in TBST at 
room temperature 
for 1 hour 
HSD17β7  
(H00051478-
M01) 
Mouse 
monoclonal 
Abnova 1:1,000 in 1% 
milk in TBST 
incubated over 
night at 4oC 
1:2,000 in 1% 
milk in TBST at 
room temperature 
for 1 hour 
HSD17β12  
(H00051144-
M08) 
Mouse 
monoclonal 
Abnova 1:1,000 in 1% 
milk in TBST 
incubated over 
night at 4oC 
1:2,000 in 1% 
milk in TBST at 
room temperature 
for 1 hour 
PAPSS1 
(ab56398) 
Mouse 
monoclonal 
Abcam 1:1000 in 10% 
milk in TBST 
incubated over 
night at 4oC 
1:1000 in TBST at 
room temperature 
for 1 hour 
PAPSS2 
(ab56393) 
Mouse 
monoclonal 
Abcam 1:1000 in 10% 
milk in TBST 
incubated over 
night at 4oC 
1:1000 in TBST at 
room temperature 
for 1 hour 
GPER 
(sc-48525-R) 
Rabbit 
polyclonal 
Santa 
Cruz™ 
1:500 in TBST in 
1%milk incubated 
overnight at 4oC 
1:2,000 in TBST 
incubated at room 
temperature for 1 
hour 
Goat anti- 
mouse 
(sc-2005) 
Polyclonal Santa 
Cruz™ 
- - 
Goat anti-
rabbit 
(sc-2004) 
Polyclonal Santa 
Cruz™ 
- - 
 
2.10 PLASMID BULK-UP 
Plasmids purchased from Origene (Origene Technologies, Inc. Rockville, USA) 
included human STS (RC210431), and empty vector control (VO, pCMV6-Neo) with 
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maps displayed in Figure 2.2. The plasmids were reconstituted in water as per 
Origene instructions; add 10 µl dH2O (creating a 1 µg/µl solution) and incubate at 
room temperature for 10 minutes, store at -20oC. 
 
 
Figure 2.2 Diagram of plasmids used for transfection into HCT116 cells. Purchased 
from Origene. (A) empty vector (VO) and (B) STS. Both plasmids when expressed 
enable resistance to G418 (neomycin). 
 
2.10.1 Bacterial Transformation  
Plasmids were diluted to a working solution of 2 ng/µl and 10 ng added to 100 µl of 
α-select competent cells silver (Bioline Reagent Ltd, London, UK). A positive control 
provided by the manufacturer was also used. The competent cells and plasmid were 
incubated on ice for 30 minutes before being heat shocked for 30 seconds at 42oC 
and then placed back on ice for 2 minutes. The competent cells and plasmid were 
then added to LB broth (Sigma-Aldrich, Poole, UK) containing 1:1000 (50 µg/µl) 
ampicillin and incubated for 1 hour at 30oC. The plasmids contained ampicillin 
resistance therefore only plasmid containing cells grew in the broth. After incubation 
cells were centrifuged for 3 minutes at 13,000 rpm and supernatant discarded. The 
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pellet was resuspended in ampicillin LB broth, spread over ampicillin (1:1000) agar 
(Sigma-Aldrich, Poole, UK) plates and incubated overnight at 37oC. Colonies were 
selected and part transferred to 2 mls of ampicillin LB broth and shaken at 37oC for 
6-8 hours. This broth cell mix was then transferred to 150 ml and shaken overnight 
to be used for maxi-prep on the following day. 
 
2.10.2 Maxi-Prep 
Maxi-prep was performed as per manufacturer instructions (Sigma-Aldrich, Poole, 
UK). The 150 ml culture (section 2.10.1) was pelleted by centrifugation at 5000 g 
for 10 minutes and resuspended in resuspension/RNAse A solution. Lysis solution 
was added and after 3-5 minutes the solution turned clear indicating the need to 
add chilled neutralising solution. The lysed cell mixture was added to binding 
solution and poured into a syringe barrel for 5 minutes. The binding column was 
prepared and lysed cells passed through the syringe into the column followed by 
centrifugation at 3000 g for 2 minutes. The columns were then washed and plasmid 
eluted with 3 mls of elution solution. Nano drop (section 2.3.3) confirmed the 
concentration and then the plasmids were prepared for sequencing. 
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2.10.3 Plasmid Sequencing 
AltaBiosciences at The University of Birmingham sequence plasmids. The following 
mix was supplied:  
 3.2 pmol primer (both forward and reverse provided by Origene) 
 200-500 ng plasmid 
 Total to 10 µl dH2O 
Sequences were confirmed using Blast®. 
 
2.11 PLASMID TRANSFECTION 
2.11.1 Concentration of Selective Medium 
The plasmids used for STS (RC210431) and VO (pCMV6-Neo) contained G418 
resistance allowing to select for plasmid containing cells only. For each cell line 
transfected the optimum concentration of G418 selective media was determined. 
Cells were seeded at 175,000 cells per well in a 6 well plate (Corning Ltd, UK) and 
treated in duplicate with G418 concentrations 0 mg/ml, 100 µg/ml, 200 µg/ml, 500 
µg/ml, 1 mg/ml or 2 mg/ml. Media was refreshed on days 3 and 6. On day 8 wells 
were examined and the lowest concentration achieving cell death deemed optimum 
concentration; Colo205 cells 200 µg/ml, Caco-2 cells 500 µg/ml and HCT116 1 
mg/ml. Only results from HCT116 cell transfection are discussed in this thesis. 
 
2.11.2 Plasmid Transfection 
Cells were seeded at a density of 250,000 per well in a 6 well plate. Plasmids (STS 
0.4 µg/µl or vector only (VO) 0.148 µg/µl) diluted in Optimem (Life Technologies, 
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Grand Island, NY, USA) were added to Lipofectamine (Invitrogen, Paisley, UK) also 
diluted in Optimem and incubated at room temperature for 5 minutes, allowing 
complexes to form. The lipofectamine-plasmid complexes were then gently dropped 
onto each well. To ensure any changes in expression were plasmid related 
Optimem and Lipofectamine only controls were performed alongside. After 24 hours 
cells from each condition (STS plasmid, VO plasmid, Lipofectamine only and 
Optimem only) were harvested for protein (section 2.2.2), RNA (section 2.3.1) and 
transferred into T25 flasks containing the appropriate concentration of G418 
selective media.  
 
2.11.3 Transfection Validation 
To confirm successful transfection and therefore overexpression of STS, real time 
PCR was performed as described in section 2.6, comparing VO, wild-type (WT) and 
STS overexpressing cells. Western blotting (section 2.9) was also performed for 
STS as the plasmids contained a DDK tag and to ensure STS was functional an 
STS activity assay (section 2.8.2). These stably transfected cells were not grown 
from a single cell and therefore were a heterogeneous population. This 
heterogeneous approach was thought to be more representative of colon tumours. 
Expression and activity of STS were monitored and declined over time despite 
selective medium. For this reason cells were only cultured for up to 15 passages 
post transfection. 
 
Chapter 2  Materials and Methods 
68 
 
2.12 MASS SPECTROMETRY EXTRACTION 
A novel uPLC-MS/MS method for quantifying both oestrogens and their sulphates 
was created with the help of Dr A. E. Taylor and optimised using Multi-objective 
Unbiased optimisation of Spectrometry via Closed Loop Experimentation 
(MUSCLE) software, developed at the University of Birmingham (Viant et al.); see 
Chapter 3 for full method including validation.  
 
2.13 HUMAN TISSUE SAMPLES AND ETHICS 
Human CRC samples with matched normal tissue control were provided by the 
Human Biomaterial Resource Centre (HBRC) and subjected to selection criteria. 
Samples were adenocarcinomas, females were post-menopausal and those with 
inflammatory bowel disease or known familial mutations were excluded. Further 
details can be seen in Appendix I and II. Colorectal tissue was collected from HBRC 
in accordance to local ethical guidelines. The HBRC is ethically approved by North 
West 5 Research Ethics Committee, Haydock Park; Ref 09/H1010/75 and 
authorised to release samples that satisfy the Access Review Panel. All 
experiments complied with the Human Tissue Act.  
 
2.14 STATISTICAL ANALYSIS 
The statistical test applied for each experimental question is stated in the relevant 
figure legend. The majority of experiments involved multiple comparisons and so 
were analysed using two-way ANOVAs with Bonferroni post-test. A p value < 0.05 
was deemed significant. Results are expressed as mean ± standard error of the 
mean unless otherwise stated.  
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For STS human data the analysis was performed in assistance with Dr Alice Sitch 
(Lecturer in Medical Statistics, University of Birmingham). Relationships between 
STS activity and STS mRNA expression were investigated by plotting the data and 
calculating correlation coefficients. Further analyses used random effects linear 
regression modelling (with outcomes transformed where appropriate to reduce the 
impact of outliers) to allow for normal and cancer samples being patient matched. 
To investigate differences in STS activity, models were fitted with and without 
adjustment for patient characteristics (sex, age and BMI) and stage (T and Dukes’). 
Results are shown as 95% confidence interval (CI) of the mean unless otherwise 
stated. STS activity model required log transformation and the estimates obtained 
are interpreted as approximate percentage differences. 
 
 
  
 
 
 
 
CHAPTER 3. DEVELOPMENT, 
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LIQUID CHROMATOGRAPHY, TANDEM 
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3.1 INTRODUCTION 
Commonly used oestrogen quantification methods include enzyme-linked 
immunosorbent assays (ELISA) and radioimmunoassay (RIA). However, mass 
spectrometry (MS) use, especially liquid chromatography-tandem MS (LC-MS/MS), 
has increased over the last two decades and this trend is expected to continue 
(Shackleton, 2010). ELISA and RIA are disadvantaged as they can only quantify a 
single compound at a time and exhibit cross-reactivity from structurally similar 
molecules and metabolites (both from an endogenous source or drugs). They can 
also lack specificity which fluctuates between kits (Krasowski et al., 2014). Large 
variations between commercially available ELISAs for three commonly studied 
steroids; testosterone, oestradiol and progesterone, can ultimately cause data 
inaccuracies between studies and centres (Soldin and Soldin, 2009). RIA has the 
additional drawback of expensive radioactive substrates, risk of user radiation 
exposure and specialist disposal requirements. 
 
Oestrogen concentration comparisons between pre and postmenopausal women 
using three methods; immunoassay, RIA and LC-MS/MS showed results were well 
correlated. However, LC-MS/MS was more accurate for lower concentrations found 
in postmenopausal women, highlighting one of the main advantages of LC-MS/MS; 
superior sensitivity (Faupel-Badger et al., 2010). MS is the solution to immunoassay 
problems as it can overcome cross reactivity and is able to quantify multiple analytes 
in a single, high throughput and sensitive assay. Therefore, LC-MS/MS was chosen 
to study oestrogen metabolism in CRC cell lines.  
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Sensitive and rapid methods were available for E1 and E2, such as a recent 
publication by Owen et al. (Owen et al., 2014) and for sulphated oestrogens, such 
as Corona et al. (Corona et al., 2010). However, few methods combined oestrogens 
and their sulphates in a single assay. No commercial LC-MS/MS kits for measuring 
oestrogens and their sulphates in a single assay were available.  
 
The aim was to quantify oestrogen metabolites in CRC cell culture medium, 
including active oestrogens E1 and E2 and their inactive sulphates E1S and E2S, 
respectively. There are differences in CRC cell line growth responses to oestrogen 
which are described in detail in Chapter 5 and 6. It was hypothesised that variable 
proliferative effects were due to disparities in oestrogen metabolism. A novel LC-
MS/MS method that rapidly quantifies these four compounds was required. For high 
quality data by LC-MS/MS, assays need validating according to industry standards 
(Taylor et al., 2015); described in this chapter in detail. 
 
3.2 MASS SPECTROMETRY PRINCIPLES 
Mass spectrometry is an analytical method used to quantify known compounds, 
identify unknown substances and provide structural and chemical information. It 
does this by separating gas phase ions according to their mass to charge ratio (m/z) 
using electrical and/or magnetic fields within a vacuum. 
 
The LC-MS/MS configuration used in these experiments was a Waters uPLC-ESI-
triple quadrupole MS. Sample components are initially separated using an ultra 
performance liquid chromatography (uPLC) column, which retains analytes based 
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on their polarity. Components are then converted to gas phase ions, such as with 
Electrospray ionisation (ESI), and enter a mass analyser. In a triple quadrupole 
configuration, gas phase ions are subsequently fragmented to achieve the 
selectivity and sensitivity required for quantitative analysis. Each ion is separated 
by mass to charge ratio (m/z) and the detector gives a signal depending on number 
of ions detected (Premier Biosoft, 2016, Chromacademy, 2016b). The main 
components of a MS are shown in Figure 3.1 
 
 
Figure 3.1 Screenshot from Waters Xevo MS with an Acquity uPLC liquid 
chromatography system Masslynx software. The main components of a MS are 
sample introduction system which maintains a vacuum, an ion source to produce 
the gaseous ions from the analyte (desolvation by ESI), analyser to resolve the ions 
according to m/z (Triple Quadrupole; MS1, collision cell and MS2), detector to 
identify the ions and record their relative abundance and a computer to manipulate 
and display the data. 
 
The quadrupole was designed by Paul and Steinwegen at Bonn University in 1953 
(Paul and Steinwedel, 1953) and is displayed in Figure 3.2. Quadrupole analysers 
use the stability of trajectories in oscillating electric fields (radio-frequency (RF) and 
direct current (DC)) to separate ions according to their m/z ratios. Ions travel along 
a central axis of four parallel circular/ hyperbolic rods. Only ions with a stable, non-
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collisional trajectory (relating to a specific m/z ratio) will be detected as all other ions 
collide with a rod and will discharge (Chromacademy, 2016a).  
 
 
Figure 3.2 Simplified diagram of a quadrupole. There are four parallel identical rods 
which form two opposing pairs. One rod pair is connected to a certain direct current 
(DC) and radio frequency (RF) and the other pair had the opposite applied creating 
an oscillating electrical field. As ions enter they oscillate; the green ion follows a 
stable trajectory and is detected and the red ion has an unstable trajectory, collides 
with a rod and so discharges and is not detected. When only RF is applied to the 
quadrupole, such as in the collision cell, all ions selected pass through it (Lundanes 
et al., 2014). 
 
A triple quadrupole MS, also known as a tandem MS, consists of three quadrupoles 
arranged in series. The first and last are transmission quadrupoles (MS1 and MS2 
in Figure 3.1) and between them is a radio-frequency (RF) only quadrupole which 
acts as a collision cell. Ions are selected by MS1, fragmented in the collision cell 
and the resultant product ions analysed by MS2 (Mallet and Down, 2010, Lundanes 
et al., 2014). Within the collision cell is inert gas (here Argon) and the energy of the 
gaseous ions can be altered to produce stable product ions fragmented from MS1 
ion selection, increasing selectivity and sensitivity. 
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3.3 MASS SPECTROMETRY ASSAY METHOD DEVELOPMENT AND 
VALIDATION   
Multiple steps are needed to develop an LC-MS/MS method, followed by validation 
to prove the method is robust and reliable. Developing a method is time consuming, 
subjective and often involves compromising on certain aspects, such as resolution 
or run time. To develop an oestrogen and oestrogen sulphate method the following 
steps were completed (National Measurement System, 2014): 
1. Determining ions for quantification: Direct infusion of E1, E2, E1S and E2S 
into the MS and ascertaining MS parameters, such as ions in positive ([M]+, 
[M+H]+, [M+adduct]+, [M-H2O]+, [M-2H2O]+), or negative ([M]-, [M+H]-, 
[M+adduct]-, [M-H2O]-, [M-2H2O]-) mode. 
2. Cone voltage: Adjusted to give maximum signal for each ion. 
3. Collision energy: Ions enter the collision cell and voltage is increased until 
stable fragments are observed. 
4. Cone voltage: Adjusted again to give maximum signal for each fragment. 
5. Determination of sensitive MRMs (Multiple reaction monitoring) for 
quantification: Each compound is run through a simple gradient and 
fragments assessed for peak area and shape. Two MRMs are used; largest 
peak area with good shape is typically used as the quantifier and lower peak 
area for qualifier.  
6. Optimising chromatography: Chromatography for combined analytes is 
optimised to achieve good sample separation using different polar/non polar 
contributions in the uPLC column (here methanol/water). This step is 
particularly time consuming, especially with large numbers of analytes. 
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7. Internal standards (IS): Representative IS are selected and for each analyte 
and steps one through five are repeated. IS are structurally similar to the 
compound being measured and a known quantity is added to every sample. 
Typically they have added deuterium or carbon 13 and should behave in the 
same manner as the target analytes. This enables a ratio of the IS and 
analyte ion abundance to be calculated aiding accuracy of quantification. 
8. Method validation: Measuring specificity, sensitivity, accuracy, precision, 
extraction efficiency/ recovery and matrix effects. This was completed for 
each analyte.  
 
Developing an LC-MS/MS method can take weeks to months. This can depend on 
how easily the compounds ionise and are fragmented into stable MRMs. 
Development of chromatography is also time consuming with multiple factors such 
as gradient, run time, column type and mobile phase choice.  
 
3.4 MUSCLE SOFTWARE 
A novel uPLC MS/MS method for all four oestrogens was developed by building 
upon a published LC-MS/MS method for E1 and E2 (Owen et al., 2014) and further 
optimised using MUSCLE (Multi-objective Unbiased Spectrometry via Closed Loop 
Experimentation) software.  
 
MUSCLE software, developed at The University of Birmingham (Bradbury et al., 
2015), is designed to reduce LC and MS method development time. It does this by 
simultaneously investigating multiple parameters and highlighting optimal solutions, 
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thus combining steps 2-6 in section 3.3 above. The MS is programmed to 
independently run multiple experiments while MUSCLE software uses a multi-
objective optimisation algorithm to maximise total peak area, total number of peaks 
and minimise run time (time of last eluting peak). The MS can be run out of hours, 
without the need for technical staff, improving efficiency and reducing costs. 
 
Parameters can be pre-selected and in addition to run time include maximal 
separation and signal intensity, methanol gradient, cone voltage, collision energy 
and column temperature. Objectives are optimised simultaneously, thus a single 
solution cannot be provided. Instead pareto-efficient solutions are displayed for the 
user to choose depending on their priorities e.g. shortest run time, best peak 
resolution or a trade-off between the two. MUSCLE software produces a graphical 
summary, allowing the analyst to quickly and efficiently review optimisation 
experiments, comparing experimental conditions (Figure 3.3). 
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Figure 3.3 Screenshots from MUSCLE software. (A) Summary of all runs performed 
by MUSCLE prioritised for run time and sensitivity (peak area). Each red dot 
represents a method run by MUSCLE and shows its corresponding run time in 
minutes (affecting throughput) on the x axis and peak area on the y axis (relating to 
sensitivity). (B) A single run is selected (cross hatch). The method parameters of a 
selected point are displayed on the right hand side, such as methanol and water % 
gradient, and can be used to further optimise a method if desired. 
Chapter 3  LC-MS/MS Method Development 
79 
 
Figure 3.4 Screenshots of runs selected by MUSCLE. (A) Four runs selected by 
MUSCLE software based on run time (in minutes) and total peak area (sensitivity). 
(B-E) Resolution (number of peaks) of four methods. 
 
For this oestrogen method, optimisation time was reduced from weeks to days with 
200 samples run by MUSCLE in 48 hours. Figure 3.4 shows the pareto-optimal 
methods recommended by MUSCLE based on run time and sensitivity. Methods 
identifying four chromatographic peaks were examined however these had poor 
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peak shape (broad with tailing) and intensity (Figure 3.4 D and E). By reviewing 
methods with shorter run times (Figure 3.4 B and C) an optimum 4 minute method 
was selected with higher peak intensity that separated E1 and E2, the sulphates co-
eluted, but could be mass separated. This method was further optimised with the 
final method rapidly analysing E1S, E2S, E1 and E2 with good sensitivity and 
resolution, separating within 5 minutes.  
 
3.5 MATERIALS AND METHODS 
E1 (Estrone), E2 (17β-Estradiol), E1S (Estrone 3-sulfate sodium), E2S (β-Estradiol 
3-sulfate sodium), internal standard 13C-E2 (17β-Estradiol-2, 3, 4-13C3) and 
ammonium fluoride were all purchased from Sigma-Aldrich, Dorset, UK. Deuterium 
labelled internal standards for oestrogen sulphates, E1S-d4 (sodium Estrone-2, 4, 
16, 16-d4 3-sulfate) and E2S-d4 (sodium 17β-Estradiol-2, 4, 16, 16-d4 3-sulfate) 
were purchased from Cambridge Isotopes Laboratories, Inc., USA. LC-MS grade 
methanol and water were purchased from Greyhound Scientific, Merseyside, UK.  
 
A Waters Xevo MS with an Acquity uPLC liquid chromatography system was used 
in these experiments and an electrospray ionisation source was employed in both 
positive and negative ionisation mode. The validated method separated oestrogens 
on an Acquity UPLC® HSS C18 SB 1.8 µm, 2.1 mm X 30 mm Column from Waters 
at 60oC using a methanol/ water gradient system with 0.3mM ammonium fluoride 
added to the aqueous phase. Initial experiments used a C18 and HSS T2 column 
with formic acid added to the mobile phase. Changing to a shorter column and use 
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of ammonium fluoride as described by Owen et al. improved E1 and E2 separation 
and doubled sensitivity (Owen et al., 2014).  
 
Steroid solutions 1 mg/ml solutions in methanol were stored for up to 3 months at -
20oC. A working solution of 1000 ng/ml in methanol was infused into the MS. The 
instrument was manually tuned to each steroid, collision and cone voltage was 
optimised and mass transitions were determined in both positive and negative 
mode. Negative mode gave higher intensity ions and thus was used for all further 
experiments (Table 3.1). A stock solution containing a mix of E1, E2, E1S and E2S 
(1000 ng/ml) was used to produce a calibration series. IS was E1S-d4, E2S-d4, 13C-
E2, E2-d4, (1000 ng/ml), 20 μl of this was added to every sample prior to extraction. 
 
Table 3.1 MRMs for oestrogens, oestrogen sulphates and internal standards 
determined in negative mode. 
Compound Abbrev. MRM transitions 
Retention 
time 
(min) 
Collision 
energy 
(eV) 
Cone 
voltage 
(V) 
Oestrone E1 
269.1 > 145.1 
2.8 
62 30 
269.1 > 183.1 62 36 
      
17β-oestradiol E2 
271.2 > 183.1 
3.07 
62 36 
271.2 > 145.1 62 30 
      
Oestrone 3-sulphate E1S 
349.1 > 269.1 
0.7 
42 32 
349.1 > 145.0 42 54 
      
β-oestradiol 3-sulphate E2S 
351.1 > 271.2 
0.74 
48 36 
   351.1 > 145.1 48 56 
      
17β-oestradiol-2, 3, 4-13C3 13C-E2 
274.2 > 148.1 
3 
92 34 
   274.2 > 160.6 62 32 
      
Oestrone-2, 4, 16, 16-d4 3-sulphate E1S-d4 
353.2 > 273.2 
0.7 
44 30 
353.2 > 147.0 44 54 
      
17β-oestradiol-2, 4, 16, 16-d4 3-sulphate E2S-d4 
 355.2 > 275.2 
35 5.2 > 147.0 
0.74 
48 
48 
30 
54 
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This method was validated following a protocol described by Honour in 2011 
(Honour, 2011). 
 
3.6 EXTRACTION OPTIMISATION 
Desirable MS methods have minimal sample preparation which reduces overall 
processing time. Two common methods for sample preparation are liquid-liquid 
extraction (LLE) or solid phase extraction (SPE). 
 
LLE is simple, rapid and has reasonable selectivity (depending on sample type). 
With aqueous samples, an addition of an immiscible organic solvent, such as methyl 
tertiary-butyl ether (MTBE), followed by mixing, partitions analytes between the two 
phases (Chromacademy, 2016c). However, this only works for hydrophobic 
analytes so could not be used to extract E1S and E2S.   
 
SPE separates compounds using a column/ solid (stationary phase) and either the 
desired or undesired components are retained on the column; if retained they can 
be eluted using a specific solvent or mixture of solvents. ISOLUTE® C18 SPE 
columns (Biotage, Sweden) were used here. These are retentive, non-polar sorbent 
suitable for a wide range of analytes from aqueous samples using a non-polar 
retention mechanism, providing hydrophobic (reversed phase) interactions 
(Biotage, 2016). In this method hydrophobic E1 and E2 and hydrophilic E1S and E2S 
were extracted simultaneously and retained on the stationary phase. Thus, SPE 
enabled both sulphated and non-sulphated oestrogens to be extracted in one step. 
SPE method steps were: 
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1. Add 20 µl of internal standard solution to 1 ml of sample 
2. Activate SPE column with 2 ml methanol 
3. Wash SPE column with 2 ml water 
4. Add sample to SPE column 
5. Add 2 ml methanol to SPE column and collect eluent in sylinised TLC tube 
6. Evaporate to dryness under nitrogen at 55oC 
7. Reconstitute in 200 µl 50/50 methanol/water prior to LC-MS/MS analysis 
 
3.6.1 Dansyl Chloride Derivatisation 
Dansyl chloride derivatisation (hydroxyl group addition increasing molecular mass 
by 234) was investigated as many have shown this improves sensitivity (Kushnir et 
al., 2010, Nelson et al., 2004). After SPE extraction dansyl chloride (1 mg/ml in 
acetone) was added to samples and heated at 60oC for 30 minutes before LC-
MS/MS analysis. Dansyl chloride was used initially, aiming to improve ionisation 
efficiencies and maximise sensitivity. However, in addition to increasing sample 
preparation time and cost, derivatisation with dansyl chloride was inconsistent 
leading to poor correlation coefficient values from calibration curves (data not 
shown). Therefore, it was not used in this method. 
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3.7 RESULTS 
3.7.1 Run Time 
The optimised method parameters are described in Table 3.2 with change in 
methanol (%B) and water with 0.3mM ammonium fluoride (%A) over time with a 
flow rate of 0.45 ml per minute. 
 
Table 3.2 Mobile phase elution gradient. Change in water with 0.3mM ammonium 
fluoride (A) and methanol (B) over time. Gradient profiles 6 represents linear 
gradient, 11 is the wash step. 
Time (min) 
Flow rate 
(ml/min) 
Mobile Phase A 
(%) 
Mobile Phase B 
(%) 
Gradient 
Initial 0.45 90 10  
2.2 0.45 50 50 6 
5.0 0.45 0 100 6 
6.5 0.45 90 10 11 
 
3.7.2 Selectivity 
Selectivity is the ability to positively identify the compound of interest relative to 
authentic reference standards.  
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Figure 3.5 Chromatogram from the optimised MUSCLE method showing time (min) 
versus relative abundance for oestrone (E1), oestradiol (E2), oestrone-sulphate 
(E1S) and oestradiol-sulphate (E2S).  E1 and E2 peaks are separated 
chromatographically. Note over column life-time there can be drift of retention times. 
 
All four analytes could be selectively quantified by mass and/or chromatographic 
separation. E1 and E2 peaks were well resolved chromatographically. E1S and E2S 
coeluted however due to unique MRMs (Table 3.1) E1S and E2S were identified and 
quantified. Figure 3.5 demonstrates a typical chromatogram. 
 
3.7.3 Calibration Curve 
By comparison to calibration curves it is possible to accurately quantify steroids 
within a sample. Thus, calibration curves should cover the expected concentration 
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range and where possible be made in the same matrix as samples. They should 
consist of a blank (no added analyte) and six to eight calibrants.  
 
Three sets of calibrations made in phenol red free cell media were extracted using 
SPE as described in section 3.6. Calibration curves for cell culture covered the 
range 0, 0.5, 1, 5, 10, 25, 50, 100, 150, 250 and 500 ng/ml for all four steroids. 
Figure 3.6 shows for each oestrogen three overlaid calibration curves and 
acceptable linear coefficient of correlation values ranging from 0.9933 to 0.9991 
(Honour, 2011).  
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Figure 3.6 Overlay of three calibration curves across the concentration range 0-500 
ng/ml for (A) oestrone, (B) oestradiol, (C) oestrone-sulphate and (D) oestradiol-
sulphate. Response is sample peak area divided by internal standard peak area. 
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The LLOQ is the lowest concentration with a peak which has a 3:1 signal to noise 
ratio and provides a reproducible concentration with a precision of 20% RSD 
(relative standard deviation, ((standard deviation/mean) x100)). LLOQ for each 
oestrogen are shown in Table 3.3. 
 
Table 3.3 Limit of detection data with signal to noise.  
Oestrogen LLOQ (ng/ml) Coefficient variant (%) Signal:Noise 
E1 5.0 16.2 183 
E2 5.0 16.5 165 
E1S 0.5 7.6 79 
E2S 0.5 8.4 59 
 
To note over the course of sample analyses there was a build-up on the cone that 
reduced MS sensitivity. By altering cone gas and angle of ESI probe the reduction 
in sensitivity was delayed. To ensure no loss of sensitivity the cone was cleaned 
after each batch, or every 50 samples. 
 
3.7.4 Accuracy and Precision 
Accuracy is a measure of how close the values obtained are to the true value. 
Acceptable variation is < 15% for mid and high calibrants and < 20% at the LLOQ. 
Accuracy was measured with six samples at low (5 ng/ml), medium (20 ng/ml) and 
high (150 ng/ml) concentration. These were extracted and variability between 
samples assessed using %RSD in instrument response (peak area) as shown in 
Table.3.4.  
 
Precision is “the closeness of multiple measurements on the same sample” (Mallet 
and Down, 2010). Acceptable variation is < 20% for LLOQ and < 15% at higher 
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levels. Precision was measured by multiple injections of the same sample with 
%RSD calculated at three concentration levels for each analyte and all fell within 
acceptable limits.  
 
Table 3.4 shows that E1S and E2S had lower precision variability across all ranges 
than E1 and E2. 
 
Table 3.4 Low (5 ng/ml), medium (20 ng/ml) and high (150 ng/ml) concentration 
accuracy and precision measured using variability over six injections. 
Compound Level Concentration 
(ng/ml) 
RSD(%) 
Accuracy Precision 
 
E1 
Low 5 11.6 16.2 
Medium 20 6.3 8.0 
High 150 4.9 6.8 
     
E2 
Low 5 3.2 16.5 
Medium 20 4.6 7.0 
High 150 11.3 6.7 
     
E1S 
Low 5 3.0 2.7 
Medium 20 5.2 2.6 
High 150 11.8 3.1 
     
E2S 
Low 5 2.9 1.1 
Medium 20 5.2 2.1 
High 150 14.5 3.8 
 
3.7.5 Recovery 
Recovery measures how efficient the extraction process is by measuring the 
detected response for the extracted analyte and internal standard compared to a 
non-extracted pure sample. It is not necessary for recovery to be 100%, but it does 
need to be reproducible with %RSD < 20%.  For this method recovery for all steroids 
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ranged from 102-105% with low variation in extraction efficiency (%RSD) across the 
concentration range (6-16%, Table 3.5). Recovery over 100% reflects the variation 
in measurements within the assay as detailed in section 3.7.4. 
 
Table 3.5 Recovery (%) for E1, E2, E1S and E2S. 
 E1 E2 E1S E2S 
10 (ng/ml) 114 124 111 108 
25 (ng/ml) 97 98 100 103 
250 (ng/ml) 96 93 95 96 
Average 102 105 102 102 
SD 10.4 16.6 7.8 6.1 
RSD (%) 10.1 15.8 7.6 6.9 
 
These concentrations were representative of expected values within cell culture 
experiments. 
 
3.7.6 Matrix Effects 
Matrix effects are any influence exerted by components of the analyte containing 
solution which affects the signal, in this case cell media. The presence of other 
substances within media which elute off the column at the same time as each steroid 
could potentially interfere with the ionisation process of the analytes leading to ion-
suppression or enhancement.  
 
There are various methods that can minimise interference from co-eluting matrix 
compounds, however there is no standardised strategy for reducing effects and 
several methods may have to be employed (Trufelli et al., 2011): 
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 Sample preparation can reduce potential interfering compounds with SPE 
reported to be the most efficient way of overcoming matrix effects. 
 Chromatographic conditions can be modified to shift retention times of target 
analytes away from interfering matrix compound. 
 IS can compensate for signal alteration. 
 Potentially use an alternative ionisation source, or ionisation mode which 
may be less sensitive to matrix effects. 
 
 
Figure 3.7 No matrix effects. (A) E1, (B) E2, (C) E1S and (D) E2S by injection of water 
(below) or extracted cell culture medium (above) and continuous post-column 
infusion of 1000 ng/ml of E1, E2, E1S and E2S. (A) The peak at 2.8 min represents 
E1 in the medium sample (B) The peak at 3.07 min is E2. (C) The peak at 0.7 min is 
E1S. (D) The peak at 0.74 is E2S. There was no loss or enhancement of signal due 
to components within the matrix.  
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Matrix effects were assessed for each of the four oestrogens using the post column 
infusion method (Taylor, 2005). This is a qualitative assessment whereby each 
individual analyte (1000 ng/ml for each steroid) is constantly infused, followed by 
injection of an extracted blank sample (cell culture medium). Variation in signal 
response of the steroid by co-elution of interfering compounds would indicate 
ionisation suppression or enhancement. Figure 3.7 demonstrates no matrix effects 
as there is no peak/trough at retention time of analytes. The top graphs represent 
cell culture medium injection with peaks corresponding to each steroid from post 
column infusion and the bottom graphs are baseline. In graph A there is a peak at 
3.5 min within the matrix. However, as it has a different retention time this is not an 
issue. Although in graphs B-D second plots look to have high peaks, the abundance 
is low with signal < 50 whereas in the top graphs signals are x 104 or higher. 
Therefore the signals observed at baseline are not interfering components within 
the matrix. 
 
3.8 DISCUSSION 
Costs of using MS are falling along with improved sensitivity whilst maintaining 
specificity and multi-analyte capability (Handelsman and Wartofsky, 2013). 
However, LC-MS/MS remains expensive and still requires specialist knowledge, 
therefore alternative methods such as immunoassay and RIA are still commonly 
used (Krasowski et al., 2014). This may change as a leading journal, The Journal 
of Clinical Endocrinology and Metabolism, has strongly suggested that manuscripts 
reporting sex steroid assays as important endpoints should always use MS-based 
assays (Handelsman and Wartofsky, 2013).  However, the use of “well validated 
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assays” is still acceptable in most studies considering that an immediate change to 
LC-MS/MS was unrealistic for many groups (Taylor et al., 2015). 
 
This LC-MS/MS method is high throughput, quantifying E1, E2, E1S and E2S from 
the same extract in less than 5 minutes. Oestrogen sulphates are not routinely 
measured despite their significant role as an active oestrogen reservoir (Reed et al., 
2005). Analysing both conjugated and unconjugated steroids is more challenging 
with many methods opting to quantifying them by dividing extracted samples and 
performing two separate LC-MS/MS analyses. This can involve both positive and 
negative ion modes, different ionisation techniques and changing columns (Galuska 
et al., 2013). This is good for improving sensitivity, but increases sample preparation 
time and costs, reducing sample throughput. This method has been fully validated 
to industry standards. LLOQ was 5 ng/ml for E1 and E2 and 0.5 ng/ml for E1S and 
E2S which was acceptable for cell culture experimental models. Owing to instrument 
limitations these are too high to measure oestrogens in male and postmenopausal 
female serum as their concentrations are low (Handelsman and Wartofsky, 2013, 
Huhtaniemi et al., 2012, Lee et al., 2006, Mayo Clinic, 2015). E1 reference ranges 
in adult males and postmenopausal females are similar at 10-40 pg/ml and 0-40 
pg/ml, respectively. E2 ranges are 10-40 pg/ml for adult males and < 10 pg/ml for 
postmenopausal females (Staros, 2015, Mayo Clinic, 2015). Increasing starting 
sample volume would increase final concentration of the sample to be injected and 
so on the column, which could improve sensitivity, but could also potentially 
increase matrix effects. Additionally, a newer MS, such as the Waters Xevo TQ-S,  
could achieve limits of detection in the pmol/l range as demonstrated by Owen et 
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al. 2014 (Owen et al., 2014) and so potentially could be applied to lower 
concentration samples such as serum. 
 
A major asset for this method development was use of MUSCLE software, vastly 
increasing the speed and optimisation process. The main advantage of MUSCLE 
over other programs was the ability to modify and optimise multiple parameters 
simultaneously. Additionally, MUSCLE, free to download, controlled the LC-MS/MS 
system and thus was set up to perform overnight and at weekends, maximising 
productivity whilst reducing cost. Overall MUSCLE reduced optimisation time from 
weeks to days. 
 
This method was applied to CRC HCT116, Colo205, HT29 and Caco-2 cell lines as 
described in Chapter 5. 
 
3.9 CONCLUSION 
A novel high- throughput LC-MS/MS method validated to industry standards 
capable of quantifying E1, E2, E1S and E2S simultaneously in cell culture media was 
achieved. The optimised extraction and mass spectrometry method allows 
investigation of oestrogen metabolism in CRC cell lines. In future, expansions of 
this method to include other oestrogen metabolites would be beneficial to further 
elucidate oestrogen metabolism in CRC and other malignancies. 
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4.1 INTRODUCTION 
Cancer is a heterogeneous disease and classification using stage, grade and cell 
type, although helpful, does not tailor patient specific treatment and prognosis. 
Therefore, there are patients who receive unnecessary treatments and side effects 
with disease recurrence (section 1.2.5). Detailed tumour characterisation opens up 
the potential for disease classification, targeted treatment and personalised 
medicine limiting these unnecessary and undesirable side effects.  
 
The associations between oestrogens and CRC risk have been suggested for a 
number of decades. Nuns are nulliparous women with uninterrupted menstrual 
cycles and so have a higher lifetime exposure to oestrogen. They have a greater 
risk of CRC and breast cancer (Fraumeni et al., 1969) and women with higher 
circulating oestrogens are also at increased risk (Clendenen et al., 2009). Tumour 
oestrogen metabolism research has shown that increased desulphation (STS) and 
decreased sulphation (SULT1E1) enzyme expression with higher tumoural 
oestrogen concentrations reduce CRC survival (Sato et al., 2009). Also, oxidative 
pathways (HSD17β2 and 4) are reduced in CRC potentially increasing the more 
potent E2 (English et al., 2000). Thus, tumour oestrogen metabolism enzyme 
expression and activity offer a credible CRC subclassification as well as treatment 
targets. No research group has yet looked at the pathway as a whole and with no 
hormonal treatments currently in use for CRC this is an area that needs further 
exploration. 
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Here oestrogen metabolism is examined in human CRC tissue with matched normal 
colon controls. The focus is on the enzymes within the sulphatase pathway that lead 
to E2 generation from circulating E1S. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Human Tissue 
Selected tissue from HBRC (section 2.13) were all CRC adenocarcinomas and 
either male or post-menopausal females with no known risk factors such as genetic 
family history or IBD. Table 4.1 shows a summary of basic characteristics with 
further detail in Appendices I. These were matched normal and cancerous colon 
tissue from the same patient. 
 
Table 4.1 Human colorectal tissue samples disease stage and average ages. 
Further details in Appendices I. 
 Stage 1 Stage 2 Stage 3 Stage 4 Total Age 
Female 6 13 10 2 31 71 (55-87) 
Male 5 10 17 0 32 73 (50-90) 
Total 11 23 27 2 63 72 (50-90) 
 
4.2.2 RNA extraction, cDNA synthesis and Real Time PCR 
Human tissue RNA extraction followed by cDNA synthesis and cDNA quantification 
using Picogreen assay were performed as described in section 2.3 to 2.5. Real-time 
PCR was used to quantify mRNA expression for key oestrogen metabolism 
enzymes as described in section 2.6 using the primers and probes for HSD17β1, 
HSD17β2, HSD17β7, HSD17β12, STS, PAPSS1, PAPSS2 and internal standard 
gene RPLPO (Table 2.2). Validations of duplex reactions and choice of internal 
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standard are shown in Appendix II. SULT1E1 was not validated in either singleplex 
or duplex as shown in Appendix II and so mRNA expression could not be assessed.  
 
4.2.3 Protein Extraction and Quantification 
Human tissue protein was extracted using RIPA buffer and protein quantified using 
BCA assay as described in section 2.2. 
 
4.2.4 Western Blotting 
Western blotting was implemented as per procedure described in section 2.9. 
Primary and secondary antibodies were optimised and included HSD17β1, 2, 12, 
PAPSS1 and PAPSS2 with β-actin as loading control (Table 2.3). Despite extensive 
optimisation the commercial SULT1E1 and STS antibodies were not consistent and 
so the data was discarded. 
 
4.2.5 STS Activity Assay 
STS activity assay on human tissue was performed as described in section 2.8 
using protein lysate. 
 
4.3 RESULTS 
4.3.1 Oxidative HSD17β2 Expression 
HSD17β2 enzyme oxidises E2 to E1, reducing oestrogen’s efficacy on ERs. 
HSD17β2 mRNA expression was detected in colon tissue with expression reduced 
in CRC (p < 0.01). When separated by gender HSD17β2 mRNA expression was 
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reduced in both females and males (p < 0.05, (Figure 4.1). This may change the E1 
and E2 ratio, leading to an increase in the more potent oestrogen E2 in CRC.  
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HSD17β2 mRNA 
Expression (dCt) 
All  
(n = 44) 
Female  
(n = 19) 
Male  
(n = 25) 
Normal 4.15 [3.33,4.96] 2.99 [2.06,3.92] 5.02 [3.84,6.21] 
Cancer 6.33 [5.27,7.39] 5.25 [3.66,6.84] 7.15 [5.71,8.58] 
 
Figure 4.1 HSD17β2 mRNA expression is reduced in human colorectal cancer. 
HSD17β2 mRNA expression in human colorectal cancer compared to matched 
normal tissue (arbitrary units (AU)) (error bars are SEM). Mean dCt values and 95% 
CI displayed in brackets in the table below. HSD17β2 mRNA expression reduced 
overall in colorectal cancer (**p < 0.01) and in females and males (*p < 0.05). 
Normal and cancer samples were matched and analysed using two-way ANOVA 
with Bonferroni post-test. 
 
CRC HSD17β2 protein expression as determined by Western blot did not 
correspond with mRNA data.  HSD17β2 mRNA was consistently reduced in CRC 
(Figure 4.1) however protein expression was less consistent in both male and 
female samples (Figure 4.2). In many patients there even appeared to be an 
increase rather than decrease in expression. 
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Figure 4.2 Western blot of HSD17β2 expression in matched colorectal cancer 
tissue. Western blots of HSD17β2 in female (A and B) and male (C and D) colorectal 
normal (N) and tumour (T) matched tissue with Caco-2 cells used as positive control 
(+). No consistent change in protein expression of HSD17β2 between normal and 
cancerous colon tissue was seen. β-actin was used as loading control and 25 μg 
protein was loaded into each well, except positive control which was 15 μg. 
 
4.3.2 Reductive HSD17β Expression  
4.3.2.1 HSD17β1 Expression 
HSD17β1 expression was examined in a selection of matched (CRC and normal 
tissue from same patient) human samples including seven female and six males. 
However, HSD17β1 mRNA was not detected in any samples. Western blots on six 
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of these tissues (three females and three males, Figure 4.3) showed no protein 
detection in normal or cancerous colon, but can clearly be seen to be expressed in 
the positive control JEG3 placental cell line. 
 
 
Figure 4.3 HSD17β1 is not expressed in the colon. Western blot for HSD17β1 with 
JEG3 cells used as positive control (+). (A) Three female CRC (T) tissue samples 
with matched normal (N) tissue. (B) Three male samples. No HSD17β1 protein was 
detected in normal or cancerous colon tissue of both genders. β-actin was used as 
loading control with 25 μg protein loaded into each well, except positive control, 
which was 15 μg. 
 
4.3.2.2 HSD17β7 mRNA Expression  
Figure 4.4 shows mRNA expression of enzyme HSD17β7 in paired human CRC 
and normal tissue. HSD17β7 was identified in the colon and more highly expressed 
in CRC independent of sex. HSD17β7 was higher in females than males in normal 
and cancerous colon tissue.  
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HSD17β7 mRNA 
Expression (dCt) 
All  
(n = 41) 
Female  
(n = 21) 
Male  
(n = 20) 
Normal 8.56 [7.88,9.23] 7.81 [6.86,8.76] 9.34 [8.42,10.26] 
Cancer 7.23 [6.86,7.59] 6.56 [6.18,6.93]  7.93 [7.42,8.43] 
 
Figure 4.4 HSD17β7 mRNA is increased in colorectal cancer. HSD17β7 mRNA 
expression in human colorectal cancer compared to matched normal tissue 
expressed in arbitrary units (AU) (error bars are SEM). Mean dCt values and 95% 
CI displayed in brackets in the table below. HSD17β7 was expressed in both normal 
and cancerous colon tissue with higher mRNA expression in colorectal cancer (***p 
< 0.001) in both females and males (*p < 0.05). Females have higher expression 
than males in both normal (**p < 0.01) and cancerous (*p < 0.05) colon. Normal and 
cancer samples were matched and analysed using two-way ANOVA with Bonferroni 
post-test.  
 
Immunoblot with HSD17β7 bands at correct sizing was not possible and so protein 
expression was not assessed (see example in Figure 5.4). 
 
4.3.2.3 HSD17β12 mRNA Expression 
HSD17β12 was expressed in both heathy and cancerous colon tissue (Figure 4.5). 
HSD17β12 enzyme was more highly expressed in CRC in both males and females. 
Males also had higher normal HSD17β12 expression than females.  
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HSD17β12 mRNA 
Expression (dCt) 
All  
(n = 40) 
Female  
(n = 21) 
Male  
(n = 19) 
Normal 4.39 [3.84,4.95] 4.99 [4.26,5.73] 3.73 [2.94,4.53] 
Cancer 2.76 [2.41,3.12] 3.06 [2.60,3.52] 2.44 [1.88,2.99] 
 
Figure 4.5 HSD17β12 mRNA is increased in colorectal cancer. HSD17β12 mRNA 
expression in human colorectal cancer compared to matched normal tissue 
expressed in arbitrary units (AU) (error bars are SEM). Mean dCt values and 95% 
CI displayed in brackets in the table below. HSD17β12 is higher in colorectal cancer 
tissue compared to matched normal control (***p < 0.001) in both females (***p < 
0.001) and males (**p < 0.01). Females have lower expression than males in normal 
colon tissue (*p < 0.05). Normal and cancer samples were matched and analysed 
using two-way ANOVA with Bonferroni post-test.  
 
HSD17β12 Westerns for females and males are shown in Figure 4.6 and as with 
HSD17β2, protein expression did not match mRNA expression and was not 
detected in all samples. 
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Figure 4.6 Western blot of HSD17β12 expression in matched colorectal cancer 
tissue. Female (A-C) and male (D-F) HSD17β12 Western blot of human colorectal 
cancer tissue (T) with matched normal (N) and HCT116 cells as positive control (+). 
β-actin is used as loading control and 25 μg of colon tissue protein was loaded into 
each well and 15 µg of HCT116 protein. 
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4.3.3 PAPPS1 and PAPSS2 Expression  
There was no validated SULT1E1 mRNA primer and probe or consistent 
commercial antibody for protein detection thus expression could not be determined. 
Attempts were made to develop a SULT1E1 activity assay in extracted protein. 
However, problems arose with PAPS purity and it was hypothesised that the RIPA 
buffer used may have affected SULT1E1 structure and function.  
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PAPSS1 mRNA 
Expression (dCt) 
All  
(n = 42) 
Female  
(n = 19) 
Male  
(n = 23) 
Normal 9.89 [8.85,10.92] 8.73 [7.04,10.41] 10.84 [9.60,12.09] 
Cancer 8.79 [8.16,9.42] 7.91 [6.96,8.86] 9.51 [8.73,10.28] 
 
Figure 4.7 PAPPS1 mRNA expression in matched colorectal cancer tissue. 
PAPPS1 mRNA expression in human colorectal cancer compared to matched 
normal tissue (arbitrary units (AU)) (error bars are SEM). Mean dCt values and 95% 
CI displayed in brackets in the table below. PAPPS1 was detected in both normal 
and cancerous colon tissue. There was large expression variability with significant 
increases in male CRC (*p < 0.05) and expression in normal female colon was 
higher than normal male colon (*p < 0.05). Normal and cancer samples were 
matched and analysed using two-way ANOVA with Bonferroni post-test. 
 
PAPSS is required to generate the universal sulphate donor (PAPS) for SULT1E1 
action and impacts on SULT1E1 regulation (section 1.6.2). Therefore, PAPSS 
expression was investigated as a possible marker of sulphation activity within CRC. 
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PAPSS1 and 2 expression were explored, though it should be noted they are not a 
validated substitute for measurement of SULT1E1. PAPSS1 (Figure 4.7) mRNA 
was statistically different in CRC in all samples and males. However, the actual 
difference was small questioning the physiological impact.  
 
PAPSS2 mRNA expression appeared to be reduced in CRC however this trend was 
not significant (Figure 4.8).  
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PAPSS2 mRNA 
Expression (dCt) 
All  
(n = 44) 
Female  
(n = 20) 
Male  
(n = 24) 
Normal 9.34 [8.46,10.23] 8.93 [7.49,10.37] 9.69 [8.52,10.87] 
Cancer 9.30 [8.57,10.04] 9.41 [8.22,10.60] 9.21 [8.22,10.20]  
 
Figure 4.8 PAPPS2 mRNA expression in matched colorectal cancer tissue. 
PAPPS2 mRNA expression in human colorectal cancer compared to matched 
normal tissue (arbitrary units (AU)) (error bars are SEM). Mean dCt values and 95% 
CI displayed in brackets in the table below. PAPPS2 was detected in both normal 
and cancerous colon tissue however there were no significant differences between 
normal tissue and cancerous tissue. 
 
 
PAPSS1 and PAPSS2 protein expression was assessed by WB and samples 
followed similar trends to their mRNA expression (Figure 4.9). 
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Figure 4.9 Western blot of PAPSS1 and 2 expression in colorectal cancer tissue (T) 
with matched normal (N) and HT29 cells used as positive control (+). β-actin is used 
as loading control and 25 μg of colon tissue protein was loaded into each well and 
15 µg of HT29 protein. Western blot of PAPSS1 female (A), male (B) and PAPSS2 
female (C) and male (D) protein expression. 
 
4.3.4 STS Expression and Activity  
STS mRNA expression was identified in the colon however no significant changes 
in expression were observed between normal and cancerous matched colon tissue 
in either males or females (Figure 4.10). 
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STS mRNA 
Expression 
(dCt) 
All  
(n = 45) 
Female  
(n = 20) 
Male  
(n = 25) 
Normal 11.51 [10.57,12.45] 11.09 [9.53,12.65] 11.85 [10.62,13.09] 
Cancer 11.24 [10.50,11.98] 10.71 [9.67,11.75] 11.67 [10.60,12.74] 
 
Figure 4.10 STS mRNA expression is unchanged in colorectal cancer. STS mRNA 
expression in human colorectal cancer compared to matched normal tissue 
(arbitrary units (AU)) (error bars are SEM). Mean dCt values and 95% CI displayed 
in brackets in the table below. STS was detected in both normal and cancerous 
colon tissue. There were no significant differences between normal tissue and 
cancerous tissue expression in either males or females. 
 
STS mRNA could not be compared to STS protein expression using Western 
blotting as no consistent commercial antibody was available. This was despite 
optimisation attempts using antibodies from different manufacturers (Abcam, 
Abnova). STS can undergo post-translational modification, impacting on activity. 
Therefore, mRNA and protein expression may not necessarily coincide with activity 
(section 1.5.1). STS activity measured using a reliable 3HE1S assay was the 
preferred method to quantify functional differences in STS in CRC. Figure 4.11 
demonstrates a significant increase in STS activity in CRC compared to normal 
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matched controls. This shows the disparity in expression and activity and highlights 
why multiple analysis methods are required before conclusions can be made.  
N T N T N T
-2
-1
0
1
2
All Female Male
*
*** **
T
ra
n
s
fo
rm
e
d
 L
o
g
 S
T
S
 A
c
ti
vi
ty
 
E1S to E1 
(nmol/mg/hr) 
All  
(n = 61) 
Female  
(n = 29) 
Male  
(n = 32) 
Normal 1.30 [1.20,1.40] 1.35 [1.20, 1.51] 1.25 [1.11,1.39] 
Cancer 1.56 [1.36, 1.75] 1.72 [1.37,2.07] 1.42 [1.22,1.62] 
 
Figure 4.11 STS activity is increased in colorectal cancer. Homogenised human 
colorectal tissue was subjected to 3HE1S assay and conversion to E1 measured in 
nmol/mg/hour with mean and 95% CI displayed in brackets in the table. As STS 
activity was not normally distributed, further analyses used random effects linear 
regression modelling (with outcomes transformed where appropriate to reduce the 
impact of outliers) to allow for normal and cancer samples being patient matched. 
Results were further log transformed and the estimates obtained are interpreted as 
approximate percentage differences. STS activity was increased in colorectal 
cancer in both females and males. Two-tailed paired t-test, * p < 0.05, ** p < 0.01, 
*** p < 0.001, error bars are SD. 
 
4.3.4.1 STS Activity, HSD17β and PAPSS Expression Correlations 
Changes seen in CRC included decreased HSD17β2, increased HSD17β7 and 12 
and increased STS activity with no changes in STS mRNA. To assess if any 
changes in CRC were likely to occur together correlations between these enzymes 
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were examined. HSD17β7 and 12 perform the same reductive E1 to E2 function and 
mRNA expression for both was increased in CRC. When HSD17β7 was plotted 
against HSD17β712 it can be seen that mRNA expression correlated in normal but 
not in cancerous tissue (Figure 4.12 (C)). Therefore, in cancer both do not increase 
simultaneously. HSD17β2 mRNA is decreased in CRC and was plotted against 
HSD17β7 and 12 mRNA. These also did not correlate in either normal or cancerous 
colon tissue (Figure 4.12 (A and B)). STS mRNA expression was unchanged 
between normal and cancerous colon however STS activity was found to be 
increased. It was therefore hypothesised that due to post-translational modifications 
there would be no correlation between STS mRNA expression and STS activity. 
Figure 4.12 (H) shows no correlation between mRNA and activity for STS in either 
normal or cancerous colonic tissue. STS action can lead to generation of active 
oestrogens through desulphation and has been shown to be involved in feedback 
mechanisms to regulate oestrogen concentrations within tissues. HSD17β enzymes 
affect the potency of local oestrogens and may also be subject to feedback loops 
and so correlations were investigated between STS activity and each of the 
HSD17β enzymes. However no correlations were identified (Figure 4.12 (D to F)). 
PAPSS1 and 2 mRNA were also compared to see if there was any correlation 
between expression in normal and cancerous colon tissue. In normal healthy colon 
PAPSS1 and 2 expression did correlate (p = 0.03) however this was not the case in 
CRC (Figure 4.12 (G)). Taken together there were no correlations in normal or 
cancerous colon between these oestrogen enzymes. 
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Figure 4.12 No correlations between CRC oestrogen enzymes. HSD17β7 (A) and 
12 (B) mRNA plotted against HSD17β2 mRNA. Expression did not correlate in 
either normal or cancerous colon tissue (n = 28 and 26, respectively). (C) HSD17β7 
and 12 mRNA. Expression correlated in normal (R2 = 0.161, *p = 0.01) but not in 
cancerous colon tissue (R2 = 0.002, p = 0.79) (n = 38). Log STS activity was 
compared to HSD17β2 (D), HSD17β7 (E) and HSD17β12 (F) but no correlation was 
seen. (G) PAPSS1 and PAPSS2 mRNA. Expression correlated in normal (R2 = 
0.0997, *p = 0.03) but not in cancerous colon tissue (R2 = 0.02768, p = 0.12). (H) 
STS activity did not correlate with STS expression (dCT) in normal or cancerous 
colon tissue. 
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As mRNA expression of oxidative HSD17β2 was decreased and reductive 
HSD17β7 and 12 were increased, changes in the ratio of the mRNA of these 
enzymes was assessed. Although there appeared to be an increase in the ratio of 
reductive/ oxidative mRNA, this was not significant (Figure 4.13). 
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Figure 4.13 Ratio of HSD17β7:HSD17β2 and HSD17β12:HSD17β2 mRNA 
expression changes in colorectal cancer. (A) HSD17β7 and (B) HSD17β12 over 
HSD17β2 mRNA (arbitrary unites (AU) on log scale, error bars are SEM).  
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4.3.5 HSD17β Expression and STS Activity by Disease Stage 
To assess if HSD17β2, HSD17β7 and 12 mRNA and STS activity in CRC were 
related to TNM stage patients were divided into two groups; TNM stage I and II, or 
III and IV. 
 
4.3.5.1 HSD17β2 
Later stage disease was associated with lower expression of HSD17β2 mRNA in 
both males and females however this trend was not significant (Figure 4.14).  
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HSD17β2 mRNA 
Expression (dCt) 
All Female Male 
Stage I/II 5.36 [3.82,6.90] 4.31 [2.19,6.42] 6.57 [4.39, 8.74] 
Stage III/IV 6.88 [5.42,8.33] 6.55 [3.84,9.26] 7.08 [5.10,9.06] 
 
Figure 4.14 HSD17β2 mRNA expression is reduced in later stage colorectal cancer. 
HSD17β2 mRNA expression (arbitrary units (AU)) (error bars are SEM). Mean dCt 
values and 95% CI displayed in brackets in the table below for CRC TNM stage. 
Expression is lower in latter colorectal cancer disease stage; however this trend was 
not significant. Stage I/II n = 11 for females and n = 11 males. Stage III/IV n = 8 for 
females and n = 13 for males. 
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4.3.5.2 HSD17β7  
HSD17β7 mRNA expression in all CRC patients appeared similar in earlier and later 
disease stage. However, when divided into gender males had increased HSD17β7 
in stage III/IV compared to stage I/II (Figure 4.15). 
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HSD17β7 mRNA 
Expression (dCt) 
All Female Male 
Stage I/II 7.19 [6.63,7.75]  6.34 [5.92,6.76]  8.62 [8.10,9.13]  
Stage III/IV  7.35 [6.87,7.83]  7.32 [6.54,8.11]  7.36 [6.67,8.06]  
 
Figure 4.15 HSD17β7 mRNA expression is different in males and females in later 
stages of colorectal cancer. HSD17β7 mRNA expression (arbitrary units (AU)) (error 
bars are SEM). Mean dCt values and 95% CI displayed in brackets in the table 
below for CRC TNM stage. Expression was increased in males in later stage 
disease (*p < 0.05). Two-way ANOVA with Bonferroni post-test analysis. Stage I/II 
n = 15 for females and n = 9 males. Stage III/IV n = 5 for females and n = 11 for 
males. 
 
4.3.5.3 HSD17β12 
HSD17β12 mRNA expression was unchanged across CRC disease stages. This 
enzyme also showed some gender disparity with HSD17β12 reduced in later 
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disease stages for females and increased in males (Figure 4.16), though this did 
not reach significance.  
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HSD17β12 mRNA 
Expression (dCt) 
All Female Male 
Stage I/II 2.94 [2.40,3.48]  2.91 [2.27,3.55]  2.99 [1.76,4.21]  
Stage III/IV 2.51 [1.99,3.03]  3.37 [2.33, 4.42]  2.04 [1.58,2.49]  
 
Figure 4.16 HSD17β12 mRNA expression is similar across colorectal cancer 
disease stages in males and females. HSD17β12 mRNA expression (arbitrary units 
(AU)) (error bars are SEM). Mean dCt values and 95% CI displayed in brackets in 
the table below for CRC TNM stage. Stage I/II n = 13 for females and n = 8 males. 
Stage III/IV n = 6 for females and n = 11 for males. 
 
4.3.5.4 STS 
The relationship between CRC TNM stage and STS activity was also explored and 
results displayed in Figure 4.17. There were no significant differences between the 
groups.  
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All Female Male 
Stage I/II 1.61 [1.35,1.87]  1.69 [1.27,2.11]  1.52 [1.18,1.85]  
Stage III/IV 1.58 [1.26,1.91]  1.87 [1.13,2.60]  1.40 [1.10,1.67]  
 
Figure 4.17 STS activity is similar across colorectal cancer disease stages in males 
and females. As STS activity was not normally distributed, further analyses used 
random effects linear regression modelling (with outcomes transformed where 
appropriate to reduce the impact of outliers) to allow for normal and cancer samples 
being patient matched. Results were further log transformed and the estimates 
obtained are interpreted as approximate percentage differences. Error bars are 
SEM. The table below shows the mean STS activity (E1S to E1) in nmol/mg/hr for 
CRC TNM stage with 95% CI in brackets. Stage I/II n = 15 for females and n = 13 
males. Stage III/IV n = 10 for females and n = 15 for males. 
 
4.4 DISCUSSION 
4.4.1 Oestrogen Oxidoreductive Pathways in Colorectal Cancer 
Here HSD17β1, 2, 7 and 12 have been examined in human CRC. There is a 
reduction in HSD17β2 mRNA expression suggesting E2 to E1 oxidation is down-
regulated in CRC (Figure 4.1). Normal female colon tissue had higher HSD17β2 
mRNA expression compared to normal male tissue, though this was not statistically 
significant. It is well documented that many females experience bowel changes 
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during their menstrual cycle with oestrogen frequently causing constipation 
(Bernstein et al., 2014, Oh et al., 2013). Gender differences may be due to a higher 
lifetime exposure to circulating oestrogen concentrations in women compared to 
men. The colon may have higher oxidative capacity to reduce oestrogen potency in 
an attempt to maintain homeostasis. These changes may then continue to persist 
after the menopause. Oxidoreductive pathways have previously been examined in 
CRC (English et al., 2001) and this data supports published findings of decreased 
HSD17β2 expression in CRC. However, here the dataset is larger and shows novel 
gender disparities. 
 
Ratios of HSD17β7 and 12 to HSD17β2 mRNA showed a shift towards reductive 
HSD17β expression, though this was not significant (Figure 4.13). Additionally, this 
was mRNA only and may not relate to activity of these enzymes. In addition to 
measuring activity it would be beneficial to expand mRNA and protein expression 
of this sample set to include other HSD17β types that may alter E1/E2 metabolism. 
HSD17β4 is potentially able to oxidise E2 to E1 but in vivo evidence suggests its 
main role is in peroxisomal fatty acid β-oxidation (Breitling et al., 2001, Qin et al., 
1997, Day et al., 2008b) with only a minor role in steroid metabolism (Miettinen et 
al., 1999).  Nevertheless, HSD17β4 has also been shown to be down-regulated in 
CRC (English et al., 2000). Thus, a collective decrease in E2 oxidation via HSD17β2, 
4 would potentially increase the ratio of E2 to E1 in CRC. There is also evidence that 
HSD17β8 inactivates E2 however it also has reductive activity (Fomitcheva et al., 
1998). HSD17β8 is located in mitochondria and suspected to have a larger role in 
fatty acid metabolism (Chen et al., 2009) thus the role in steroidogenesis is currently 
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unclear.  A proteomic study did find HSD17β8 to be increased in late stage CRC 
(Luque-García et al., 2010), but due to its dual activity it is unclear what effect this 
would have on the E1/E2 ratio. 
 
HSD17β2 protein expression as assessed semi-quantitatively by Western blot did 
not follow the same expression pattern as mRNA. Protein was detected in the 
majority of samples tested (Figure 4.2), but some CRC samples had increased and 
others decreased HSD17β2 compared to matched normal tissue. This is in keeping 
with published data (English et al., 2000). It is not unusual to find discrepancies 
between mRNA and protein; mRNA is not a surrogate for corresponding protein 
levels or activity without further verification (Kendrick, 2014). There are many 
biological and technical factors as to why this occurs such as translation efficiency 
and protein half-life, additionally post-translational modifications and co-factor 
availability are important for enzymatic activity (Guo et al., 2008, Maier et al., 2009). 
In breast cancer cell lines activity assays of HSD17β1 and 2 have shown high 
association with mRNA expression (Day et al., 2006). Additionally, colon oxidative 
enzymatic activity has been shown to more closely follow mRNA expression; 
healthy colon favours E2 to E1 metabolism which was reduced in CRC (English et 
al., 2000). Unfortunately without activity data it is not possible to conclude that 
HSD17β2 activity is reduced in CRC.  
 
HSD17β1 is the principal enzyme for E1 to E2 conversion (Martel et al., 1992, 
Peltoketo et al., 1996) and is found in hormonal and reproductive tissues such as 
breast, endometrium and cervix (Setiawan et al., 2004, Tomaszewska et al., 2015). 
Chapter 4  Human Colon Characterisation 
118 
 
Reductive activity of E1 to E2 has previously been measured in the colon (English et 
al., 1999). Some papers have noted HSD17β1 expression in the colon with lower 
expression in CRC (Rawluszko et al., 2011). However, mRNA and protein 
expression were not detected in the present study (Figure 4.3). Alternative E1 to E2 
HSD17β enzymes that may be expressed in the colon were explored including 
HSD17β7 and 12 (Torn et al., 2003).  Here detection of HSD17β7 and 12 is shown 
for the first time in the normal and cancerous colon (Figure 4.4 to Figure 4.6). 
Additionally, mRNA was increased in CRC for both enzymes. HSD17β12 was 
detected using WB, but as with HSD17β2 did not follow the same pattern as mRNA. 
HSD17β7 mRNA expression was lower than HSD17β12 and not detected by WB. 
It is possible that HSD17β7 protein is not expressed in the colon, or alternatively the 
problems with detection could be antibody related or due to the protein extraction 
method used i.e. RIPA buffer.  
 
At the time of this thesis methods pertaining to HSD17β enzyme activity in fresh or 
homogenised human colon tissue were not available to confirm E2/E1 ratio changes 
suggested by mRNA expression. Although there were clear oxidoreductive HSD17β 
enzymes mRNA changes in CRC, protein expression was highly variable and 
unfortunately it was impossible to deduce enzyme activity from current available 
data.  
 
4.4.2 Sulphatase Pathway in Colorectal Cancer 
STS mRNA, protein and activity have been shown to increase in many hormonal 
cancers such as breast and prostate (Reed et al., 2005, McNamara et al., 2013). 
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Previously STS upregulation and SULT1E1 downregulation in the colon has been 
associated with a poorer prognosis and the reverse was also shown; low STS and 
high SULT1E1 correlated with improved survival (Sato et al., 2009). Here the 
dataset was smaller but also identified STS mRNA in the colon but with no change 
in expression in CRC compared to matched normal tissue (Figure 4.10). STS 
protein would have been assessed using WB but there was no usable commercial 
WB antibody, however post-translational modification of the STS enzyme can 
significantly alter activity (section 1.5.1). Thus, protein quantification would not 
accurately determine functional desulphation changes in CRC and consequential 
oestrogen activation. Instead STS activity was measured using 3HE1S. STS activity 
was increased in CRC (Figure 4.11) supporting previous research (Sato et al., 
2009). As mRNA had remained unchanged in CRC it was unsurprising that STS 
mRNA and activity did not correlate (Figure 4.12 (H)). Therefore, factors other than 
increased transcription or E1S availability must affect STS activity in CRC. For 
example as discussed in section 1.5.1 the STS enzyme can undergo post-
translational glycosylation impacting on activity (Stengel et al., 2008). Additionally, 
C75 to FGly occurs at the active site and is regulated by SUMF1 and 2 availability 
(Thomas and Potter, 2013, Schmidt et al., 1995). 
 
4.4.3 SULT1E1 and PAPSS in Colorectal Cancer 
A limitation of this study was the inability to measure SULT1E1 either mRNA, protein 
or activity. Despite careful optimisation, real time primers and probes could not be 
validated and Western Blots revealed no consistent bands. As PAPS is a universal 
sulphate donor and can affect SULT1E1 activity (section 1.6.2) PAPSS1 and 
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PAPSS2 expression was explored. Changes in PAPSS may have a knock-on effect 
with SULT1E1 but are not a validated substitute or indirect measurement. PAPSS1 
was significantly increased in male CRC compared to matched normal tissue 
(Figure 4.7) and WB followed mRNA expression (Figure 4.9). However, the actual 
increase was small so the physiological impact is unclear.  
 
4.4.4 Oestrogen Enzyme Correlations 
The pattern emerging from mRNA and STS activity data implied in human CRC 
there was an increase in active E2 synthesis compared to normal colon; reduced 
HSD17β2, increased HSD17β7 and 12 and increased STS activity. To assess if 
there was a relationship between these changes correlations were explored. There 
were positive correlations in normal colon between HSD17β7 and 12 and PAPSS1 
and PAPSS2 (Figure 4.12 (C and G, respectively)) but none were found in CRC. 
This suggests that whereas these enzymes are regulated and subject to feedback 
mechanisms under normal healthy conditions this is not the case in CRC where 
dysregulation occurs. It also implies that in CRC expression of HSD17β and activity 
of STS are not co-ordinated and so patients may present with a mix of enzyme 
changes. This would fit with CRC being a heterogeneous disease. Thus, if these 
pathways were to be targeted therapeutically it would be essential to determine 
which patients would benefit from which treatment e.g. STS inhibitors and/or 
HSD17β inhibitors, to avoid unnecessary side-effects.  
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4.4.5 Colorectal Cancer Stage and Oestrogen Metabolism 
There was no change in STS activity across CRC disease stage (Stage I and II 
versus III and IV) suggesting that higher activity is not associated with advanced 
CRC (Figure 4.17) and instead may be an earlier stage event. It is not clear where 
it would sit in the accruing mutation hypothesis (Fearon and Vogelstein, 1990). STS 
can be regulated by inflammatory modulators such as TNFα and IL-6. Pre-
cancerous adenomas are associated with inflammation (Bilinski et al., 2012) and 
through increased STS activity could lead to an early local active oestrogen 
concentration rise. Additionally, this STS pathway may also be active in IBD, 
particularly when severe or poorly controlled. Disease severity is linked with higher 
risk of CRC (Barral et al., 2015), whether STS activity contributes to this is currently 
unknown. Additionally, the menstrual cycle and oestrogen use such as 
contraceptives can affect IBD symptoms; some women have worsening symptoms 
and others improved (Nee and Feuerstein, 2015). The sulphatase pathway may 
also be inhibited by anti-inflammatories, reducing CRC risk (Smalley and DuBois, 
1997). TNFα and IL-6 regulation of STS is discussed in Chapter 7. 
 
Decrease in HSD17β2 mRNA in CRC appeared to occur more commonly in latter 
stage disease (Figure 4.14) however, this trend was not significant. Increased 
HSD17β12 expression also did not change across disease stages (Figure 4.16). 
HSD17β7 however was increased in males at more advanced CRC (Figure 4.15). 
HSD17β12 showed a similar trend but was not significant. This emphasises the 
gender disparities in CRC and the importance of stratification of disease to deliver 
personalised medicine. 
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4.4.6 Summary of Human Colorectal Cancer Oestrogen Enzyme Changes 
Figure 4.18 shows the summary of changes in CRC in the entire dataset. These 
data suggest that STS activity is frequently raised in CRC and as an early event if 
STS activity is found to be linked with tumour proliferation it would be an attractive 
treatment target for all cancer stages. HSD17β2 mRNA is often downregulated at 
latter disease stages and HSD17β7 and 12 mRNA are increased in CRC. Therefore, 
if E2 increases CRC proliferation HSD17β7 and 12 are also potential treatment 
targets. Although both males and females followed the same trends in oestrogen 
enzyme expression/ activity overall there were gender differences within CRC 
disease staging. In later stages HSD17β7 mRNA was lower in female disease but 
higher in males and a similar pattern was seen for HSD17β12 mRNA. This may 
reflect some of the differences in survival between men and women. 
 
 
Figure 4.18 Summary of oestrogen metabolism changes in colorectal cancer. In 
colorectal cancer there was increased STS activity, increased HSD17β7 and 12 and 
reduced HSD17β2 mRNA. 
 
Evidence suggests that higher STS expression reduces survival (Sato et al., 2009) 
implying active oestrogens are detrimental in CRC. However, Oduwole showed that 
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reduced HSD17β2 and potentially higher E2/E1 ratio was associated with improved 
prognosis in females (Oduwole et al., 2003). This is contradicted by English and 
colleagues, where E2 was suggested to be the ‘bad’ oestrogen and E1 ‘good’. 
However, rather than the direct effect of oestrogens the improved survival witnessed 
by Oduwole et al. may instead reflect more on the tumour’s response to therapy. 
Oestrogen responsive tumours might be associated with less aggressive, lower 
grade tumours and more sensitive to current chemotherapeutics. Further studies 
would be needed to investigate this. These conflicting results may also be because 
in each of these studies only part of the oestrogen metabolism pathway was 
examined and results were not categorised by gender. It is necessary to evaluate 
the entire oestrogen pathway as changes depend on gender and disease stage. It 
is not clear how these oestrogen metabolism changes influence prognosis and 
recurrence, but this would be an interesting advancement of this thesis.   
 
4.5 CONCLUSION 
In human CRC there is a frequent rise in STS activity, reduction in HSD17β2 mRNA 
expression and increase in HSD17β7 and 12 mRNA expression. Increased 
desulphation via STS would increase E1 concentrations locally as E1S circulates at 
high concentrations. Combined with a loss of HSD17β2 and increased HSD17β7 
and 12 there may be a shift in the E2/E1 ratio in favour of E2.  E2 could then bind to 
ERs with greater affinity, potentiating oestrogen action in CRC.  
  
 
 
 
 
 
CHAPTER 5. COLORECTAL CELL LINE 
CHARACTERISATION AND 
PROLIFERATION  
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5.1 INTRODUCTION 
To examine CRC behaviour in vitro there are multiple immortalised cell lines. By 
characterising matched human CRC tissue (Chapter 4) and CRC cell lines 
important commonalities between them should be ascertained, increasing 
understanding of CRC behaviour and aiding identification of potential therapeutics. 
However, there are published inconsistencies for CRC cell line oestrogen 
proliferation responses in vitro such as E2 both inhibiting (Hsu et al., 2014) and 
stimulating (Santolla et al., 2012) LoVo cells. E2 also increased proliferation in Caco-
2 cells (Di Domenico et al., 1996) whereas E1 decreased proliferation in SW620 
cells (English et al., 1999). Thus, CRC cell lines respond differently to oestrogens 
and are hypothesised to have variable oestrogen enzyme profiles, possibly 
reflecting subtypes of colorectal adenocarcinomas. Currently it is unclear how 
oestrogen is metabolised, how it exerts its effects in the colon and if it is beneficial 
or unfavourable in colon carcinogenesis. The aim of this chapter was to characterise 
oestrogen metabolism in commonly used CRC cell lines and assess how oestrogen 
impacts on their proliferation.  
 
5.2 MATERIALS AND METHODS 
5.2.1 Cell Culture 
Cells selected were cultured as described in section 2.1. These CRC cell lines are 
all adenocarcinomas and originate from both men and women (Table 2.1). Two 
breast cancer cell lines (MCF7 and MDA-MB-231) and a placental cell line (JEG3) 
were chosen to use as positive controls for mRNA and protein expression. 
Additionally, protein from HEK (human embryonic kidney) cells overexpressing 
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PAPSS1 or PAPSS2 was kindly donated from Dr. Jan Idkowiak (University of 
Birmingham) and used as positive control for WB. 
 
FBS is usually added to cell culture medium however it contains oestrogens (Dang 
and Lowik, 2005, Aakvaag et al., 1990). Phenol red, a cell media constituent is 
commonly used as a media pH indicator and also binds to ERs (Berthois et al., 
1986). To enable accurate oestrogen proliferation responses cells were cultured 72 
hours prior to experiments in charcoal stripped FBS (SFBS, Sigma-Aldrich, Dorset, 
UK) phenol red free media. Dextran treated charcoal selectively removes hormones 
including steroids such as oestrogens ensuring only oestrogens added to the media 
are responsible for the effects seen. To note other components are depleted in 
SFBS including vitamins, thyroid hormones and electrolytes (Cao et al., 2009). 
 
5.2.2 RNA Extraction, cDNA Synthesis and Real Time PCR 
Cell line RNA extraction followed by cDNA synthesis and cDNA quantification using 
Picogreen assay were performed as described in section 2.3 to 2.5. Real-time PCR 
was used to quantify mRNA expression for key oestrogen metabolism enzymes as 
described in section 2.6 using the primers and probes for HSD17β1, HSD17β2, 
HSD17β7, HSD17β12, STS, PAPSS1, PAPSS2 and internal standard gene RPLPO 
(Table 2.2). Validations of duplex reactions and choice of internal standard are 
shown in Appendix II. SULT1E1 was not able to be validated in either singleplex or 
duplex as shown in Appendix II and so mRNA expression could not be assessed.  
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5.2.3 Protein Extraction and Quantification 
Cell line protein was extracted using RIPA buffer and protein quantified using BCA 
assay as described in section 2.2. 
 
5.2.4 Proliferation Assay 
Proliferation was assessed using CyQUANT or BrdU as described in section 2.7. 
The method used is stated for each experiment. Cells were treated with E1, E2, E1S 
or E2S in SFBS phenol red free media across 0-500 nM range for 48 hours with 
media refreshed daily to maintain oestrogen concentrations. 
 
5.2.5 Western Blotting 
Western blotting was implemented as per procedure described in section 2.9. 
Primary and secondary antibodies were optimised and included HSD17β1, 2, 12, 
PAPSS1 and PAPSS2 with β-actin as loading control (Table 2.3). SULT1E1 and 
STS antibody were not assessed as previously described as there were no 
consistent commercial antibodies. 
 
5.2.6 STS Activity Assay 
STS activity assay was performed as described in section 2.8 with 100,000 cells 
seeded per well of a 6 well plate. Cells were also treated with STX64 (1 µM), a 
selective, potent, irreversible and non-toxic STS inhibitor (Malini et al., 2000, 
Stanway et al., 2006). 
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5.2.7 Stable Overexpressing STS HCT116 Cells 
HCT116 cell lines overexpressing STS (HCT116STS) or VO (HCT116VO) were 
developed as described in sections 2.10 and 2.11. STS and VO plasmids contained 
G418 resistance to select out transfected cells (Figure 2.2) however G418 was not 
used during experimental conditions owing to potential off-target effects.  
 
5.2.8 LC-MS/MS Method 
Cells were seeded at 250,000 per well into 6 well plates. Once the cells were 
adhered the media was removed and cells washed twice with PBS. Cells were then 
treated with SFBS phenol red free media containing E1 100 nmol/l, E2 100 nmol/l or 
E1S 500 nmol/l for 24 hours. Media was collected and frozen at -20oC until extraction 
and analysis using LC-MS/MS as described in Chapter 3. Cell protein was also 
harvested with concentration determined by BCA assay (section 2.2).  
 
5.3 RESULTS 
5.3.1 Colorectal Cell Line Characterisation 
5.3.1.1 Oxidative HSD17β2 Expression 
HSD17β2 mRNA expression was detected in three of the four CRC cell lines 
examined. HCT116 cells did not express HSD17β2 mRNA and Colo205 cells had 
the highest mRNA expression (Figure 5.1). Protein expression as determined by 
WB (Figure 5.2) revealed HSD17β2 protein did not correlate with mRNA detection 
of HSD17β2 in all cell lines. Colo205 had the lowest protein expression and HCT116 
did express HSD17β2. 
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Cell Line HCT116 Colo205 HT29 Caco-2 
dCt ± SEM 18.64 ± 0.66 1.78 ± 1.03 3.74 ± 0.43 4.19 ± 0.18 
 
Figure 5.1 HSD17β2 mRNA expression in colorectal cancer cells. HSD17β2 mRNA 
expression (arbitrary units (AU)) in Colo205, HT29 and Caco-2 (n = 3) cells, but not 
seen in HCT116 (n = 2) cells. The table below shows dCt values ± SEM.  
 
 
Figure 5.2 Protein expression of HSD17β2 in colorectal cancer cells does not follow 
same pattern as mRNA. Western blot of HSD17β2 in colorectal cancer cell lines 
HCT116, Colo205, HT29 and Caco-2. Breast cancer cell lines MCF7 and MDA-MB-
231 were used as controls. β- actin was used as loading control with 15 μg protein 
loaded into each well 
 
5.3.1.2 Reductive HSD17β Expression  
CRC cell lines had either very low or no HSD17β1 mRNA and protein expression 
(data not shown) which was consistent with human colon tissue (Chapter 4). Thus, 
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any E1 reductive activity would be via an alternative enzyme such as HSD17β7 or 
12.  
 
HSD17β7 and 12 mRNA were expressed in CRC cells as shown in Figure 5.3. As 
in human colon tissue (section 4.3.2) HSD17β12 was more highly expressed than 
HSD17β7 in all CRC cells tested. 
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Cell Line HCT116 HT29 Caco-2 
HSD17β7 11.61 ± 0.28 11.65 ± 0.51 9.98 ± 0.37 
HSD17β12   9.15 ± 0.34   7.77 ± 0.13 7.45 ± 0.30 
 
Figure 5.3 HSD17β12 mRNA expression is higher than HSD17β7 in colorectal 
cancer cell lines. HSD17β7 and 12 mRNA expression in untreated colorectal cancer 
cell lines expressed in arbitrary units (AU) (n = 3). The table below shows dCt values 
± SEM. *** p < 0.001, two-way ANOVA with Bonferroni post-test. 
 
HSD17β7 protein was not clearly detected by Western blot in any CRC or breast 
cancer cell lines despite strategic optimisation and technical assistance from 
company manufacturer. Figure 5.4 shows a typical immunoblot with no bands at 
predicted size.  
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Figure 5.4 HSD17β7 protein expression in colorectal cancer cells. Western blot of 
HSD17β7 in breast cancer cell lines MCF7 and MDAMB231 and colorectal cancer 
cell lines HCT116, Colo205, HT29 and Caco-2. β-actin is used as loading control 
and 15 μg of protein was loaded into each well. Note no bands appeared at the 
predicted size of 32-37 kDa. 
 
As with colon tissue HSD17β12 mRNA and protein did not correlate. Protein was 
expressed in HCT116 and HT29 cells with low expression in Caco-2 whereas Caco-
2 had the highest mRNA expression of these cell lines (Figure 5.5).  
 
Figure 5.5 Protein expression of HSD17β12 in colorectal cancer cells does not 
follow same pattern as mRNA.  Western blot of HSD17β12 in breast cancer cell 
lines MCF7 and MDAMB231 and colorectal cancer cell lines HCT116, Colo205, 
HT29 and Caco-2. β-actin is used as loading control and 15 μg of protein was loaded 
into each well. 
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5.3.1.3 PAPSS1 and PAPSS2 
SULT1E1 could not be examined in cell lines so PAPSS was used as a surrogate 
marker for sulphation activity (also see section 4.3.3). All cell lines expressed 
PAPSS1 mRNA and PAPSS1 was more highly expressed than PAPSS2 in Colo205 
and Caco-2 cells (Figure 5.6). Protein expression as assessed by WB showed 
similar findings to mRNA with PAPSS1 clearly expressed in all cell lines. PAPSS2 
was not present in Colo205 cells and had only minimal detection in Caco-2 cells 
(Figure 5.7). 
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Cell Line HCT116 Colo205 HT29 Caco-2 
PAPSS1 5.32 ± 0.64  5.66 ± 0.93 6.66 ± 1.30 4.78 ± 1.55 
PAPSS2 8.86 ± 0.50 14.79 ± 0.63 6.02 ± 0.07 11.59 ± 1.88 
  
Figure 5.6 PAPSS1 mRNA expression is higher than PAPSS2 in colorectal cancer 
cell lines. PAPSS1 and PAPSS2 mRNA expression (arbitrary units (AU)) in 
HCT116, Colo205, HT29 and Caco-2 cells (n = 3-4). The table below shows dCt 
values ± SEM. PAPSS1 expression was significantly higher than PAPSS2 in 
Colo205 and Caco-2 cells (**p < 0.01, ***p < 0.001, two-way ANOVA with Bonferroni 
post-test). 
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Figure 5.7 PAPSS1 and PAPSS2 protein expression in colorectal cancer cell lines. 
Western blot of PAPSS1 and PAPSS2 expression in CRC cancer cells. (A) PAPSS1 
is expressed in all CRC cells tested and breast cancer cell lines MCF7 and 
MDAMB231 with HEK cells overexpressing PAPSS1 used as positive control and 
β-actin as loading control. (B) PAPSS2 is expressed in HT29 and HCT116 cells but 
not in Colo205 or Caco-2 cells. There is some expression in breast cancer cell lines 
MCF7 and MDAMB231. HEK cells overexpressing PAPSS2 were used as positive 
control and β-actin as loading control. 
 
5.3.1.4 STS Expression and Activity in Colorectal Cancer Cell Lines 
STS mRNA was expressed in all CRC cell lines with highest expression in Colo205 
cells, though this was not statistically significant (Figure 5.8).  
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Cell Line HCT116 Colo205 HT29 Caco-2 
dCt ± SEM 11.27 ± 1.74  7.56 ± 1.68  8.03 ± 1.56  7.79 ± 0.74  
 
Figure 5.8 STS mRNA in CRC cell lines. STS mRNA expression (arbitrary units 
(AU)) in HCT116 (n = 4), Colo205 (n = 6), HT29 (n = 3) and Caco-2 (n = 9) cells. All 
CRC cell lines expressed STS mRNA with the highest expression found in Colo205 
cells. The table below shows dCt values ± SEM.  
 
 
STS activity varied across the CRC cell lines and did not follow the same pattern as 
STS mRNA. Highest activity was seen in Caco-2 cells whereas it was Colo205 cells 
that had the most abundant mRNA. When treated with STS inhibitor, STX64, STS 
activity reduced (Figure 5.9). 
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Figure 5.9 STS activity is highest in Caco-2 cells. STS activity in CRC cells lines 
measured using 3HE1S assay with Jeg3 cells as a positive control. Caco-2 cells have 
the highest activity of CRC cells tested. When cells were treated with potent STS 
inhibitor, STX64 (1 µM), activity was inhibited (n = 3). *** p < 0.001, two-way ANOVA 
with Bonferroni post- test. 
 
5.3.2 Generation of Stable STS Overexpression in HCT116 cells 
Human CRC had increased STS activity compared to normal colon tissue (section 
4.2.5). Previously, STS expression has been linked with tumoural oestrogen 
concentrations and survival (Sato et al., 2009). To explore if STS influences 
proliferation in CRC HCT116 cells were transfected to stably overexpress STS. 
These cells were chosen as they had the lowest STS expression and activity of the 
CRC cell lines and so an effect on proliferation would be more easily identifiable.  
 
Wild-type HCT116 cells (HCT116WT) and HCT116VO cells have low STS mRNA 
expression and when transfected with STS plasmid (HCT116STS) expression 
increased (Figure 5.10 (A)). Transfected STS plasmid was functional as activity 
increased from 5.42 ± 0.85 pmol/mg/hr in HCT116VO cells to 85.35 ± 7.35 
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pmol/mg/hr in HCT116STS cells (Figure 5.10 (B)). To ensure transfection was 
maintained STS activity was periodically monitored and remained stable for up to 
15 passages (data not shown). 
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Figure 5.10 Stable overexpression of STS in HCT116 cells. (A) Transfection of STS 
into HCT116 cells increased STS mRNA expression (one-way ANOVA with 
Bonferroni post-test). (B) STS activity increase in HCT116STS cells compared to 
HCT116VO (n = 3) and inhibition by STS inhibitor, STX64 (1 µM) (two-way ANOVA 
with Bonferroni post-test. Wild-type (WT), vector only (VO), over expression of 
steroid sulphatase (STS). ***p < 0.001. 
 
Proliferation of HCT116STS and HCT116VO cultured in complete media was 
measured using CyQUANT assay. HCT116STS cells proliferated more than 
HCT116VO cells and this was attenuated by STS inhibitor STX64 (Figure 5.11). This 
experiment lasted 5 days and supports previous studies showing STX64 is non-
toxic (Stanway et al., 2006). 
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Figure 5.11 HCT116STS cells proliferate faster than HCT116VO. Growth of HCT116 
cells overexpressing STS or VO in complete media over 4 days expressed as mean 
± SD. HCT116STS cells have an increased proliferation rate which is reduced by 
STS inhibitor, STX64 (1 µM) (n = 3). Two-way ANOVA, **p < 0.01, ***p < 0.001. 
 
5.3.3 STS Overexpression Increases Proliferation in HCT116 Cells 
Stable HCT116STS cells proliferated more than WT and VO HCT116 cell types in 
complete media. To assess if STS increased proliferation without oestrogen in the 
media SFBS was used and proliferation measured by BrdU assay. HCT116STS cells 
proliferated more than HCT116WT or HCT116VO in SFBS media and this effect was 
abolished by STX64. Growth was greater in all HCT116 cell types treated with E2S 
(100 nmol/l) but more pronounced in HCT116STS cells. E2S growth effect was also 
abrogated in all cell types by STX64 (Figure 5.12). 
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Figure 5.12 HCT116STS cells have increased proliferation with oestradiol sulphate 
treatment compared to HCT116VO. Proliferation measured using BrdU incorporation 
assay. Cells were treated for 48 hours with E2S (100 nmol/l) and/or STX64 (1 µM) 
and compared to SFBS HCT116VO. HCT116STS cells had increased proliferation 
(**p < 0.01) inhibited by STS inhibitor (STX64, **p < 0.01). E2S increased 
proliferation in all cells (***p < 0.001) with highest rates in HCT116STS cells (***p < 
0.001). The increase in proliferation due to E2S was inhibited by STX64 (***p < 
0.001). Two-way ANOVA with Bonferroni post-test. These experiments were 
performed with intercalating medical student Habibur Rahman. 
 
5.3.4 Oestrogen Stimulates Proliferation in HCT116 and HT29 Cells  
E2S increased proliferation in HCT116WT cells despite low STS activity. Therefore, 
only small oestrogen changes may be required to have an effect on colon growth. 
The effect of active oestrogen (E1 and E2) bypassing the need for STS and inactive 
oestrogen (E1S) requiring STS action on proliferation in CRC cell lines HCT116, 
HT29 and Caco-2 cells was assessed and they had different responses.  
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Figure 5.13 Oestrogen increases proliferation in HCT116 and HT29 cells but not 
Caco-2 cells. HT29, HCT116 and Caco-2 cells cultured in SFBS for 72 hours were 
treated with E1, E2 or E1S 0.01-500 nmol/l for 48 hours. Proliferation was measured 
using BrdU assay. HT29 (A) and HCT116 (B) proliferated in a dose dependent 
manner in response to treatment, whereas Caco-2 growth (C) remained static (n = 
3). D-F show proliferation as percentage change from SFBS controls; note the 
slower growth rate of Caco-2 cells and the lack of proliferative response to E1 (D) 
and E2 (E). HCT116 and HT29 also proliferated in response to E1S (F). Experiments 
performed in conjunction with intercalating medical student Habibur Rahman.Two-
way ANOVA with Bonferroni post-test *p < 0.05, **p < 0.01, ***p < 0.001.     
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HT29 cells have low STS activity and proliferation increased with all oestrogen 
treatments in a dose dependent manner with E2 having the greatest effect (Figure 
5.13 (A)). HCT116 cells ((Figure 5.13 (B)) had a similar response to HT29 cells. 
Significant growth responses in HT29 and HCT116 cells occurred at 0.1 and 1 
nmol/l respectively. EC50 values for HT29 cells were 2.5, 1.4 and 5.3 nmol/l for E1, 
E2 and E1S, respectively. EC50 for HCT116 cells were 4.8, 2.4 and 16.2 nmol/l for 
E1, E2 and E1S, respectively. Oestrogen had no impact on Caco-2 cell growth 
((Figure 5.13 (C)). Oestrogen proliferation responses for these cell lines were 
compared using percent change from SFBS for E1 ((Figure 5.13 (D)), E2 ((Figure 
5.13 (E)) and E1S ((Figure 5.13 (F)). 
 
5.3.5 Oestrogen Metabolism in CRC Cell Lines 
As HCT116 and HT29 had similar proliferation responses to oestrogen (Figure 5.13) 
it was predicted that they metabolised oestrogen similarly. As Caco-2 cells did not 
proliferate in oestrogen media it was hypothesised they metabolised oestrogen 
differently to HCT116 and HT29 cells. HCT116, HT29 and Caco-2 cell metabolism 
of E1, E2 and E1S was assessed using extracted media collected from oestrogen 
treated cells and analysed by LC-MS/MS. Due to LLOQ and LLOD on the LC-
MS/MS method concentrations below 14 nmol/l for E1 and E2 and 18 nmol/l for E1S 
and E2S could not be determined. The percentage of E1, E2 and E1S remaining in 
cell media after 24 hours of treatment in HCT116, HT29 and Caco-2 cells is shown 
in Figure 5.14 (A).  
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Figure 5.14 Colorectal cancer cell lines do not metabolise oestrogen equally. (A) 
HCT116, Caco-2 and HT29 cells were treated with E1, E2 (100 nmol/l) E1S (500 
nmol/l) or SFBS for 24 hours and media collected for LC-MS/MS analysis. The 
percentage change in media of E1, E2 or E1S concentration was calculated in 
comparison to non-metabolised 100% solution (stock). The remaining E1, E2 or E1S 
in cell media (%) is displayed. After 24 hours of treatment, Caco-2 cell media 
appeared to have less E2 than starting stock concentration and HT29 cell media 
appeared to have less E1 and E2 compared to stock concentration. (B) Caco-2 cells 
were treated with E2 for 24 hours and cell media subjected to LC-MS/MS analysis. 
E1, E2, E1S and E2S were quantified with concentrations of E1 and E2 in stock 
solution and Caco-2 cell media displayed. E2 Stock had some E1 contamination. 
After 24 hours Caco-2 cell media had less E2 and more E1 than original stock 
treatment, suggesting oxidative activity. Two-way ANOVA with Bonferroni post-test 
*p < 0.05, **p < 0.01, ***p < 0.001, n=3.     
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HCT116 cells had minimal changes in E1 and E2 concentration and Caco-2 cells 
seemed to metabolise E2 but not E1. HT29 cells appeared to metabolise E1 and E2. 
Neither cell line metabolised E1S. 
 
HT29 cells metabolism of E1 and E2 were to steroids uncharacterised in these 
experiments as there was no increase in the oestrogens detectable by this LC-
MS/MS method (E1, E2, E1S and E2S). However, Caco-2 cells metabolised E2 to E1 
(Figure 5.14 (B)). E2 treatment solution (stock) consisted mainly of E2 with minor E1 
contamination and Caco-2 cell media collected 24 hours after E2 treatment is 
comprised mainly of E1 with low E2 concentration. Thus, Caco-2 cells oxidised the 
majority of E2 to E1 implying HSD17β2 activity. 
 
5.4 DISCUSSION 
5.4.1 Colorectal Cancer Cell Line Comparison to Colon Tissue 
There were some similarities between these authenticated CRC cell lines and the 
human colon cancer tissue samples in Chapter 4. HSD17β1 mRNA was not 
detected in colon tissue or CRC cell lines. As an alternative, enzymes HSD17β7 
and 12 mRNA were explored and as with colon tissue were shown here for the first 
time in CRC cell lines. Additionally, HSD17β12 mRNA was more highly expressed 
than HSD17β7 in colon tissue and CRC cell lines (Figure 5.3). Mirroring human 
samples HSD17β2 and 12 mRNA did not match protein expression on Western blot. 
For example, Caco-2 cells had the highest HSD17β12 mRNA expression but the 
lowest protein expression on WB (Figure 5.5). HSD17β2 mRNA was not detected 
in HCT116 cells (Figure 5.1) but protein was detected by WB. Colo205 cells had the 
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highest expression of HSD17β2 mRNA at a similar expression level to healthy 
human colon tissue.  
 
These cells all expressed STS mRNA and had STS activity. HCT116 displayed the 
lowest STS activity of 1.66 ± 0.14 pmol/mg/hr and Caco-2 cells the highest at 165.48 
± 28.51 pmol/mg/hr. However, STS activity was not as high as in colon tissue 
(normal 1.30 [1.20,1.40] nmol/mg/hr and cancer 1.56 [1.36,1.75] nmol/mg/hr). It 
should be noted though that colon tissue was a lysate whereas CRC cell lines in 
these experiments were intact and so direct comparison is not possible. Not being 
able to measure STS protein by WB due to poor antibody did not limit this study as 
STS function through an activity assay gave more reliable data.  
 
The large variability seen with this small selection of commonly used CRC cell lines 
shows the difficulty in applying in vitro findings to in vivo situations. Although, there 
are similarities between these cells and human colon tissue, no cell line reflected 
what was measured in human CRC. Human CRC is heterogeneous, influenced by 
genetics and environment, with one therapy unlikely to apply to all. Unlike 
immortalised CRC cell lines, homogenised human tissue is not a pure cell 
population and in addition to colon cells may contain other cell types such as from 
inflammatory infiltrate. Medicine is becoming more personalised; however 
individualised therapy is, at least currently, impractical and too expensive especially 
for NHS services. If large CRC subtype groups that predict response to therapy can 
be identified, for example through oestrogen enzyme expression, patients can be 
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stratified by disease type allowing for tailored treatment whilst crucially remaining 
affordable.  
 
5.4.2 Proliferative Effect of Oestrogen in the Colon 
HCT116 and HT29 both proliferated in response to E1, E2 and E1S in a dose 
dependent manner. Conversely, Caco-2 cell growth remained static (Figure 5.13). 
This is different to published findings whereby Caco-2 cells proliferated in response 
to E2, but not E1 (Di Domenico et al., 1996). These discrepancies may be due to 
method differences. Here these authenticated cell lines were treated with higher 
oestrogen concentrations; 1-500 nmol/l compared to 0.5-10 nmol/l of E2. Also, 
Domenico and colleagues measured proliferation using cell counting rather than a 
BrdU colourimetric assay which have different sensitivities. Here BrdU assay was 
performed with six replicates with cells seeded after counting using a 
haemocytometer to maximise seeding uniformity.  
 
These three CRC cell lines had differing responses to oestrogen demonstrating 
CRC heterogeneity and the potential importance of individualised medicine 
stratification. It was predicted that oestrogen proliferation differences were due to 
how oestrogen was metabolised. E1S and E1 have low affinity for ERs (Zhu et al., 
2006) and therefore it is unlikely to be their direct action increasing proliferation in 
HCT116 and HT29 cells. Despite HCT116 and HT29 displaying similar proliferative 
responses, oestrogen metabolism varied across all three CRC cell lines (Figure 
5.14). With the LC-MS/MS method limitations of LLOQ and LLOD meant E1 and E2 
were unquantifiable below 14 nmol/l. Therefore low level oxidation and reduction 
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could not be determined (Chapter 3). However, HCT116 cells had minimal 
oestrogen metabolism, whereas HT29 cells appeared to metabolise both E1 and E2 
to metabolites not detectable by this LC-MS/MS method. Thus, despite similar 
proliferative responses to oestrogen HCT116 and HT29 cells have very different 
oestrogen profiles and so activated receptors and down-stream signalling may also 
differ. It would be beneficial to extend this LC-MS/MS method to include additional 
oestrogen metabolites such as 2-methoxy-estradiol and oestriol to understand 
further how oestrogen is metabolised. 
 
Caco-2 cells oxidised the majority of E2 to the much less potent E1 (Figure 5.14), 
implying they had HSD17β2 activity and agreeing with the HSD17β2 mRNA 
expression data (Figure 5.1 and Figure 5.2). E1 binds to ERα with 10% affinity of E2, 
2% for ERβ (Zhu et al., 2006) and just 0.1% for GPER (Thomas et al., 2005). 
Reduction of oestrogen potency may explain why in this study proliferation was 
unchanged in Caco-2 cells. E1 to E2 metabolism was not demonstrated in any of 
these cell lines but may occur at concentrations lower than detectable by this LC-
MS/MS method.  
 
Caco-2 cells have the highest STS activity of these three cell lines and HCT116 
cells the least (Figure 5.9). E1S has negligible binding affinity for ERα or ERβ (Zhu 
et al., 2006) however the sulphate group is unstable. This is partly counteracted by 
the addition of Tris stabiliser but the sulphate group can still dissociate and thus 
become E1 without the need for STS action. To minimise this effect media was 
refreshed daily and E1S stored at -20oC. However, this cannot fully explain how E1S 
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increased proliferation in HCT116 and HT29 cells as LC-MS/MS analysis showed 
no sulphate loss. The maintained E1S concentration may instead be through 
SULT1E1 activity or there may be desulphation activity below limits of detection of 
this method with only very low concentrations of E2 required to increase growth. 
These CRC cell lines did express PAPSS which is required for sulphation action. 
They all had higher PAPSS1 than PAPSS2 expression both in mRNA and protein 
(Figure 5.6 and Figure 5.7). However, despite multiple attempts and optimisation it 
was unfortunate and limiting not to be able to asses SULT1E1 mRNA, protein or 
activity in these cell lines. 
 
HCT116 cells were transfected to stably overexpress STS as they had the least 
baseline activity. Predictably this resulted in increased STS mRNA expression and 
activity (Figure 5.10) that remained for at least 15 passages. Raising desulphation 
ability increased proliferation of HCT116 cells in both complete and starved media 
(Figure 5.11 and 5.12) which was abrogated by the potent STS inhibitor STX64 
(Figure 5.11). As STS increased proliferation in oestrogen stripped SFBS media this 
suggests that the effect is not just active oestrogen related. To assess if driving 
oestrogen desulphation also increased proliferation all HCT116 cell types were 
treated with E2S. This required only one enzyme step to procure potent E2 and not 
rely on additional HSD17β action. E2S increased growth in all HCT116 cell types 
but more so in overexpressing STS cells. This effect was inhibited by STX64 
implying desulphation of E2S to E2 via STS action also increases HCT116 cell 
growth and is not off target plasmid effect. 
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In these authenticated cell lines ERα and ERβ were not detected by Western blot 
in HCT116 or HT29s and only low expression in Caco-2s (Appendix III). Some 
groups have shown ERβ expression in HCT116 (Fiorelli et al., 1999) Caco-2 and 
HT29 cells (Campbell-Thompson et al., 2001). Additionally, studies have shown that 
in CRC cell lines E2 induces apoptosis. This is thought to be through ERβ action 
(Qiu et al., 2002, Fiorelli et al., 1999). It is currently unclear how oestrogen acts to 
induce proliferation in the HCT116 and HT29 cells used in this thesis as they do not 
express ERs. As an alternative how oestrogen increases proliferation through 
GPER is explored in Chapter 6. 
 
5.5 CONCLUSION 
CRC cell lines have some oestrogen metabolism similarities to human cancerous 
colon tissue. However, there are differences such as lower STS activity in CRC 
cells. These cell lines also had differing proliferation responses to oestrogen which 
is partly explained by their oestrogen metabolism profiles. Active oestrogens 
generated through STS desulphation action increased proliferation in HCT116 cells, 
which may be due to efficacious receptor binding. As STS activity is increased in 
human colon cancer tissue this is an attractive treatment target. However, with low 
or undetectable ERα and ERβ expression in CRC cells and colon tissue how 
oestrogen increases proliferation is yet unclear. 
  
  
 
 
 
 
 
CHAPTER 6. GPER EXPRESSION AND 
EFFECT OF ACTIVATION ON COLON 
CANCER PROLIFERATION 
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6.1 INTRODUCTION 
Oestrogen metabolism is altered in CRC with a drive towards active E2 generation 
(Chapter 4). Previous research has shown that raised tumoural oestrogen 
concentrations are associated with poorer prognosis (Sato et al., 2009). Chapter 5 
shows in vitro oestrogens increase proliferation in HCT116 and HT29 CRC cells 
and overexpressing STS in HCT116 cells (HCT116STS) also increases proliferation. 
It is currently unclear and controversial how oestrogen exerts proliferative effects in 
the colon. It is generally accepted that in the healthy colon pro-apoptotic ERβ is 
predominant and assists in normal colon cell turnover (Caiazza et al., 2015). In CRC 
ERβ is reduced or lost (Niv, 2015) leading to loss of differentiation and decreased 
apoptosis (Elbanna et al., 2012). Pro-mitogenic ERα if present in the colon is only 
at low concentrations (Campbell-Thompson et al., 2001) thus unlikely to account for 
unregulated proliferation. A relatively new ER, the G protein- coupled oestrogen 
receptor (GPER), has been detected in the colon myenteric plexus where it is 
thought to impact on peristalsis and be responsible for change in bowel frequency 
seen by many women over their menstrual cycle (Li et al., 2015). Although there is 
minimal research on GPER in CRC, GPER stimulation is associated with 
proliferation in breast (Pandey et al., 2009), endometrial (Vivacqua et al., 2006b) 
and ovarian (Albanito et al., 2007) cancer cell lines.  
 
Oestrogen initially regulates cell-turn over in the colon through ERβ and this 
regulation is lost in CRC due to reduced ERβ expression. Here is it hypothesised 
that increased active oestrogen generation through STS activity instead stimulates 
GPER promoting colorectal tumourigenesis. This may explain the apparent dual 
Chapter 6  GPER Expression and Activation 
150 
 
role of oestrogen in the colon with evidence for both protection against and 
increasing CRC risk (Rossouw et al., 2013).  
 
The aims of this chapter were to assess GPER stimulation on CRC cell line 
proliferation in vitro and in vivo. 
 
6.2 MATERIALS AND METHODS 
6.2.1 Real Time PCR 
RNA extraction from cells and colon tissue followed by cDNA synthesis and cDNA 
quantification using Picogreen were undertaken as described in section 2.6 with 
primers and probes for GPER and RPLPO (Table 2.2). 
 
6.2.2 Western blotting 
Western blotting was performed as described in section 2.9 using GPER and β-
actin antibodies as described in Table 2.3. 
 
6.2.3 BrdU 
Proliferation was quantified using BrdU assay as described in section 2.7.2. After 
72 hours grown in SFBS phenol red free media cells were treated with GPER 
agonist, G1 (0-500 nM) or antagonist, G15 (1 µM) for 48 hours. The G15 dose used 
was chosen as it was 10 fold that of effective G1 (100 nM) to make sure receptors 
were saturated. 
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6.2.4 Xenograft Models 
All experiments were performed under conditions complying with UK Home Office 
Animals (Scientific Procedures) Act 1986 and local institutional ethical guidelines. 
Athymic nude mice were purchased from Harlan (Bicester, Oxfordshire, UK) at five 
weeks old and allowed to acclimatise for one week. They had a 12 hour light and 
dark cycle with free access to normal chow and water. 5 x 106 HCT116STS cells were 
inoculated into the right flank of 20 mice. After one week mice were randomly 
divided into two groups; 10 received GPER antagonist G15 (50 µg/kg i.p three times 
per week in 100 µl aqueous vehicle (0.9% NaCl with 0.1% albumin and 0.1% 
Tween-20) and 10 vehicle (100 µl aqueous vehicle). These concentrations and 
medium were chosen from in vivo literature published on G15 (Dennis et al., 2009). 
Throughout the study, mice were weighed and tumour volumes (length x width2/2) 
calculated using electronic callipers. For ethical reasons once tumours exceeded 
1.4 cm diameter the study was terminated and mice euthanised by cervical 
dislocation. Xenograft tumours were harvested and frozen in liquid nitrogen for 
future study.  
 
6.3 RESULTS 
6.3.1 GPER Expression in CRC Cell Lines 
GPER mRNA expression was low in CRC cell lines HCT116 and HT29 and 
undetectable in Caco-2 cells (data not shown). However, protein expression was 
detected in all CRC cell lines (Figure 6.1). HCT116 cells had the lowest protein 
expression and Caco-2 cells the highest. Breast cancer cell lines MCF7 and MDA-
MB231 cells both showed GPER protein expression.  
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Figure 6.1 GPER is expressed in colorectal cancer cell lines. Typical Western blot 
of GPER in breast cancer cell lines MCF7 and MDAMB231 and colorectal cancer 
cell lines HCT116, Colo205, HT29 and Caco-2. β-actin used as a loading control 
with 15 μg loaded into each well. 
 
6.3.2 GPER Stimulation Increases Proliferation in CRC Cell Lines 
Directly stimulating GPER through agonist G1 instead of through a ligand such as 
E2 bypassed the possibility of the ligand being metabolised to a non-stimulatory 
substrate such as E2S. GPER agonist G1 increased proliferation in CRC cell lines 
HCT116, HT29 and Caco-2 after 48 hours as assessed using BrdU. Absorbance 
values over G1 concentration range for all three cell lines are shown in Figure 6.2 
(A) with (B) displaying percentage change compared to SFBS control. Unlike with 
E1 and E2 treatment whereby HCT116 and HT29 cells proliferated but Caco-2 cells 
did not (Figure 5.13) all three cell lines responded to G1. Caco-2 cells have higher 
overall absorbance values meaning they incorporated more BrdU during the 4 hour 
incubation (see section 2.7.2), but their response to G1 was not as pronounced 
compared to HCT116 and HT29 cells. Instead G1 EC50 was 0.11, 3.56 and ~12.78 
nmol/l for HCT116, HT29 and Caco-2 cells, respectively. 
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Figure 6.2 GPER stimulation increased proliferation in colorectal cancer cell lines. 
Cells lines were treated with G1 between 0-500 nmol/l for 48 hours and proliferation 
measured using BrdU assay. (A) Absorbance values and (B) percentage change 
from SFBS. Proliferation increased in all cell lines. G1 EC50 was 0.11, 3.56 and 
~12.78 nmol/l for HCT116, HT29 and Caco-2 cells, respectively. (A) One-way 
ANOVA with Bonferroni post-test *p < 0.05, **p < 0.01, ***p < 0.001, (n = 3-4). (B) 
The response of HCT116 and HT29 cells to G1 was greater than Caco-2 cells (***p 
< 0.001, two-way ANOVA with Bonferroni post-test). Experiments performed with 
medical student Habibur Rahman. 
 
In complete media, SFBS media and SFBS media supplemented with E2S 
HCT116STS have higher proliferation rates than HCT116WT or HCT116VO cells  and 
this effect is lost in each case with STS inhibitor STX64 (Figure 5.11). To test if E2 
generated by STS desulphation acts through GPER HCT116 cells were treated with 
GPER antagonist G15 and E2 (Figure 6.3). E2 treatment increased proliferation in 
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all HCT116 cell types and this was inhibited by G15, suggesting E2 acting via GPER 
increases proliferation in HCT116 cells. 
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Figure 6.3 GPER inhibition reduces proliferation in oestrogen stimulated HCT116 
cells. HCT116WT, HCT116VO and HCT116STS cells were treated with SFBS, GPER 
antagonist, G15 (1 µM), E2 (100 nM) or E2 plus G15 for 48 hours. Proliferation was 
measured by BrdU incorporation assay. G15 inhibited all cell types when treated 
with proliferation promoting E2. These n = 3 experiments were performed with 
intercalating medical student Habibur Rahman. Two-way ANOVA with Bonferroni 
post-test *p < 0.05, **p < 0.01, ***p < 0.001.     
 
6.3.3 GPER Expression in Human Colon Tissue 
GPER has previously been demonstrated in the myenteric plexus of human colon 
(Li et al., 2015). Here, GPER mRNA expression was detected in normal and 
cancerous colon tissue with no significant expression change between matched 
normal and cancerous tissue (Figure 6.4). However, there was a significant 
difference in expression between female and male colon with higher GPER 
expression in both normal and diseased female colon tissue samples. 
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GPER mRNA 
Expression (dCt) 
All 
(n = 37) 
Female 
(n = 18) 
Male 
(n = 19) 
Normal 7.33 [6.10,8.55]  4.57 [3.84,5.29]  9.94 [8.38,11.49]  
Cancer 7.10 [5.89,8.31]  4.22 [3.76,4.68]  9.83 [8.36,11.29]  
 
Figure 6.4 GPER is expressed in healthy and cancerous human colon. GPER 
mRNA expression (arbitrary units (AU)) in human colorectal cancer tissue with 
matched normal controls (error bars are SEM). Mean dCt values and 95% CI 
displayed in brackets in the table below. Significantly higher expression of GPER 
was seen in females compared to males in both normal and tumour tissue. Two-
way ANOVA with Bonferroni post-test ***p < 0.001.     
 
WB showed GPER protein was expressed in female and male human colon. GPER 
was detected in all samples tested but expression varied between patients with no 
consistent changes between healthy and cancerous colon (Figure 6.5). 
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Figure 6.5 GPER protein expression in match human colorectal cancer. Western 
blot of GPER in human female (A) and male (B) colorectal cancer tissue (T) with 
matched normal (N) control. MCF7 cells are used as a positive control (+). β-actin 
is used as loading control and 25 μg of colon tissue protein was loaded into each 
well and 15 µg of MCF7 protein. 
 
6.3.4 In vivo 
In vitro overexpression of STS and E2 treatment in HCT116 cells increased 
proliferation. These effects were inhibited by GPER antagonist G15 (Figure 6.3). 
Directly stimulating GPER with agonist G1 also increased proliferation in vitro 
(Figure 6.2). In vivo research within the group has supported these in vitro findings. 
HCT116STS cell xenografts in intact female athymic nude mice proliferated faster 
than HCT116VO cells and this effect was abolished by STS inhibitor STX64 
(unpublished, Appendix III). This suggests that STS desulphation or oestrogen 
increases proliferation both in vitro and in vivo.  
 
To assess if the increase in proliferation caused by STS activity in vivo was due to 
GPER action mice bearing HCT116STS xenografts were treated with G15. 
HCT116STS cells were implanted into the right flanks of athymic nude mice. Mice 
Chapter 6  GPER Expression and Activation 
157 
 
were treated three times per week with G15 (50 µg/kg) or vehicle control and tumour 
sizes (mm3) monitored. After 19 days the experiment was terminated due to large 
tumour size. G15 treatment inhibited tumour growth in HCT116STS xenografts (406.7 
± 51.4mm3) compared to aqueous vehicle control (580.7 ± 91.5mm3, p = 0.007, 
Figure 6.6).  
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Figure 6.6 G15 inhibits HCT116STS cell growth in vivo. Mice treated with G15 (50 
µg/kg) three times per week i.p had reduced growth of HCT116STS xenograft 
tumours compared to aqueous vehicle (two-way ANOVA **p = 0.007). (A) 
HCT116STS tumour volume (mm3) change over time. (B) Percentage change in 
tumour volume (mm3) compared to day 0. Control n = 10 and G15 treated n = 9. 
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6.4 DISCUSSION 
6.4.1 GPER Expression and Function in the Colon in vitro 
GPER appears to have multiple functions with roles in reproduction and fertility, 
vasculature, kidney, brain, adipocyte function and cancers (Barton, 2016). It has 
been located within intracellular membranes and on the cell surface undergoing 
endocytosis (Gaudet et al., 2015). Within the colon GPER has only been shown in 
the myenteric plexus and is thought to have a role in changes in GI motility 
throughout the menstrual cycle (Li et al., 2015). Here, GPER expression is shown 
in both normal and cancerous colon homogenate (Figure 6.4) and CRC cell lines 
(Figure 6.1). Colon tissue homogenate will contain a mix of cell types and thus 
cannot distinguish which cells express functional GPER. However, its presence in 
both healthy colon and in cancer is important as it offers a potential receptor for 
oestrogen stimulated growth.  
 
HCT116 and HT29 CRC cells did not have detectable ERα or ERβ however they 
did express GPER (Figure 6.1). This receptor could account for their increased 
proliferation in response to oestrogen (Chapter 5, Figure 5.13). Despite GPER 
expression Caco-2 cell growth remained static in response to oestrogens. This 
could be explained by their oestrogen metabolism profile showing E1 generation 
when given E2, probably through HSD17β2 activity. E1 has less than 0.1% affinity 
for GPER compared to E2 (Thomas et al., 2005) and so may not lead to the 
oestrogen growth effects seen in HCT116 and HT29 cells. 
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Both HCT116 and HT29 cells proliferated in a dose-dependent manner with 
oestrogen treatment (E1, E2 and E1S) (Figure 6.2). However, although Caco-2 cells 
did not have a growth response to E1 or E2 (Figure 5.13) G1 did increase their 
growth. Caco-2 cell response to G1 was not as large as HCT116 and HT29 cells 
despite having a prominent GPER band on Western blot (Figure 6.1). This suggests 
that GPER stimulation may only play a limited role in proliferation in Caco-2 cells.  
 
GPER has been identified both on the plasma membrane and intracellularly 
(Gaudet et al., 2015) and it is not currently clear how cellular location affects GPER 
action. In breast cancer GPER expression has been linked with tumour proliferation 
(Marjon et al., 2014). Also, in breast cancer the cellular location of GPER has been 
associated with prognosis with predominately cytoplasmic localisation correlating 
with a better outcome (Samartzis et al., 2014). Further studies investigating GPER 
location and intracellular trafficking in these CRC cell lines may reveal a difference 
and explain the smaller proliferative response in Caco-2 cells. 
 
Other studies have shown different findings to those presented here. They found 
Caco-2 cell growth increased with E2 and was inhibited by GPER agonists tamoxifen 
and ICI 182,780 (Di Domenico et al., 1996, Thomas et al., 2005). However, 
Domenico and colleagues demonstrated ER expression in Caco-2 cells. The cells 
presented here have been authenticated (DNA Diagnostics Centre, 2015) and ERα 
and ERβ were only minimally detected in Caco-2 cells and were not expressed in 
HCT116 and HT29 cells (Appendix III). Although low, ERβ expression may account 
for the reduced oestrogen proliferative response of Caco-2 cells compared to 
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HCT116 and HT29 as ERβ action may induce apoptosis. Low or non-existent ER 
expression is in keeping with human CRC where the usually dominant ERβ is down-
regulated (Campbell-Thompson et al., 2001, Elbanna et al., 2012, Niv, 2015).  
 
HCT116STS cells proliferated more than HCT116VO and HCT116WT and this effect 
was inhibited by STS inhibitor STX64 (Chapter 5, Figure 5.12) and GPER antagonist 
G15 (Figure 6.3). E2 stimulated growth in these three HCT116 cell types was also 
inhibited by G15 (Figure 6.3). Together these results suggest desulphation of 
oestrogens by STS leads to GPER activation and proliferation in vitro.  
 
6.4.2 GPER Expression and Function in the Colon in vivo 
To investigate GPER action in CRC in vivo HCT116STS cell xenografts were injected 
into the right flank of athymic nude mice resulting in rapidly growing tumours. 
Proliferation was slower in HCT116STS tumours treated with G15 indicating GPER 
inhibition can reduce tumour growth in vivo (Figure 6.6) as well as in vitro. Previous 
research (unpublished, Appendix III) has shown that overexpressing STS in 
HCT116 cells increases tumour proliferation in vivo compared to HCT116VO and this 
effect is inhibited by STX64. Together this demonstrates that STS increases 
proliferation in CRC and this effect can be inhibited by GPER antagonist. Thus, a 
potential novel pathway has been demonstrated. Active oestrogens generated 
through increased STS desulphation and loss of pro-apoptotic ERβ leads to GPER 
action and increased CRC proliferation (Figure 6.7).  
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Figure 6.7 Oestrogen metabolism pathway in colorectal cancer. Locally generated 
oestradiol acts on GPER to stimulate proliferation. 
 
6.5 CONCLUSION 
Oestrogen receptor GPER is expressed in both normal and cancerous colon tissue 
and is pro-mitogenic in vitro. GPER antagonist G15 can inhibit oestrogen 
proliferative effects in vitro and in vivo demonstrating a novel pathway for which 
locally produced E2 can cause CRC proliferation, potentially offering new treatment 
targets.  
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7.1 INTRODUCTION 
Chronic inflammation is an acquired tumour cell trait necessary for growth, survival 
and metastasis (Hanahan and Weinberg, 2000, Colotta et al., 2009, Hanahan and 
Weinberg, 2011). IBD and obesity are two inflammatory states that raise CRC risk 
and so chronic inflammation may also initiate and promote tumour growth (Flores 
et al., 2012, Flores et al., 2015, Barral et al., 2015). Oestrogens influence 
inflammatory processes, but the relationship is not straightforward with evidence for 
both pro and anti-inflammatory effects (Straub, 2007).  
 
Inflammation around a solid malignancy such as CRC accumulates a variety of 
inflammatory cells that produce an assortment of inflammatory mediators, including 
TNFα and IL-6 (Peddareddigari et al., 2010). TNFα and IL-6 can regulate STS 
leading to increased expression and/or activity in breast and prostate cancer cell 
lines (Newman et al., 2000, Suh et al., 2011). Chapter 5 demonstrates immortalised 
CRC cell lines display diversity in STS activity, oestrogen enzyme mRNA 
expression and protein expression. Chapter 4 also shows patients had increased 
STS activity in tumour tissue without changes to STS mRNA expression implying 
post translational modification of STS. Thus, TNFα and IL-6 within the tumour 
microenvironment could be responsible for STS dysregulation and ultimately alter 
oestrogen metabolism. 
 
A link between STS activity and inflammation has been demonstrated previously. 
Elevated STS activity, commonly found in human CRC (see Chapter 4), increases 
CRC proliferation. The aim of this chapter was to investigate the effects of TNFα 
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and IL-6 on STS activity in the colon in vitro and in vivo. TNFα receptors have been 
shown to be expressed in the colon and CRC cells (Hamilton et al., 2011, Mizoguchi 
et al., 2002, Chopra et al., 2013, Peng et al., 2012, Naude et al., 2011). 
 
7.2 MATERIALS AND METHODS 
7.2.1 Cell Culture  
HCT116, Colo205 and Caco-2 cells were cultured as described in section 2.1.  
 
7.2.2 STS Activity Assay 
7.2.2.1 TNFα and IL-6 Treatment 
HCT116, Colo205 and Caco-2 cells were seeded into T25 flasks at 250,000 cells 
per flask and treated with 40 ng/ml TNFα (PeproTech), 10 ng/ml IL-6 (PeproTech), 
both TNFα and IL-6 or PBS as a control. After 48 hours media was removed and 
STS assay performed as described in section 2.8.2 with results expressed as E1S 
to E1 conversion in pmol/mg/hr. The concentrations of TNFα and 48 hour time point 
were chosen as a result of experiments by technician Anne-Marie Hewitt and 
BMedSci student Alice Ross (Appendix III). IL-6 concentration was chosen at a dose 
that other research groups had used in STS activity and expression studies for 
prostate and breast cancer cell lines in vitro (Im et al., 2012, Honma et al., 2002, 
Speirs et al., 1993). Further optimisation of IL-6 and TNFα concentrations and time 
points would be beneficial. 
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7.2.2.2 TNFα mice  
Mice that globally overexpress human TNFα (Tg-TNF) are used in inflammatory 
arthritis studies (Keffer et al., 1991, Hardy et al., 2016). Once culled these 9 week 
old Tg-TNF mice were kindly donated along with age-matched WT controls from Dr 
Rowan Hardy at The University of Birmingham. Liver, lung, kidney, heart, large 
bowel, spleen, adipose tissue and skin were harvested and snap frozen in liquid 
nitrogen before being stored at -80oC. Tissues were then homogenised to collect 
both RNA and protein as described in sections 2.2 and 2.3. Protein was used to 
assess STS activity as described in section 2.8.1. 
 
7.2.3 RT-PCR 
RNA extraction, cDNA synthesis, cDNA quantification followed by real-time PCR 
were performed as described in section 2.3- 2.6 using STS, HSD17β2, HSD17β7, 
HSD17β12 and RPLPO genes in CRC cell lines. Additionally, il-6, TNFα, sts, 
hsd17β2 and gapdh were measured in mouse tissue (Table 2.2).  
 
7.3 RESULTS 
7.3.1 TNFα and IL-6 Increase STS Activity in CRC Cell Lines 
The effect of TNFα and IL-6 on STS activity in Colo205, Caco-2 and HCT116 cells 
was assessed by treating cells with TNFα and IL-6 for 48 hours followed by STS 
activity assay. Figure 7.1 shows all three CRC cell lines had similar response trends 
e.g. STS activity increased with TNFα and TNFα plus IL-6 treatment. STS activity 
was significantly higher in treated Colo205 and Caco-2 cells whereas the upwards 
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trend in HCT116 cells was not significant. STS mRNA expression remained 
unchanged (data not shown). 
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Figure 7.1 TNFα and IL-6 increase STS activity in colorectal cancer cell lines. STS 
activity significantly increased in Colo205 and Caco-2 cells treated with 
inflammatory mediators TNFα (40 ng/ml) and IL-6 (10 ng/ml) for 48 hours (n = 3). 
HCT116 cells followed a similar trend, but the increase in STS activity was not 
significant (n = 4). Owo-way ANOVA with Bonferroni post-test, **p < 0.01. 
Experiments performed with laboratory technician Anne-Marie Hewitt. 
 
7.3.2 TNFα, IL-6 and HSD17β Expression  
In human CRC STS activity is increased, HSD17β2 mRNA is decreased and 
HSD17β7 and 12 mRNA are up-regulated (Chapter 4). TNFα and IL-6 increased 
STS activity in CRC cells lines (Figure 7.1). The effect on HSD17β expression was 
also explored to assess if TNFα and IL-6’s impact was extended to other oestrogen 
metabolism enzymes. Colo205 and Caco-2 cells treated with TNFα and IL-6 for 48 
hours showed a reduced HSD17β2 mRNA expression trend. However, only 
significant changes were noted in Caco-2 cells treated with combination treatment 
(*p < 0.05, Figure 7.2). As HCT116 had undetectable HSD17β2 mRNA (Figure 5.1) 
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they were not examined. HSD17β7 and 12 mRNA remained unchanged with TNFα 
and IL-6 treatment (data not shown, n = 2-3). 
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Figure 7.2 HSD17β2 mRNA is not regulated by TNFα and IL-6. HSD17β2 mRNA 
was quantified using real time PCR in CRC cells treated with TNFα (40 ng/ml) and 
IL-6 (10 ng/ml) for 48 hours and displayed in arbitrary units (AU). Caco-2 cells had 
significant reduction in HSD17β2 mRNA after combination treatment, but no change 
was seen in Colo205 cells. One-way ANOVA with Bonferroni post-test, n = 3, *p < 
0.05. 
 
7.3.3 STS Activity is Increased Globally in Tg-TNF Mice  
Tg-TNF mice globally overexpress human TNFα. To assess if TNFα regulates STS 
in vivo, protein and RNA were harvested from various tissues of 9 week old Tg-TNF 
mice and age-matched WT controls and STS activity measured. STS activity 
appeared higher in almost all tissues collected with significant increases in liver 
(Figure 7.3). There was not enough numbers to separate mice into males and 
females so gender differences could not be confirmed. 
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Figure 7.3 TNFα increases STS activity in multiple tissue types. Tg-TNF mice have 
global increased STS activity. STS activity was measured in multiple tissues and 
found to be elevated in TNF-Tg mouse tissues compared to wild-type controls (WT); 
significant increases seen in the liver (n = 6-7). Experiments performed with masters 
student Mai Nguyen. Two-way ANOVA with Bonferroni post-test, ***p < 0.001. 
 
7.3.4 Tg-TNF Mice Oestrogen Enzyme mRNA Expression 
To explore if increased STS activity (non-significant) found in the large bowel of Tg-
TNF mice was related to STS mRNA expression real time PCR was performed. 
There was no change in STS mRNA and overall expression was low (Figure 7.4). 
IL-6 mRNA expression was also low in both Tg-TNF and WT mice with no significant 
changes (Figure 7.4 (A and C)). HSD17β2 mRNA was present but there were no 
differences between Tg-TNF and WT mice. HSD17β2 mRNA appeared higher in 
male WT mice compared to females however due to large variations in expression 
this was not significant (Figure 7.4 (B)). These Tg-TNF mice are understood to have 
global overexpression of human TNFα (Kontoyiannis et al., 1999, Keffer et al., 
1991). However, human TNFα mRNA expression was low in both WT and Tg-TNF 
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mice (data not shown), with only a small but notable increase in female Tg-TNF 
colon (Figure 7.4 (D)). 
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Figure 7.4 STS and HSD17β2 mRNA is not regulated by TNFα in vivo. (A) STS (B) 
HSD17β2 (C) IL-6 mRNA expression is unchanged in the large bowel of male and 
female Tg-TNF mice. (D) Human TNFα was increased in female mice only (n = 5-6 
for females and males). Two-way ANOVA with Bonferroni post-test ***p < 0.01. 
 
7.4 DISCUSSION 
7.4.1 TNFα Regulates Colon STS Activity in vitro 
TNFα increased STS activity in Colo205 and Caco-2 cells. HCT116 cells had an 
upwards trend in STS activity but it was not significant (Figure 7.1) which may be 
due to their comparatively lower basal STS activity (Figure 5.9). These data are in 
keeping with other cell lines; TNFα has been shown to increase STS activity in 
MCF7 breast cancer cells (Newman et al., 2000) and STS expression in LNCaP 
and PC-2 prostate cancer cell lines (Suh et al., 2011). The increase in STS activity 
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in CRC cell lines was not due to higher STS mRNA expression and so gene 
transcription indicating TNFα and/or IL-6 may increase STS activity through post-
translational modification e.g. STS has four N-linked glycosylation sites with two 
(Asn47 and Asn259) affecting activity (Stengel et al., 2008). Alternatively, TNFα 
may increase STS substrate availability, such as altering E1S transport across the 
cell membrane. 
 
HSD17β2 mRNA was reduced in human CRC and HSD17β7 and 12 increased 
(section 4.3.1). HSD17β2 has previously been shown to be regulated by retinoic 
acid (Su et al., 2007) and progesterone (Yang et al., 2001) and HSD17β7 
upregulated by oestradiol (Shehu et al., 2011). TNFα and IL-6 do not appear to 
regulate HSD17β enzymes as expression remained essentially unaltered in CRC 
cell lines. Rises in STS activity could have a knock-on effect and increase HSD17β 
activity due to increased substrate, but in the results presented here, this may be 
limited by co-factor availability. As E1 binds to ERα with 10% affinity of E2, 2% for 
ERβ (Zhu et al., 2006) and just 0.1% for GPER (Thomas et al., 2005) only small 
changes in E1/E2 ratio could lead to large downstream effects. HSD17β2, 7 and 12 
could be considered as therapeutic targets however due to the multitude of HSD17β 
enzymes and functional overlap this would be challenging. Nevertheless, the benefit 
of variable tissue expression could allow for tissue targeted inhibitors reducing side-
effects. 
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7.4.2 TNFα Regulates STS Activity in vivo 
To explore if TNFα induced STS activity was a phenomenon confined to cancer 
models, activity was also measured in a non-cancerous model. Tg-TNF mice 
globally overexpress human TNFα and have been developed for the study of 
inflammatory arthritis. Overall Tg-TNF tissues showed higher STS activity 
compared to WT but only liver showed significant increases (Figure 7.3). Therefore, 
TNFα also increases STS activity in noncancerous tissues and consequently may 
be part of a fundamental homeostatic response to inflammation rather than confined 
to a malignant phenomenon.  
 
Tg-TNF mice are designed to have global overexpression of human TNFα. They 
are used primarily as an inflammatory arthritis model, (Keffer et al., 1991) however 
in addition to joint symptoms, overexpression of TNFα can lead to colitis. CRC has 
not been described. (Kontoyiannis et al., 1999). Conversely, when TNFα mRNA 
was measured, it was not raised in male mouse colon and only marginally increased 
in female mice (Figure 7.4). There was evidence of active arthritis in these animals 
despite their young age (9 weeks) and human TNFα increases were identified in 
other tissues such as muscle and joint (Keffer et al., 1991, Hardy et al., 2016). It is 
possible colon TNFα expression occurs later in their growth. However, despite low 
TNFα mRNA expression in male colon or increased STS mRNA expression in 
males and females, colonic STS activity appeared higher in both genders. As these 
experiments were in homogenised lysed tissue, alterations in cell membrane 
transport leading to increased E1S availability could not explain the increase in STS 
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activity. This suggests systemic inflammation rather than local TNFα exposure could 
post-translationally modify STS to increase activity in the colon.  
 
7.4.3 Inflammatory Bowel Disease and STS 
A proportion of IBD patients have systemic symptoms including arthritis however 
IBD associated arthritis does not lead to joint destruction and deformity and so is 
distinct from other inflammatory arthritides, such as rheumatoid (Gravallese and 
Kantrowitz, 1988). IBD increases CRC risk (Barral et al., 2015) however patients 
with rheumatoid arthritis actually have a reduced CRC risk. This is thought to be 
due to anti-inflammatory medications (Simon et al., 2015) as long-term use of 
nonsteroidal anti-inflammatories (NSAIDS) can reduce CRC risk by 40-50% 
(Smalley and DuBois, 1997). NSAIDS act through inhibition of cyclooxygenase -2 
(COX-2) rather than TNFα. However, TNFα has been shown to increase COX-2 
expression (Zhu et al., 2013, Medeiros et al., 2010, Shishodia et al., 2004) and so 
NSAIDS may indirectly affect STS. There is a growing body of evidence that shows 
TNFα regulates STS through NFκB pathways. STS expression in human MG-63 
preosteoblasts was induced by NFκB (Dias and Selcer, 2016). Also, in prostate 
cancer PC-3 cells STS was induced by IGF-II via a PI3-kinase/AKt-NFκB pathway 
(Sung et al., 2013). Additionally, in hepatic tissue STS activated oestrogens also 
attenuated NFκB mediated inflammation showing a negative feedback loop (Jiang 
et al., 2016). Together these data suggests STS is regulated as part of the 
inflammatory response in multiple tissue types. In cancers such as CRC this TNFα-
NFκB-STS pathway may become dysregulated leading to increased active 
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oestrogen production however further research would need to be done to confirm 
this. 
 
7.4.4 STS and Colorectal Cancer Prognosis 
Higher STS expression has been linked with poorer prognosis in CRC however 
functional STS activity was not examined (Sato et al., 2009). The relationship 
between STS activity and prognosis would be important to determine as due to STS 
post translational modifications mRNA and protein are not necessarily proportional 
to activity. In human CRC tissue, CRC cell lines treated with TNFα and Tg-TNF 
mouse colon STS mRNA remained unchanged despite increased STS activity. In 
CRC STS activity appears to be increased at an early disease stage (Chapter 4) 
but it is currently unclear whether higher STS activity has a positive or negative 
impact on CRC prognosis. Additionally, the effect of STS on IBD symptoms and 
CRC are unknown. Despite clinical and histopathologic differences between UC 
associated CRC and sporadic CRC, survival outcomes are similar. Females with 
UC-CRC have an improved outcome compared to males (Leowardi et al., 2016). 
This may be due to the consequences of differences in oestrogen enzyme 
expression between males and females (Chapter 4). Increased STS activity and 
higher local oestrogen concentrations in women may have a greater protective 
effect. Alternatively, STS may increase local androgens in males which may be 
detrimental to survival (Amos-Landgraf et al., 2014).  
 
In mouse models inflamed stroma has been shown to promote progression of 
adenomas to adenocarcimonas (Okada et al., 2000). However, it is unclear if higher 
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STS activity and subsequent oestrogen increase is beneficial or detrimental. Acute 
inflammation and increased STS effects may vary per individual. However, chronic 
and sustained inflammation with increased STS activity may contribute to 
adenomas and CRC. ERβ loss in CRC (discussed further in Chapter 6) could switch 
oestrogen effects from apoptotic to pro-mitogenic with tumour cells exploiting initial 
protective measures to aid proliferation and metastasis.  
 
7.5 CONCLUSION 
TNFα increases STS expression and/ or activity in multiple cancer types including 
breast, prostate and CRC. However, TNFα associated STS activity is not a 
phenomenon confined to malignancy and occurs in multiple tissues types by STS 
post translational modification. Consequently, TNFα regulated STS activity may be 
a normal physiological homeostatic response of which the mechanism has yet to be 
fully elucidated. TNFα and increased STS activity may be detrimental in chronic 
inflammatory states such as poorly controlled IBD, obesity and cancer and in these 
circumstances anti-inflammatories and STS inhibition may be of clinical benefit. 
 
 
 
 
 
  
  
 
 
 
 
 
CHAPTER 8. FINAL DISCUSSIONS AND 
FUTURE STUDIES 
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The work presented in this thesis describes a pathway for localised colonic active 
oestrogen generation that ultimately increases proliferation in colorectal tumours, 
highlighting multiple potential drug targets. Previous published research has 
described parts of this oestrogen pathway. English and colleagues identified 
decreased oxidative HSD17β in CRC with reduced E2 to E1 conversion (English et 
al., 1999). Also, Sato and colleagues found STS expression was frequently raised 
in CRC. They also found higher STS mRNA and lower SULT1E1 mRNA correlated 
with a poorer outcome and the reverse with improved patient survival (Sato et al., 
2009). Data presented here supports these published findings and attempts to 
combine both HSD17β and STS data finding CRC metabolism is frequently altered 
towards E2 generation. Previous research focus has been on traditional oestrogen 
receptors ERα and ERβ however here it is shown that active oestrogens exert their 
effects in the colon through GPER increasing proliferation.  
 
8.1 LC-MS/MS OESTROGEN METHOD DEVELOPMENT 
Oestrogen sulphates are frequently ignored in quantitative analysis with focus on 
active unconjugated forms. However, E1S circulates at higher concentrations than 
either E1, E2 or in combination and has a significantly longer half-life. E1S acts as a 
reservoir for active oestrogen generation (Reed et al., 2005). Tissues able to uptake 
E1S and have STS activity can locally alter active oestrogen concentrations. The 
effect of E1S and STS activity has been recognised in breast cancer where STS 
expression is 50-200 times that of aromatase (Pasqualini et al., 1996) and STS 
inhibitors are in Phase II clinical trials (Stanway et al., 2006, Palmieri et al., 2016a, 
Palmieri et al., 2016b). However, despite this E1S is not routinely measured either 
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systemically or in tissue. This novel LC-MS/MS method acknowledges the 
importance of including E1S concentrations in oestrogen responsive tissues such 
as the colon. 
 
Previous LC-MS/MS methods have analysed unconjugated oestrogens (Owen et 
al., 2014), E1S (Corona et al., 2010), or used two extractions and two LC-MS/MS 
methods to enable both sulphated and non-sulphated oestrogens to be quantified 
(Galuska et al., 2013). Alternatively, IA have been used to measure oestrogen 
sulphates separately or lengthy GCMS analysis (Stanway et al., 2007, Ranadive et 
al., 1998). This is a novel high-throughput LC-MS/MS method to quantify oestrogen 
and their sulphates simultaneously in cell culture validated to industry standard. In 
comparison to other methods this uses a single SPE without any derivitisation to 
quantify E1, E2, E1S and E2S in a five minute run. With a LLOQ of 14 nmol/l for E1 
and E2 and 18 nmol/l for E1S and E2S it was not as sensitive as other oestrogen 
methods described above. With a more sensitive MS the more desirable pmol/l 
concentrations could be achieved and so be applied to serum and colon tissue. This 
method has been applied successfully to CRC cell lines in culture and showed 
differences in oestrogen metabolism which can potentially explain the differences 
in their proliferative responses. 
 
8.2 COLORECTAL CANCER FAVOURS OESTRADIOL PRODUCTION 
To characterise oestrogen metabolism in CRC and matched human colon tissue, 
expression of oestrogen metabolism enzymes were assessed. Findings were 
supportive of previous published research with reduced HSD17β2 expression and 
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increased STS activity. Here for a novel holistic view oestrogen oxidoreductive 
metabolism and desulphation were combined in one dataset.  
 
STS activity is frequently overlooked with most studies focusing on mRNA and 
protein expression. STS can undergo extensive post translational modifications 
impacting on desulphation capability and thus measuring STS activity assesses 
functional changes. As there was no alteration in STS mRNA expression these data 
suggest that post translational STS modifications contribute significantly to STS 
activity in CRC and mRNA and protein data alone are insufficient. Sato and 
colleagues measured expression with STS/SULT1E1 expression ratio correlating 
with prognosis (Sato et al., 2009). The increase in STS activity shown in this thesis 
does follow a similar pattern to the expression findings by Sato and colleagues. 
However, here STS activity was also assessed by disease stage showing increases 
in STS activity occurred in early disease in both males and females and this was 
likely regulated by localised inflammation. SULT1E1 was impossible to assess here 
through a lack of cDNA primers and probes, suitable commercial WB antibodies 
and ex-vivo activity assays. Sulphated oestrogens have negligible ER receptor 
binding capability and are considered biologically inactive (Zhu et al., 2006). E2 is 
also much more potent than E1 (Zhu et al., 2006, Thomas et al., 2005). Therefore, 
only small STS/SULT1E1 and E1/E2 ratio changes could produce dramatic 
downstream effects. SULT expression is generally thought to be down-regulated in 
cancer (Mueller et al., 2015). However, even without assessing SULT1E1 activity 
here this increase in STS activity is an important finding suggesting a new biological 
target for CRC.  
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HSD17β1 is the principal enzyme responsible for E1 to E2 reduction however as with 
other published research was not expressed in colon tissue or CRC cell lines. 
Alternative enzymes therefore had to be responsible for this conversion. HSD17β7 
and 12 were examined and both mRNAs were found to be expressed in CRC cell 
lines, benign and cancerous CRC human tissue with expression increased in CRC. 
HSD17β7 protein was not able to be examined by Western blot. HSD17β12 protein 
was detected and like HSD17β2 there was a mismatch between mRNA and protein 
with significant increases in mRNA not mirrored by protein. This discrepancy 
between HSD17β mRNA and protein has been previously described and 
acknowledged by other groups (Day et al., 2006, English et al., 1999). HSD17β 
activity has been found to closely correlate with mRNA rather than protein stipulating 
that co-factor availability may be the cause (Day et al., 2006, English et al., 1999). 
Overall HSD17β activity was shown in CRC cells using LC-MS/MS. However, this 
was not sensitive enough to show lower levels of activity and no inhibitors were 
available to assess oxidation and reduction reactions individually. Also, it was 
currently not possible to assess specific HSD17β activity in fresh tissue or protein 
extracts therefore although enzyme expressions are altered in CRC, end results 
remain to be defined.  
 
Sex differences in mRNA were noted for HSD17β enzymes. Compared to males, 
females had lower HSD17β12 in healthy colon and higher HSD17β7 mRNA 
expression in both healthy and cancerous colon. Also, in advanced disease males 
had higher HSD17β7, females appeared to have lower HSD17β7 but this was not 
significant. This may be why there are differences in incidence and prognosis 
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between men and women and could lead to gender based treatment. However, 
overall these results show a potential drive towards E2 generation in the majority of 
CRCs regardless of disease stage or sex: an increase in oestrogen desulphation 
via STS, reduced HSD17β oxidative expression and increased HSD17β reductive 
expression. HSD17β inhibitors appear to be attractive treatment targets and are 
currently being explored with HSD17β1 being targeted in breast cancer and 
endometrial disease and HSD17β3 in prostate cancer (Saloniemi et al., 2010, Day 
et al., 2008b). However, they have not yet reached clinical trials. 
 
8.3 INCREASED STS ACTIVITY ENHANCES PROLIFERATION 
Oestrogen-dependent cancers include endometrial, breast and ovarian and limiting 
oestrogen availability can reduce proliferation. Currently in breast cancer this is 
achieved through inhibition of oestrogen receptors or aromatase e.g. tamoxifen, 
anastrozole (National Institute for Health and Care Excellence, 2009). STS 
inhibitors reduce oestrogen generation from circulating E1S and have progressed 
from Phase I (Stanway et al., 2006) to Phase II clinical trials for breast cancer 
(Palmieri et al., 2016a, Palmieri et al., 2016b).  
 
In vitro oestrogen treatments (E1, E2 and E1S) increased proliferation in a dose 
dependent manner in HCT116 and HT29 cells which was in contrast to Caco-2 cells. 
These proliferation differences were in part explained by oestrogen metabolism as 
assessed by LC-MS/MS. HCT116 and HT29 cells responded very similarly to 
oestrogen treatment however their metabolism profiles differed. Even when 
oestrogen increases proliferation in CRC cells there may be multiple mechanisms 
Chapter 8  Discussion 
181 
 
and metabolites responsible. This emphasises the difficulty in trying to extrapolate 
in vitro data to human disease. CRC is heterogeneous and thus in vitro findings may 
still be relevant but only apply to a subset of patients or cell populations. As with 
hormonal breast cancer targeting multiple oestrogen pathways is likely to be more 
successful at improving prognosis. However, care should be taken as 
steroidiogenesis can still occur through alternative pathways leading to recurrence. 
This is a particular problem in recurrent prostate cancer (Ferraldeschi et al., 2015).  
 
CRC cell lines did have similarities with human tissue with no HSD17β1 expression, 
low HSD17β2 and mismatch between HSD17β mRNA and protein. However, other 
than Caco-2 cells they had low STS activity and so no CRC cell line tested was 
really representative of CRC. To overcome this problem and develop a model 
similar to CRC stable STS overexpressing HCT116 cells were developed. These 
cells had low HSD17β2 expression and higher STS activity as seen in human CRC. 
This is a strategy utilised in breast cancer research where aromatase (Zhou et al., 
1990, Macaulay et al., 1994) or STS (James et al., 2001) was overexpressed in 
MCF7 breast cancer cell lines in order to more closely mimic activity seen in human 
breast tumours. 
 
HCT116STS had increased proliferation in complete and SFBS phenol red free 
media. It is not possible to completely remove all oestrogen traces in media however 
this does suggests it was not solely increased oestrogen generation from STS that 
amplified proliferation in HCT116STS compared to HCT116VO. E2S treatment 
augmented proliferation further in HCT116STS cells and this effect was abolished by 
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STS inhibitor STX64. This is similar to breast cancer where oestrogen generation 
through the sulphatase pathway in STS overexpressing MCF7 cells increased 
proliferation and was inhibited by STX64 (Foster et al., 2008). In colon cancer it was 
still unclear how oestrogen exerted its proliferative effects as these cells had no 
detectable ERβ or ERα expression. 
 
8.4 OESTROGEN ACTS THROUGH GPER IN THE COLON  
The colon lacks ERα expression and anti-proliferative ERβ is frequently reduced in 
cancerous colorectal tissue (Campbell-Thompson et al., 2001, Niv, 2015). These 
ER findings were supported by CRC cell lines studied here. Therefore, how 
oestrogen action occurs is not understood. The relatively newly recognised ER 
GPER may be a viable route and GPER was identified in both healthy and 
cancerous colon tissue and CRC cell lines.  
 
GPER was active in CRC cells in vitro as agonist G1 increased proliferation in all 
cell lines (HCT116, HT29 and Caco-2 cells). Caco-2 cells did not respond to E1 or 
E2 treatment and they rapidly metabolised E2 to E1 which has low affinity for GPER. 
This suggests higher HSD17β2 activity may limit oestrogen proliferative response 
in CRC. Increased proliferation of HCT116STS cells was inhibited by GPER 
antagonist G15 in both complete, SFBS and oestrogen treated media. This strongly 
suggests GPER is fundamental to oestrogen action within the CRC.  
 
Supporting in vitro data G15 significantly reduced proliferation in HCT116STS 
xenografts in vivo. In this study intact female mice were used. In humans CRC is 
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more common in men and post-menopausal women thus it would be good to follow 
this study in ovariectomised female mice and male mice with and without oestrogen 
treatment.  
 
If novel oestrogen receptor targeted treatment is to be considered for CRC then how 
oestrogen receptor inhibitors act and cross react with ERα and ERβ is important to 
consider. Tamoxifen is a prodrug and when metabolised into its active metabolites 
competitively competes with oestrogen for ER binding (Desta et al., 2004). It is a 
common and successful oestrogen positive breast cancer treatment.  However, 
tamoxifen also acts as a GPER agonist and is thought to have a role in tamoxifen 
resistant breast cancer (Catalano et al., 2014). Additionally, an older study noted 
women on tamoxifen treatment for breast cancer had an increased risk of CRC 
(Newcomb et al., 1999).  
 
The importance of aromatase in the colon is controversial with many studies finding 
low aromatase expression or activity and no change in CRC (English et al., 1999, 
Foster, 2013, Sato et al., 2009). However, the aromatase gene (CYP19A1) has 
been linked to CRC risk (Slattery et al., 2011) and in vitro studies have shown 
aromatase activity in CRC cell lines (Fiorelli et al., 1999). In 2009 Sato et al 
concluded that locally produced oestrogens in CRC were mainly derived from the 
STS pathway (Sato et al., 2009). In 2012 they explored aromatase in CRC in more 
detail. They noted the colon had functional aromatase with expression and activity 
increased in CRC. However, aromatase status did not correlate with survival as they 
found for STS/SULT1E1 expression (Sato et al., 2012). Thus, STS may be the 
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dominant pathway for oestrogen generation in the colon and so inhibiting STS 
should have the biggest impact on oestrogen availability in CRC. If anti-oestrogen 
treatment in CRC is found to be beneficial then full assessment of oestrogen 
enzymes and receptors status may be needed to stratify different treatment groups. 
 
8.5 TNFΑ INCREASES STS ACTIVITY 
There is an inflammatory component in the microenvironment of most neoplastic 
tissues including CRC. Cancer-related inflammation is the seventh hallmark of 
cancer (Colotta et al., 2009). Inflammatory mediators induce genetic instability and 
the abundance of genetic heterogeneity within tumours suggests genetic instability 
is an ongoing process throughout tumour development (Wang and Lin, 2008).  
 
Previously TNFα has been shown to increase STS expression and/or activity in 
breast MCF7 (Reed et al., 2005, Purohit et al., 1996, Reed and Purohit, 1997, 
Purohit et al., 1997) and prostate cancer LNCaP (Suh et al., 2011) cell lines. TNFα 
regulation of STS has now been expanded to include CRC cell lines in vitro and 
multiple benign tissues and organs of Tg-TNF mice in vivo. In these experiments 
TNFα increased STS activity without effecting STS mRNA suggesting TNFα may 
post-translationally modify STS or alter E1S availability across the cell membrane. 
Tg-TNF mice did not have increased TNFα expression in the colon itself indicating 
systemic inflammation can alter STS activity in the colon. STS is at least in part 
regulated by inflammatory modulator TNFα with TNFα increasing STS activity in 
benign and malignant tissues.  
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Inflammation induced STS activity may not be a unique CRC trait and in the acute 
setting may be of clinical benefit, such as modifying immune function through 
oestrogens or androgens. Interestingly, research has shown evidence that anti-
oestrogen treatment may benefit the majority of cancers independent of ER 
expression due to the effects on the immune system (Svoronos et al., 2016). 
Chronic inflammation induced STS activity with active oestrogen generation may be 
detrimental. This homeostatic response could be commandeered in CRC 
contributing to genetic instability by accruing mutations. Long-term anti-
inflammatories offer some protection against CRC reducing risk by 40-50% 
(Smalley and DuBois, 1997) This may be through TNFα and COX-2 indirectly down-
regulating STS.  
 
It would also be interesting to examine STS activity and inhibition in chronic 
inflammatory diseases such as IBD and arthritis to ascertain how STS affects 
symptoms and outcomes for these patients. By also assessing oestrogens and 
androgens this may even give insight into the gender differences in inflammatory 
disease.  
  
8.6 SUMMARY 
Together these in vitro, ex vivo and in vivo experiments support an active 
oestrogenic pathway in CRC that drives proliferation. Ultimately a combination of 
increased oestrogen availability through STS desulphation activity, alteration in 
E1/E2 ratio through decreased oxidation and increased reduction would shift towards 
the more potent E2 which then stimulates proliferation through GPER (Figure 8.1). 
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Novel findings demonstrated in this study shed light on complex oestrogen 
metabolism in CRC. Previous focus on single enzymes does not inform of the full 
metabolism profile. 
 
 
 
Figure 8.1. Illustration of oestrogen metabolism in a colorectal cancer cell. 
Circulating oestrogen sulphate (E1S) is taken up by the cell and desulphated by 
steroid sulphatase (STS) to oestrone (E1). STS is increased in CRC through post-
translational modification (PTM) by TNFα. E1/E2 ratio is shifted in favour of E2 
generation as oxidative HSD17β2 is decreased and reductive HSD17β7 and 12 are 
increased. E2 then acts on GPER to stimulate proliferation. 
 
The exact timings of these post-translational and genetic changes have not been 
fully elucidated. It can be hypothesised that STS activity occurs early in CRC which 
may be due to the presence of TNFα in the matrix surrounding tumours. HSD17β2 
reduction tends to occur in later stages and may reflect an oestrogenic switch in the 
tumour where the increase in local E1 from STS is used to advance proliferation. 
The potential stages of these data have been added to the chromosomal instability 
pathway and are depicted in red in Figure 8.2. 
 
Chapter 8  Discussion 
187 
 
 
Figure 8.2. Increase in oestradiol generation in colorectal cancer. Oestrogen 
metabolism changes in CRC overlaid on the colon cancer chromosomal instability 
pathway shown in Figure 1.4. Early adenoma causes local inflammation with 
resultant TNFα and IL-6 increasing STS activity. Later there is loss of ERβ and 
oxidoreductive HSD17β changes shifting the E1/E2 ratio to increase potent E2 
advancing progression from late adenoma to carcinoma and metastasis. 
 
8.7 FUTURE DIRECTIONS 
To affirm oestrogen metabolism alterations in CRC tumours SULT1E1 and HSD17β 
activity changes would need to be determined in CRC cells and human tissue and 
circulating and tumoural oestrogen concentrations calculated. This could be 
achieved using LC-MS/MS with a newer more sensitive MS. There is evidence 
implicating sex hormones and CRC in both men and women, which correlate 
circulating oestrogen levels with increased risk (Lin et al., 2013, Clendenen et al., 
2009). Few studies have recorded actual circulating concentrations of oestrogens 
in CRC patients due to the difficulty in measurement. A small study compared serum 
E2 of 51 Indian men with CRC against 50 age-matched controls. They demonstrated 
an increase in serum E2 in CRC patients. However, a significant limitation of this 
study is the use of immunoassay to measure E2 within serum (Basu et al., 2015) 
and it would be beneficial to confirm these findings in an LC-MS/MS study.  
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Figure 8.3 Treatments targeting the oestrogen pathway in colorectal cancer. 
Potential treatment targets identified in each chapter are highlighted in red. Further 
research could detect additional therapeutics options such as oestrogen 
metabolites able to activate GPER and downstream pathways of GPER. 
 
This thesis has strategically examined oestrogen metabolism in CRC identifying 
multiple potential therapeutic targets (Figure 8.3). Generally it is more feasible to 
design inhibitors rather than increase expression or activity of an enzyme or 
receptor. Therefore, increasing SULT1E1 activity or specific oxidative HSD17β 
action to reduce oestrogen potency would be challenging. Instead the STS pathway 
for active oestrogen generation could be targeted, such as by preventing E1S uptake 
into the cell by organic anion-transporting polypeptides (Gilligan et al., 2017). E1S 
could be prevented from being desulphated by STS inhibitors, some of which are 
currently in breast cancer trials (Stanway et al., 2006, Palmieri et al., 2016a, Palmieri 
et al., 2016b). Generation of the most potent oestrogen E2, could be reduced by 
selective reductive HSD17β inhibitors. Finally GPER inhibitors could prevent 
oestrogen proliferative action in the colon. In addition to the STS pathway the impact 
of aromatase inhibitors have yet to be assessed in CRC. As with other cancers such 
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as breast and prostate, a combination of different treatments, depending on the 
oestrogen pathway changes seen in each patient, is likely to be most effective.  
 
This thesis has also highlighted other areas of research that may lead to new CRC 
treatments. STS post-translational modification e.g. glycosylation could be targeted 
to reduce activity. Anti-inflammatories have been shown to reduce CRC risk. It 
would be interesting to examine if they have any indirect effects on oestrogen 
metabolism enzymes through COX-2 and TNFα e.g. STS, HSD17β7 and 12, GPER. 
GPER has been shown to be a strong contender for oestrogen action which could 
be further validated by demonstrating stimulation through activation of down-stream 
effects such as connective tissue growth factor (Pandey et al., 2009). Also, other 
oestrogen metabolites may be able to activate GPER and these pathways have yet 
to be examined in CRC. 
 
In addition further study is needed on how other sex steroids interact with the colonic 
environment. The colon has been documented to express progesterone (Oshima et 
al., 1999) and androgen receptors (Gu et al., 2009). In breast cancer the effect of 
sex hormones have been well studied, however using progesterone (Baird and 
Carroll) and androgens as treatment targets remains controversial (Garay and Park, 
2012). This controversy extends to CRC risk and therapeutic application with no 
consensus as to the role of either androgens or progesterone in the colon. It is 
important to note that the protective effects of HRT on CRC risk were only with 
combined oestrogen plus progestin therapy and not oestrogen alone (Ritenbaugh 
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et al., 2008). Also, androgen effects on the colon may also help explain the marked 
gender differences in CRC (Roshan et al., 2016). 
 
The drug targets identified in this thesis may be extrapolated to other cancers and 
diseases. Changes in oestrogen metabolism have been well characterised in breast 
cancer with anti-oestrogen treatment effective in many patients. Similar oestrogen 
enzyme alterations have also been documented in ovarian and endometrial cancer 
and may form future treatment targets (Ren et al., 2015, Rizner et al., 2017). 
However, what is unique to the colon is that it is an extension of the external 
environment and orally administered drugs are directly exposed to the gut. Drugs 
could be engineered to not be systemically absorbed and so could potentially be 
used uniquely to target local CRC and adenomas.  
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APPENDIX I 
Patient colorectal tissue sample characteristics. 
Female: 
 
HBRC No Patient’s Age 
and Sex 
Pathological diagnosis TNM Staging Dukes’ 
Stage 
13654 (N) 
81 F 
Adenocarcinoma distal 
sigmoid colon 
pT3 N1 Mx C1 
13655 (N) 
13656 (C) 
13657 (C) 
 13658 (C) 
73 F 
Adenocarcinoma sigmoid 
colon 
YpT3 N0 Mx B 
13659 (C) 
13660 (N) 
13661 (N) 
13662 (C) 
57F 
MSI-H adenocarcinoma with 
loss of MLHI and PMS2 
expression and BRAF 
mutation within codon 600 
pT2 N1 C 
13663 (N) 
13664 (N) 
13665 (C) 
13666 (N) 
84 F Adenocarcinoma caecum pT4 N0 Mx B 
13667 (C) 
13668 (N) 
72 F 
Caecum MSI high 
adenocarcinoma 
pT3 N2 C 
13669 (C) 
13670 (N) 
71 F 
Invasive sigmoid colon 
adenocarcinoma 
pT4 (4b-TNM 2005) 
N1 Mx 
C1 
13671 (C) 
13672 (N) 
68 F 
Adenocarcinoma, 
sigmoid/upper rectum 
pT3 N1 M1 (liver and 
lung metastases) 
D 
13673 (C) 
S029320 (N) 
85 F 
Moderately differentiated 
mucinous adenocarcinoma 
pT3 N0 B 
S029321 (C) 
S029322 (N) 
86 F 
Invasive caecal mucinous 
adenocarcinoma 
pT3 N0 Mx B 
S029323 (C) 
S029324 (C) 
70 F Adenocarcinoma pT4 N0 Mx B 
S029325 (N) 
S029326 (N) 
76 F 4 adenocarcinomas pT3 (3), pT2 (1) B 
S029327 (C) 
S029328 (N) 
61 F 
Invasive adenocarcinoma of 
caecum 
pT2 N0 Mx A 
S029329 (C) 
S029330 (N) 
86 F 
Mucinous adenocarcinoma 
of colon 
pT2 N0 Mx A 
S029331 (C) 
S029332 (N) 
66 F 
Invasive caecal 
adenocarcinoma 
pT2 N0 Mx A 
S029333 (C) 
S029334 (N) 
82 F 
Adenocarcinoma of right 
colon 
pT4 N1 Mx C1 
S029335 (C) 
S029336 (N) 
87 F MSI-H adenocarcinoma pT3 N1 C 
S029337 (C) 
S029338 (N) 
67 F 
Invasive sigmoid colon 
adenocarcinoma 
pT2 N1 Mx C1 
S029339 (C) 
S029340 (N) 
82 F 
Invasive caecal 
adenocarcinoma 
pT2 N0 Mx A 
S029341 (C) 
S029342 (N) 
63 F Adenocarcinoma pT3 N0 B 
S029343 (C) 
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HBRC No Patient’s Age 
and Sex 
Pathological diagnosis TNM Staging Dukes’ 
Stage 
S029344 (N) 
57 F 
Invasive caecal 
adeocarcinoma 
pT3 N0 Mx B 
S029345 (C) 
S029346 (N) 
72 F Adenocarcinoma pT3 N0 B 
S029347 (C) 
S045959 (N) 
58 F Adenocarcinoma pT3 N0 pMx B 
S045963 (C) 
S046076 (N) 
55 F Adenocarcinoma pT2 N0 A 
S046077 (C) 
S045965 (N) 
63 F Adenocarcinoma pT4 N0 pMx B 
S045966 (C) 
S045967 (N) 
85 F Adenocarcinoma pT4 N0 pMx B 
S045968 (C) 
S045969 (N) 
81 F Adenocarcinoma pT4 N1 Mx C 
S045970 (C) 
S045975 (N) 
72 F Adenocarcinoma pT3 N0 B 
S045976 (C) 
S045981 (N) 
69 F Adenocarcinoma pT2 N1 Mx C 
S045982 (C) 
S045983 (N) 
56 F Adenocarcinoma pT2 N0 Mx A 
S045984 (C) 
S045985 (N) 
60 F Adenocarcinoma pT3 N1 C 
S045986 (C) 
S045987 (N) 
60 F Adenoma  - 
S045988 (T) 
S045989 (N) 
63 F Adenocarcinoma pT4 N1 M1 D 
S045990 (C) 
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Male:  
  
HBRC No Patient’s Age 
and Sex 
Pathological diagnosis TNM Staging Dukes’ 
Stage 
14780 (N) 
76 M 
Advance caecal 
adenocarcinoma 
pT4 N2 C 
14781 (N) 
14782 (C) 
14783 (C) 
14784 (N) 
75 M 
Adenocarcinoma upper 
rectum 
YpT3 N1 Mx C 
14785 (C) 
14786 (N) 
55 M Left colon adenocarcinoma pT4 N0 B 
14787 (C) 
14788 (N) 
75 M 
Invasive sigmoid colon 
adenocarcinoma 
pT3 N0 Mx B 14789 (N) 
14791 (C) 
14792 (N) 
53 M 
Invasive adenocarcinoma of 
splenic flexure and sigmoid 
colon. Tumours invade 
serosa, extramural 
lymphovascular invasion 
pT4 N2 Mx C1 
14793 (C) 
14794 (C) 
14795 (C) 
84 M Adenocarcinoma pT4 N2 C 
14796 (N) 
S029282 (C) 
79 M 
Invasive sigmoid colon 
adenocarcinoma 
pT4 N2 Mx C1 
S029283 (N) 
S029284 (N) 
84 M Adenocarcinoma pT2 N1 Mx C1 
S029285 (C) 
S029286 (N) 
81 M Adenocarcinoma pT3 N1 Mx C1 
S029287 (C) 
S029288 (N) 
90 M Adenocarcinoma pT3 N1 C 
S029289 (C) 
S029290 (C) 
82 M Adenocarcinoma pT3 N1 C 
S029291 (N) 
S029292 (C) 
81 M Adenocarcinoma pT3 N0 B 
S029293 (N) 
S029294 (C) 
83 M Adenocarcinoma left colon pT3 N0 Mx B 
S029295 (N) 
S029296 (N) 
77 M 
MSI-H caecal 
adenocarcinoma 
pT2 N0 A 
S029297 (C) 
S029298 (N) 
53 M Adenocarcinoma pT2 N0 Mx A 
S029299 (C) 
S029300 (N) 
63 M 
Moderately differentiated 
adenocarcinoma 
pT2 N1 Mx C1 
S029301 (C) 
S029302 (N) 
50 M 
Adenocarcinoma of sigmoid 
colon 
ypT2 N0 Mx A 
S029303 (C) 
S029304 (N) 
72 M 
Invasive caecal 
adenocarcinoma 
pT4 N1 Mx C1 
S029305 (C) 
S029306 (N) 
75 M 
Moderately differentiated 
adenocarcinoma 
pT3 N1 C 
S029307 (C) 
S029308 (N) 
62 M Adenocarcinoma pT4 N2 Mx C2 
S029309 (C) 
S029310 (N) 
79 M 
Adenocarcinoma in sigmoid 
colon 
pT1 N0 A 
S029311 (C) 
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HBRC No 
Patient’s Age 
and Sex 
Pathological diagnosis TNM Staging 
Dukes’ 
Stage 
S029312 (N) 
68 M Adenocarcinoma pT3 N1 C 
S029313 (C) 
S029314 (N) 
60 M 
Invasive sigmoid colon 
adenocarcinoma 
pT3 N0 Mx B 
S029315 (C) 
S029316 (N) 
85 M Adenocarcinoma pT3 N0 B 
S029317 (C) 
S029318 (N) 
63 M 
Invasive sigmoid colon 
adenocarcinoma 
pT4 N0 M0 R0 B 
S029319 (C) 
S045961 (N) 
83 M Adenocarcinoma pT3 N0 Mx B 
S045962 (C) 
S045963 (N) 
67 M Adenocarcinoma pT3 N0 B 
S045964 (C) 
S045971 (N) 
79 M Adenocarcinoma pT3 N1 Mx C 
S045972 (C) 
S045973 (N) 
69 M Adenocarcinoma pT2 N0 Mx A 
S045974 (C) 
S045977 (N) 
72 M Adenocarcinoma pT3 N1 M0 C 
S045978 (C) 
S045979 (N) 
79 M Adenocarcinoma pT3 N0 Mx B 
S045980 (C) 
S045991 (N) 
72 M Adenocarcinoma pT3 N2 C 
S045992 (C) 
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APPENDIX II 
Figure II 1 shows both GeNorm and Normfinder selected RPLPO as the best 
individual standard gene for real-time PCR.  
. 
 
Figure II 1. (A) Screenshot from Normfinder showing the more genes used the more 
accurate the data, but if only one is used RPLPO is the most reliable. (B) Screenshot 
from GeNorm showing that RPLPO and HPRT are the most reliable internal 
standard genes for real-time PCR. 
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Figure II 2 shows testing for genes in duplex and singleplex. Genes not displayed 
and reactions performed on mice tissue were singleplex. Note SULT1E1 (I) could 
not be validated and so was not used  
Figure II 2. TaqManTM showing duplex and singleplex reactions for those genes 
used in duplex as standard. All other genes were performed in singleplex.  
17HSD1
20 25 30 35 40
20
25
30
35
40
R
2
=0.9920
Singleplex (Ct)
D
u
p
le
x 
(C
t)
RPLPO
0 10 20 30 40
0
10
20
30
40
R
2
=0.9990
Singleplex (Ct)
D
u
p
le
x 
(C
t)
17HSD2
20 25 30 35 40
20
25
30
35
40
R
2
=0.9948
Singleplex (Ct)
D
u
p
le
x 
(C
t)
RPLPO
0 10 20 30 40
0
10
20
30
40
R
2
=0.9425
Singleplex (Ct)
D
u
p
le
x 
(C
t)
STS
20 25 30 35 40
20
25
30
35
Singleplex (Ct)
D
u
p
le
x 
(C
t)
R
2
=0.999
RPLPO
0 10 20 30 40
0
10
20
30
40
Singleplex (Ct)
D
u
p
le
x 
(C
t)
R
2
=0.9994
(A)
(B)
(C)
 
  Appendix II 
198 
 
17HSD7
20 25 30 35 40 45
25
30
35
40
45
R
2
=0.9967
Singleplex (Ct)
D
u
p
le
x 
(C
t)
RPLPO
0 10 20 30 40
0
10
20
30
40
R
2
=0.9975
Singleplex (Ct)
D
u
p
le
x 
(C
t)
17HSD12
20 25 30 35 40
20
25
30
35
40
R
2
=0.9887
Singleplex (Ct)
D
u
p
le
x 
(C
t)
RPLPO
0 10 20 30 40
0
10
20
30
40
R
2
=0.9887
Singleplex (Ct)
D
u
p
le
x 
(C
t)
ER
20 25 30 35 40
20
25
30
35
40
Singleplex (Ct)
D
u
p
le
x 
(C
t)
R
2
=0.9986
RPLPO
0 10 20 30 40
0
10
20
30
40
Singleplex (Ct)
D
u
p
le
x 
(C
t)
R
2
=0.9981
ER
30 35 40 45
30
35
40
45
Singleplex (Ct)
D
u
p
le
x 
(C
t)
R
2
=0.9971
RPLPO
0 10 20 30 40
0
10
20
30
40
Singleplex (Ct)
D
u
p
le
x 
(C
t)
R
2
=0.9983
(D)
(E)
(F)
(G)
  Appendix II 
199 
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APPENDIX III 
CRC cell line expression performed by previous group members. 
 
Figure III 1. Western blot performed by technician Anne-Marie Hewitt showing 
ERα and ERβ expression in CRC cell lines. 
 
 
Unpublished in vivo data of HCT116 cells overexpressing STS (HCT116[STS]) or 
VO (HCT116[VO]) in nude mice xenografts. 
 
Figure III 2. HCT116 [STS] xenografts in MF-1 mice have increased proliferation in 
vivo. (A) HCT116[STS] xenografts had increased growth rate compared to 
HCT116[VO] xenografts which was inhibited by STX64 (20mg/kg/thrice weekly). 
**p<0.01, ***p<0.001. (B) Wet tumour weights at 21 days post HCT116 cell 
inoculation. HCT116[STS] resulted in increased tumour burden, which was inhibited 
by STX64. *p<0.05, ***p<0.001. (C) Tumour images after removal. Performed by Dr 
P.A. Foster. 
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Figure III 3. Cell lines treated with 10, 20 or 40 ng/ml of TNFα for 24 or 48 hours 
and STS activity measured. Only with higher concentrations and longer time points 
were any significant changes in STS activity seen. Two-way ANOVA with Bonferroni 
post-test, n=3 *p < 0.05, **p < 0.01, ***p < 0.001 
HCT116
C
on
tro
l 
TN
Fa
 1
0n
g/
m
l
TN
Fa
 2
0 
ng
/m
l
TN
Fa
 4
0 
ng
/m
l
0
5
10
15
20
24 hours
48 hours
***
*
E
1
S
 t
o
 E
1
 (
p
m
o
l/
m
g
/h
r)
HT29
C
on
tro
l 
TN
Fa
 1
0n
g/
m
l
TN
Fa
 2
0 
ng
/m
l
TN
Fa
 4
0 
ng
/m
l
0
5
10
15
24 hours
48 hours
E
1
S
 t
o
 E
1
 (
p
m
o
l/
m
g
/h
r)
Caco-2
C
on
tro
l 
TN
Fa
 1
0n
g/
m
l
TN
Fa
 2
0 
ng
/m
l
TN
Fa
 4
0 
ng
/m
l
0
100
200
300
400
24 hours
48 hours
E
1
S
 t
o
 E
1
 (
p
m
o
l/
m
g
/h
r)
(A) (B)
(C)
  References 
202 
 
REFERENCES 
AAKVAAG, A., UTAAKER, E., THORSEN, T., LEA, O. A. & LAHOOTI, H. 1990. 
Growth control of human mammary cancer cells (MCF-7 cells) in culture: 
effect of estradiol and growth factors in serum-containing medium. Cancer 
Res, 50, 7806-10. 
ADAMSKI, J., NORMAND, T., LEENDERS, F., MONTE, D., BEGUE, A., 
STEHELIN, D., JUNGBLUT, P. W. & DE LAUNOIT, Y. 1995. Molecular 
cloning of a novel widely expressed human 80 kDa 17 beta-hydroxysteroid 
dehydrogenase IV. Biochem J, 311 ( Pt 2), 437-43. 
AIT OUAKRIM, D., PIZOT, C., BONIOL, M., MALVEZZI, M., BONIOL, M., NEGRI, 
E., BOTA, M., JENKINS, M. A., BLEIBERG, H. & AUTIER, P. 2015. Trends 
in colorectal cancer mortality in Europe: retrospective analysis of the WHO 
mortality database. BMJ, 351, h4970. 
AKA, J. A., MAZUMDAR, M. & LIN, S. X. 2009. Reductive 17beta-hydroxysteroid 
dehydrogenases in the sulfatase pathway: critical in the cell proliferation of 
breast cancer. Mol Cell Endocrinol, 301, 183-90. 
ALBANITO, L., MADEO, A., LAPPANO, R., VIVACQUA, A., RAGO, V., CARPINO, 
A., OPREA, T. I., PROSSNITZ, E. R., MUSTI, A. M., ANDO, S. & 
MAGGIOLINI, M. 2007. G protein-coupled receptor 30 (GPR30) mediates 
gene expression changes and growth response to 17beta-estradiol and 
selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res, 67, 1859-
66. 
ALBERG, A. J., GORDON, G. B., HOFFMAN, S. C., COMSTOCK, G. W. & 
HELZLSOUER, K. J. 2000. Serum dehydroepiandrosterone and 
dehydroepiandrosterone sulfate and the subsequent risk of developing colon 
cancer. Cancer Epidemiol Biomarkers Prev, 9, 517-21. 
AMOS-LANDGRAF, J. M., HEIJMANS, J., WIELENGA, M. C., DUNKIN, E., 
KRENTZ, K. J., CLIPSON, L., EDERVEEN, A. G., GROOTHUIS, P. G., 
MOSSELMAN, S., MUNCAN, V., HOMMES, D. W., SHEDLOVSKY, A., 
DOVE, W. F. & VAN DEN BRINK, G. R. 2014. Sex disparity in colonic 
adenomagenesis involves promotion by male hormones, not protection by 
female hormones. Proc Natl Acad Sci U S A, 111, 16514-9. 
ANAGNOSTOPOULOU, V., PEDIADITAKIS, I., ALKAHTANI, S., ALARIFI, S. A., 
SCHMIDT, E. M., LANG, F., GRAVANIS, A., CHARALAMPOPOULOS, I. & 
STOURNARAS, C. 2013. Differential effects of dehydroepiandrosterone and 
testosterone in prostate and colon cancer cell apoptosis: the role of nerve 
growth factor (NGF) receptors. Endocrinology, 154, 2446-56. 
ANTAL, M. C., KRUST, A., CHAMBON, P. & MARK, M. 2008. Sterility and absence 
of histopathological defects in nonreproductive organs of a mouse ERbeta-
null mutant. Proc Natl Acad Sci U S A, 105, 2433-8. 
ARAI, N., STROM, A., RAFTER, J. J. & GUSTAFSSON, J. A. 2000. Estrogen 
receptor beta mRNA in colon cancer cells: growth effects of estrogen and 
genistein. Biochem Biophys Res Commun, 270, 425-31. 
ARMAGHANY, T., WILSON, J. D., CHU, Q. & MILLS, G. 2012. Genetic Alterations 
in Colorectal Cancer. Gastrointestinal Cancer Research : GCR, 5, 19-27. 
  References 
203 
 
ATCC. 2016. Cell Lines [Online]. Available: http://www.lgcstandards-
atcc.org/Search_Results.aspx?dsNav=Ntk:PrimarySearch%7ccell+lines%7
c3%7c,Ny:True,Ro:0,N:1000552-4294963975-
4294963778&searchTerms=cell+lines&redir=1 [Accessed 18th Jan 2016]. 
ATKIN, W. S., EDWARDS, R., KRALJ-HANS, I., WOOLDRAGE, K., HART, A. R., 
NORTHOVER, J. M., PARKIN, D. M., WARDLE, J., DUFFY, S. W. & 
CUZICK, J. 2010. Once-only flexible sigmoidoscopy screening in prevention 
of colorectal cancer: a multicentre randomised controlled trial. Lancet, 375, 
1624-33. 
BAIRD, R. D. & CARROLL, J. S. Understanding Oestrogen Receptor Function in 
Breast Cancer and its Interaction with the Progesterone Receptor. New 
Preclinical Findings and their Clinical Implications. Clinical Oncology, 28, 1-
3. 
BARRAL, M., DOHAN, A., ALLEZ, M., BOUDIAF, M., CAMUS, M., LAURENT, V., 
HOEFFEL, C. & SOYER, P. 2015. Gastrointestinal cancers in inflammatory 
bowel disease: An update with emphasis on imaging findings. Crit Rev Oncol 
Hematol. 
BARTON, M. 2016. Not Lost in Translation: Emerging Clinical Importance of the G 
Protein-Coupled Estrogen Receptor GPER. Steroids. 
BASU, A., SETH, S., ARORA, K. & VERMA, M. 2015. Evaluating estradiol levels in 
male patients with colorectal carcinoma. J Clin Diagn Res, 9, BC08-10. 
BAUMGART, D. C. & SANDBORN, W. J. 2007. Inflammatory bowel disease: clinical 
aspects and established and evolving therapies. Lancet, 369, 1641-57. 
BERNSTEIN, M. T., GRAFF, L. A., AVERY, L., PALATNICK, C., PARNEROWSKI, 
K. & TARGOWNIK, L. E. 2014. Gastrointestinal symptoms before and during 
menses in healthy women. BMC Womens Health, 14, 14. 
BERTHOIS, Y., KATZENELLENBOGEN, J. A. & KATZENELLENBOGEN, B. S. 
1986. Phenol red in tissue culture media is a weak estrogen: implications 
concerning the study of estrogen-responsive cells in culture. Proc Natl Acad 
Sci U S A, 83, 2496-500. 
BILINSKI, C., BURLESON, J. & FOROUHAR, F. 2012. Inflammation associated 
with neoplastic colonic polyps. Ann Clin Lab Sci, 42, 266-70. 
BIOTAGE. 2016. ISOLUTE® SPE Columns and Plates [Online]. Available: 
http://www.biotage.com/product-group/isolute-spe-columns-and-plates 
[Accessed 5th Feb 2016]. 
BLANCHARD, P. G. & LUU-THE, V. 2007. Differential androgen and estrogen 
substrates specificity in the mouse and primates type 12 17beta-
hydroxysteroid dehydrogenase. J Endocrinol, 194, 449-55. 
BORK, U., RAHBARI, N. N., SCHOLCH, S., REISSFELDER, C., KAHLERT, C., 
BUCHLER, M. W., WEITZ, J. & KOCH, M. 2015. Circulating tumour cells and 
outcome in non-metastatic colorectal cancer: a prospective study. Br J 
Cancer, 112, 1306-13. 
BOUMAN, A., HEINEMAN, M. J. & FAAS, M. M. 2005. Sex hormones and the 
immune response in humans. Hum Reprod Update, 11, 411-23. 
BRADBURY, J., GENTA-JOUVE, G., ALLWOOD, J. W., DUNN, W. B., 
GOODACRE, R., KNOWLES, J. D., HE, S. & VIANT, M. R. 2015. MUSCLE: 
automated multi-objective evolutionary optimization of targeted LC-MS/MS 
analysis. Bioinformatics, 31, 975-7. 
  References 
204 
 
BREITLING, R., MARIJANOVIC, Z., PEROVIC, D. & ADAMSKI, J. 2001. Evolution 
of 17beta-HSD type 4, a multifunctional protein of beta-oxidation. Mol Cell 
Endocrinol, 171, 205-10. 
BRUCE, L. A. & BESHUDI, F. M. 1981. Increased gastrointestinal motility in vitro 
following chronic estrogen treatment in male rats. Proc Soc Exp Biol Med, 
166, 355-9. 
BULUN, S. E. & SIMPSON, E. R. 1994. Competitive reverse transcription-
polymerase chain reaction analysis indicates that levels of aromatase 
cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and 
abdomen of women increase with advancing age. J Clin Endocrinol Metab, 
78, 428-32. 
BURISCH, J., PEDERSEN, N., CUKOVIC-CAVKA, S., TURK, N., KAIMAKLIOTIS, 
I., DURICOVA, D., BORTLIK, M., SHONOVÁ, O., VIND, I., AVNSTRØM, S., 
THORSGAARD, N., KRABBE, S., ANDERSEN, V., DAHLERUP, J. F., 
KJELDSEN, J., SALUPERE, R., OLSEN, J., NIELSEN, K. R., MANNINEN, 
P., COLLIN, P., KATSANOS, K. H., TSIANOS, E. V., LADEFOGED, K., 
LAKATOS, L., RAGNARSSON, G., BJÖRNSSON, E., BAILEY, Y., 
O'MORAIN, C., SCHWARTZ, D., ODES, S., GIANNOTTA, M., GIRARDIN, 
G., KIUDELIS, G., KUPCINSKAS, L., TURCAN, S., BARROS, L., MAGRO, 
F., LAZAR, D., GOLDIS, A., NIKULINA, I., BELOUSOVA, E., MARTINEZ-
ARES, D., HERNANDEZ, V., ALMER, S., ZHULINA, Y., HALFVARSON, J., 
AREBI, N., TSAI, H. H., SEBASTIAN, S., LAKATOS, P. L., LANGHOLZ, E. 
& MUNKHOLM, P. 2014. Environmental factors in a population-based 
inception cohort of inflammatory bowel disease patients in Europe — An 
ECCO-EpiCom study. Journal of Crohn's and Colitis, 8, 607-616. 
BUSSEY, H. J. 1987. Historical developments in familial polyposis coli. Semin Surg 
Oncol, 3, 67-70. 
CAIAZZA, F., RYAN, E. J., DOHERTY, G., WINTER, D. C. & SHEAHAN, K. 2015. 
Estrogen receptors and their implications in colorectal carcinogenesis. Front 
Oncol, 5, 19. 
CAMPBELL-THOMPSON, M., LYNCH, I. J. & BHARDWAJ, B. 2001. Expression of 
estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. 
Cancer Res, 61, 632-40. 
CANCER RESEARCH, U. 2014. Bowel Cancer Incidence Statistics [Online]. 
Available: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/bowel-cancer/incidence#heading-One 
[Accessed 6th November 2015]. 
CANCER RESEARCH UK. 2014. Bowel Cancer Survival Statistics [Online]. 
Available: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/bowel-cancer/survival#heading-Three 
[Accessed 6th November 2015]. 
CANCER RESEARCH UK. 2015a. TNM and number stages of bowel cancer 
[Online]. Available: http://www.cancerresearchuk.org/about-
cancer/type/bowel-cancer/treatment/tnm-and-number-stages-of-bowel-
cancer [Accessed 5th Jan 2016]. 
CANCER RESEARCH UK. 2015b. Types of Bowel Cancer [Online]. Available: 
http://www.cancerresearchuk.org/about-cancer/type/bowel-
cancer/about/types-of-bowel-cancer [Accessed 4th Jan 2016]. 
  References 
205 
 
CAO, Z., WEST, C., NORTON-WENZEL, C. S., REJ, R., DAVIS, F. B., DAVIS, P. 
J. & REJ, R. 2009. Effects of resin or charcoal treatment on fetal bovine 
serum and bovine calf serum. Endocr Res, 34, 101-8. 
CARMECI, C., THOMPSON, D. A., RING, H. Z., FRANCKE, U. & WEIGEL, R. J. 
1997. Identification of a gene (GPR30) with homology to the G-protein-
coupled receptor superfamily associated with estrogen receptor expression 
in breast cancer. Genomics, 45, 607-17. 
CATALANO, S., GIORDANO, C., PANZA, S., CHEMI, F., BONOFIGLIO, D., 
LANZINO, M., RIZZA, P., ROMEO, F., FUQUA, S. A., MAGGIOLINI, M., 
ANDO, S. & BARONE, I. 2014. Tamoxifen through GPER upregulates 
aromatase expression: a novel mechanism sustaining tamoxifen-resistant 
breast cancer cell growth. Breast Cancer Res Treat, 146, 273-85. 
CAVALLINI, A., MESSA, C., PRICCI, M., CARUSO, M. L., BARONE, M. & DI LEO, 
A. 2002. Distribution of estrogen receptor subtypes, expression of their 
variant forms, and clinicopathological characteristics of human colorectal 
cancer. Dig Dis Sci, 47, 2720-8. 
CHAN, Q. K., LAM, H. M., NG, C. F., LEE, A. Y., CHAN, E. S., NG, H. K., HO, S. 
M. & LAU, K. M. 2010. Activation of GPR30 inhibits the growth of prostate 
cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent 
upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ, 
17, 1511-23. 
CHEN, Z., KASTANIOTIS, A. J., MIINALAINEN, I. J., RAJARAM, V., WIERENGA, 
R. K. & HILTUNEN, J. K. 2009. 17beta-hydroxysteroid dehydrogenase type 
8 and carbonyl reductase type 4 assemble as a ketoacyl reductase of human 
mitochondrial FAS. FASEB J, 23, 3682-91. 
CHENG, S. B., QUINN, J. A., GRAEBER, C. T. & FILARDO, E. J. 2011. Down-
modulation of the G-protein-coupled estrogen receptor, GPER, from the cell 
surface occurs via a trans-Golgi-proteasome pathway. J Biol Chem, 286, 
22441-55. 
CHEVALIER, N., BOUSKINE, A. & FENICHEL, P. 2011. Role of GPER/GPR30 in 
tumoral testicular germ cells proliferation. Cancer Biol Ther, 12, 2-3. 
CHLEBOWSKI, R. T., WACTAWSKI-WENDE, J., RITENBAUGH, C., HUBBELL, F. 
A., ASCENSAO, J., RODABOUGH, R. J., ROSENBERG, C. A., TAYLOR, V. 
M., HARRIS, R., CHEN, C., ADAMS-CAMPBELL, L. L. & WHITE, E. 2004. 
Estrogen plus progestin and colorectal cancer in postmenopausal women. N 
Engl J Med, 350, 991-1004. 
CHOI, J. Y., LEE, K. M., PARK, S. K., NOH, D. Y., AHN, S. H., CHUNG, H. W., 
HAN, W., KIM, J. S., SHIN, S. G., JANG, I. J., YOO, K. Y., HIRVONEN, A. & 
KANG, D. 2005. Genetic polymorphisms of SULT1A1 and SULT1E1 and the 
risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 
1090-5. 
CHOPRA, A. S., KURATNIK, A., SCOCCHERA, E. W., WRIGHT, D. L. & 
GIARDINA, C. 2013. Identification of novel compounds that enhance colon 
cancer cell sensitivity to inflammatory apoptotic ligands. Cancer Biol Ther, 
14, 436-49. 
CHROMACADEMY, C. S. 2016a. Mass Sepctrometry Fundamental LC-MS Mass 
Analysers [Online]. Available: 
  References 
206 
 
http://www.chromacademy.com/lms/sco36/Fundamental_LC-
MS_Mass_Analysers.pdf [Accessed 4th Feb 2016]. 
CHROMACADEMY, C. S. 2016b. Mass Spectrometry Fundamental LC-MS 
Introduction [Online]. Available: http://www.chromacademy.com/mass-spec-
training.html [Accessed 4th feb 2016]. 
CHROMACADEMY, C. S. 2016c. Sample Preparation Liquid/Liquid Extraction 
Techniques [Online]. Available: 
http://www.chromacademy.com/lms/sco59/Sample_Preparation_Liquid-
Liquid_Extraction_Techniques.pdf [Accessed 5th Feb 2016]. 
CIMA, I., CORAZZA, N., DICK, B., FUHRER, A., HERREN, S., JAKOB, S., AYUNI, 
E., MUELLER, C. & BRUNNER, T. 2004. Intestinal Epithelial Cells 
Synthesize Glucocorticoids and Regulate T Cell Activation. The Journal of 
Experimental Medicine, 200, 1635-1646. 
CLELAND, W. H., MENDELSON, C. R. & SIMPSON, E. R. 1985. Effects of Aging 
and Obesity on Aromatase Activity of Human Adipose Cells. The Journal of 
Clinical Endocrinology & Metabolism, 60, 174-177. 
CLENDENEN, T. V., KOENIG, K. L., SHORE, R. E., LEVITZ, M., ARSLAN, A. A. & 
ZELENIUCH-JACQUOTTE, A. 2009. Postmenopausal levels of endogenous 
sex hormones and risk of colorectal cancer. Cancer Epidemiol Biomarkers 
Prev, 18, 275-81. 
COLE, G. B., KEUM, G., LIU, J., SMALL, G. W., SATYAMURTHY, N., KEPE, V. & 
BARRIO, J. R. 2010. Specific estrogen sulfotransferase (SULT1E1) 
substrates and molecular imaging probe candidates. Proc Natl Acad Sci U S 
A, 107, 6222-7. 
COLOTTA, F., ALLAVENA, P., SICA, A., GARLANDA, C. & MANTOVANI, A. 2009. 
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic 
instability. Carcinogenesis, 30, 1073-81. 
CONARY, J., NAUERTH, A., BURNS, G., HASILIK, A. & VON FIGURA, K. 1986. 
Steroid sulfatase. Biosynthesis and processing in normal and mutant 
fibroblasts. Eur J Biochem, 158, 71-6. 
CORBOULD, A. M., JUDD, S. J. & RODGERS, R. J. 1998. Expression of types 1, 
2, and 3 17 beta-hydroxysteroid dehydrogenase in subcutaneous abdominal 
and intra-abdominal adipose tissue of women. J Clin Endocrinol Metab, 83, 
187-94. 
CORDAIN, L., EATON, S. B., SEBASTIAN, A., MANN, N., LINDEBERG, S., 
WATKINS, B. A., O'KEEFE, J. H. & BRAND-MILLER, J. 2005. Origins and 
evolution of the Western diet: health implications for the 21st century. Am J 
Clin Nutr, 81, 341-54. 
CORONA, G., ELIA, C., CASETTA, B., DA PONTE, A., DEL PUP, L., OTTAVIAN, 
E. & TOFFOLI, G. 2010. Liquid chromatography tandem mass spectrometry 
assay for fast and sensitive quantification of estrone-sulfate. Clin Chim Acta, 
411, 574-80. 
COUGHTRIE, M. W. 2002. Sulfation through the looking glass--recent advances in 
sulfotransferase research for the curious. Pharmacogenomics J, 2, 297-308. 
CROHN, B. & ROSENBERG, H. 1925. The sigmoidoscopic picture of chronic 
ulcerative colitis (non-specific). Am J Med Sci, 170, 220-228. 
CRUZ-CORREA, M. & GIARDIELLO, F. M. 2003. Familial adenomatous polyposis. 
Gastrointest Endosc, 58, 885-94. 
  References 
207 
 
CUTOLO, M., SERIOLO, B., VILLAGGIO, B., PIZZORNI, C., CRAVIOTTO, C. & 
SULLI, A. 2002. Androgens and estrogens modulate the immune and 
inflammatory responses in rheumatoid arthritis. Ann N Y Acad Sci, 966, 131-
42. 
DALLA VALLE, L., TOFFOLO, V., NARDI, A., FIORE, C., ARMANINI, D., 
BELVEDERE, P. & COLOMBO, L. 2007. The expression of the human 
steroid sulfatase-encoding gene is driven by alternative first exons. J Steroid 
Biochem Mol Biol, 107, 22-9. 
DANG, Z. C. & LOWIK, C. W. 2005. Removal of serum factors by charcoal treatment 
promotes adipogenesis via a MAPK-dependent pathway. Mol Cell Biochem, 
268, 159-67. 
DAVIES, R. J., MILLER, R. & COLEMAN, N. 2005. Colorectal cancer screening: 
prospects for molecular stool analysis. Nat Rev Cancer, 5, 199-209. 
DAY, J. M., FOSTER, P. A., TUTILL, H. J., PARSONS, M. F., NEWMAN, S. P., 
CHANDER, S. K., ALLAN, G. M., LAWRENCE, H. R., VICKER, N., POTTER, 
B. V., REED, M. J. & PUROHIT, A. 2008a. 17beta-hydroxysteroid 
dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of 
hormone-dependent breast cancer. Int J Cancer, 122, 1931-40. 
DAY, J. M., TUTILL, H. J., NEWMAN, S. P., PUROHIT, A., LAWRENCE, H. R., 
VICKER, N., POTTER, B. V. & REED, M. J. 2006. 17Beta-hydroxysteroid 
dehydrogenase Type 1 and Type 2: association between mRNA expression 
and activity in cell lines. Mol Cell Endocrinol, 248, 246-9. 
DAY, J. M., TUTILL, H. J., PUROHIT, A. & REED, M. J. 2008b. Design and 
validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for 
therapeutic application in breast and prostate cancer, and in endometriosis. 
Endocr Relat Cancer, 15, 665-92. 
DENNIS, M. K., BURAI, R., RAMESH, C., PETRIE, W. K., ALCON, S. N., NAYAK, 
T. K., BOLOGA, C. G., LEITAO, A., BRAILOIU, E., DELIU, E., DUN, N. J., 
SKLAR, L. A., HATHAWAY, H. J., ARTERBURN, J. B., OPREA, T. I. & 
PROSSNITZ, E. R. 2009. In vivo effects of a GPR30 antagonist. Nat Chem 
Biol, 5, 421-7. 
DESTA, Z., WARD, B. A., SOUKHOVA, N. V. & FLOCKHART, D. A. 2004. 
Comprehensive evaluation of tamoxifen sequential biotransformation by the 
human cytochrome P450 system in vitro: prominent roles for CYP3A and 
CYP2D6. J Pharmacol Exp Ther, 310, 1062-75. 
DI DOMENICO, M., CASTORIA, G., BILANCIO, A., MIGLIACCIO, A. & 
AURICCHIO, F. 1996. Estradiol activation of human colon carcinoma-
derived Caco-2 cell growth. Cancer Res, 56, 4516-21. 
DIAS, N. J. & SELCER, K. W. 2016. Steroid sulfatase in the human MG-63 
preosteoblastic cell line: Antagonistic regulation by glucocorticoids and 
NFkappaB. Mol Cell Endocrinol, 420, 85-96. 
DINGER, J. C., HEINEMANN, L. A., MOHNER, S., THAI DO, M. & ASSMANN, A. 
2007. Colon cancer risk and different HRT formulations: a case-control study. 
BMC Cancer, 7, 76. 
DNA DIAGNOSTICS CENTRE. 2015. Human Cell Line Authentication and 
Mycoplasma Detection [Online]. Available: https://www.dna-
bioscience.co.uk/cell-line.php [Accessed 18th Jan 2016]. 
  References 
208 
 
DUANMU, Z., WECKLE, A., KOUKOURITAKI, S. B., HINES, R. N., FALANY, J. L., 
FALANY, C. N., KOCAREK, T. A. & RUNGE-MORRIS, M. 2006. 
Developmental expression of aryl, estrogen, and hydroxysteroid 
sulfotransferases in pre- and postnatal human liver. J Pharmacol Exp Ther, 
316, 1310-7. 
DUAX, W. L., GHOSH, D. & PLETNEV, V. 2000. Steroid dehydrogenase structures, 
mechanism of action, and disease. Vitam Horm, 58, 121-48. 
DUAX, W. L., THOMAS, J., PLETNEV, V., ADDLAGATTA, A., HUETHER, R., 
HABEGGER, L. & WEEKS, C. M. 2005. Determining structure and function 
of steroid dehydrogenase enzymes by sequence analysis, homology 
modeling, and rational mutational analysis. Ann N Y Acad Sci, 1061, 135-48. 
DUKES, C. E. 1932. The classification of cancer of the rectum. The Journal of 
Pathology and Bacteriology, 35, 323-332. 
DUNCAN, L., PUROHIT, A., HOWARTH, N. M., POTTER, B. V. & REED, M. J. 
1993. Inhibition of estrone sulfatase activity by estrone-3-
methylthiophosphonate: a potential therapeutic agent in breast cancer. 
Cancer Res, 53, 298-303. 
EDWARDS, D. P. 2005. Regulation of signal transduction pathways by estrogen 
and progesterone. Annu Rev Physiol, 67, 335-76. 
ELBANNA, H. G., EBRAHIM, M. A., ABBAS, A. M., ZALATA, K. & HASHIM, M. A. 
2012. Potential value of estrogen receptor beta expression in colorectal 
carcinoma: interaction with apoptotic index. J Gastrointest Cancer, 43, 56-
62. 
ENGLISH, M. A., HUGHES, S. V., KANE, K. F., LANGMAN, M. J., STEWART, P. 
M. & HEWISON, M. 2000. Oestrogen inactivation in the colon: analysis of 
the expression and regulation of 17beta-hydroxysteroid dehydrogenase 
isozymes in normal colon and colonic cancer. Br J Cancer, 83, 550-8. 
ENGLISH, M. A., KANE, K. F., CRUICKSHANK, N., LANGMAN, M. J., STEWART, 
P. M. & HEWISON, M. 1999. Loss of estrogen inactivation in colonic cancer. 
J Clin Endocrinol Metab, 84, 2080-5. 
ENGLISH, M. A., STEWART, P. M. & HEWISON, M. 2001. Estrogen metabolism 
and malignancy: analysis of the expression and function of 17beta-
hydroxysteroid dehydrogenases in colonic cancer. Mol Cell Endocrinol, 171, 
53-60. 
FAN, M., NAKSHATRI, H. & NEPHEW, K. P. 2004. Inhibiting proteasomal 
proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol, 18, 
2603-15. 
FANG, Y. J., LU, Z. H., WANG, F., WU, X. J., LI, L. R., ZHANG, L. Y., PAN, Z. Z. & 
WAN, D. S. 2010. Prognostic impact of ERbeta and MMP7 expression on 
overall survival in colon cancer. Tumour Biol, 31, 651-8. 
FANG, Y. J., WANG, G. Q., LU, Z. H., ZHANG, L., LI, J. B., WU, X. J., DING, P. R., 
OU, Q. J., ZHANG, M. F., JIANG, W., PAN, Z. Z. & WAN, D. S. 2012. 
Different effects of ERbeta and TROP2 expression in Chinese patients with 
early-stage colon cancer. Tumour Biol, 33, 2227-35. 
FARRAYE, F. A., ODZE, R. D., EADEN, J. & ITZKOWITZ, S. H. 2010. AGA 
technical review on the diagnosis and management of colorectal neoplasia 
in inflammatory bowel disease. Gastroenterology, 138, 746-74, 774 e1-4; 
quiz e12-3. 
  References 
209 
 
FAUPEL-BADGER, J. M., FUHRMAN, B. J., XU, X., FALK, R. T., KEEFER, L. K., 
VEENSTRA, T. D., HOOVER, R. N. & ZIEGLER, R. G. 2010. Comparison of 
liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods 
for measurement of urinary estrogens. Cancer Epidemiol Biomarkers Prev, 
19, 292-300. 
FEARON, E. R. & VOGELSTEIN, B. 1990. A genetic model for colorectal 
tumorigenesis. Cell, 61, 759-67. 
FENG, Y. & GREGOR, P. 1997. Cloning of a novel member of the G protein-coupled 
receptor family related to peptide receptors. Biochem Biophys Res Commun, 
231, 651-4. 
FERLAY, J., STELIAROVA-FOUCHER, E., LORTET-TIEULENT, J., ROSSO, S., 
COEBERGH, J. W., COMBER, H., FORMAN, D. & BRAY, F. 2013. Cancer 
incidence and mortality patterns in Europe: estimates for 40 countries in 
2012. Eur J Cancer, 49, 1374-403. 
FERRALDESCHI, R., WELTI, J., LUO, J., ATTARD, G. & DE BONO, J. S. 2015. 
Targeting the androgen receptor pathway in castration-resistant prostate 
cancer: progresses and prospects. Oncogene, 34, 1745-1757. 
FILARDO, E., QUINN, J., PANG, Y., GRAEBER, C., SHAW, S., DONG, J. & 
THOMAS, P. 2007. Activation of the novel estrogen receptor G protein-
coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology, 148, 
3236-45. 
FILARDO, E. J. 2002. Epidermal growth factor receptor (EGFR) transactivation by 
estrogen via the G-protein-coupled receptor, GPR30: a novel signaling 
pathway with potential significance for breast cancer. J Steroid Biochem Mol 
Biol, 80, 231-8. 
FILARDO, E. J., GRAEBER, C. T., QUINN, J. A., RESNICK, M. B., GIRI, D., 
DELELLIS, R. A., STEINHOFF, M. M. & SABO, E. 2006. Distribution of 
GPR30, a seven membrane-spanning estrogen receptor, in primary breast 
cancer and its association with clinicopathologic determinants of tumor 
progression. Clin Cancer Res, 12, 6359-66. 
FILARDO, E. J., QUINN, J. A., BLAND, K. I. & FRACKELTON, A. R., JR. 2000. 
Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-
coupled receptor homolog, GPR30, and occurs via trans-activation of the 
epidermal growth factor receptor through release of HB-EGF. Mol 
Endocrinol, 14, 1649-60. 
FILARDO, E. J., QUINN, J. A., FRACKELTON, A. R., JR. & BLAND, K. I. 2002. 
Estrogen action via the G protein-coupled receptor, GPR30: stimulation of 
adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth 
factor receptor-to-MAPK signaling axis. Mol Endocrinol, 16, 70-84. 
FILARDO, E. J. & THOMAS, P. 2012. Minireview: G protein-coupled estrogen 
receptor-1, GPER-1: its mechanism of action and role in female reproductive 
cancer, renal and vascular physiology. Endocrinology, 153, 2953-62. 
FIORELLI, G., PICARIELLO, L., MARTINETI, V., TONELLI, F. & BRANDI, M. L. 
1999. Functional estrogen receptor beta in colon cancer cells. Biochem 
Biophys Res Commun, 261, 521-7. 
FLORES, A., BURSTEIN, E., CIPHER, D. J. & FEAGINS, L. A. 2015. Obesity in 
Inflammatory Bowel Disease: A Marker of Less Severe Disease. Dig Dis Sci, 
60, 2436-45. 
  References 
210 
 
FLORES, M. B., ROCHA, G. Z., DAMAS-SOUZA, D. M., OSORIO-COSTA, F., 
DIAS, M. M., ROPELLE, E. R., CAMARGO, J. A., DE CARVALHO, R. B., 
CARVALHO, H. F., SAAD, M. J. & CARVALHEIRA, J. B. 2012. Obesity-
induced increase in tumor necrosis factor-alpha leads to development of 
colon cancer in mice. Gastroenterology, 143, 741-53.e1-4. 
FOMITCHEVA, J., BAKER, M. E., ANDERSON, E., LEE, G. Y. & AZIZ, N. 1998. 
Characterization of Ke 6, a new 17beta-hydroxysteroid dehydrogenase, and 
its expression in gonadal tissues. J Biol Chem, 273, 22664-71. 
FOSTER, P. A. 2013. Oestrogen and colorectal cancer: mechanisms and 
controversies. Int J Colorectal Dis, 28, 737-49. 
FOSTER, P. A., CHANDER, S. K., NEWMAN, S. P., WOO, L. W., SUTCLIFFE, O. 
B., BUBERT, C., ZHOU, D., CHEN, S., POTTER, B. V., REED, M. J. & 
PUROHIT, A. 2008. A new therapeutic strategy against hormone-dependent 
breast cancer: the preclinical development of a dual aromatase and sulfatase 
inhibitor. Clin Cancer Res, 14, 6469-77. 
FRANCO, R., BOSCIA, F., GIGANTINO, V., MARRA, L., ESPOSITO, F., 
FERRARA, D., PARIANTE, P., BOTTI, G., CARAGLIA, M., MINUCCI, S. & 
CHIEFFI, P. 2011. GPR30 is overexpressed in post-puberal testicular germ 
cell tumors. Cancer Biol Ther, 11, 609-13. 
FRANZON, V. L., GIBSON, M. A., HATZINIKOLAS, G., WOOLLATT, E., 
SUTHERLAND, G. R. & CLEARY, E. G. 1999. Molecular cloning of a novel 
human PAPS synthetase which is differentially expressed in metastatic and 
non-metastatic colon carcinoma cells. Int J Biochem Cell Biol, 31, 613-26. 
FRAUMENI, J. F., JR., LLOYD, J. W., SMITH, E. M. & WAGONER, J. K. 1969. 
Cancer mortality among nuns: role of marital status in etiology of neoplastic 
disease in women. J Natl Cancer Inst, 42, 455-68. 
GALAND, P., RODESCH, F., LEROY, F. & CHRETIEN, J. 1967. Altered duration of 
DNA synthesis and cell cycle in non-target tissues of mice treated with 
oestrogen. Nature, 216, 1211-2. 
GALUSKA, C. E., HARTMANN, M. F., SANCHEZ-GUIJO, A., BAKHAUS, K., 
GEYER, J., SCHULER, G., ZIMMER, K. P. & WUDY, S. A. 2013. Profiling 
intact steroid sulfates and unconjugated steroids in biological fluids by liquid 
chromatography-tandem mass spectrometry (LC-MS-MS). Analyst, 138, 
3792-801. 
GANGADHAR, T. & SCHILSKY, R. L. 2010. Molecular markers to individualize 
adjuvant therapy for colon cancer. Nat Rev Clin Oncol, 7, 318-25. 
GAO, F., MA, X., OSTMANN, A. B. & DAS, S. K. 2011. GPR30 Activation Opposes 
Estrogen-Dependent Uterine Growth via Inhibition of Stromal ERK1/2 and 
Estrogen Receptor Alpha (ERα) Phosphorylation Signals. Endocrinology, 
152, 1434-1447. 
GARAY, J. P. & PARK, B. H. 2012. Androgen receptor as a targeted therapy for 
breast cancer. American Journal of Cancer Research, 2, 434-445. 
GAUDET, H. M., CHENG, S. B., CHRISTENSEN, E. M. & FILARDO, E. J. 2015. 
The G-protein coupled estrogen receptor, GPER: The inside and inside-out 
story. Mol Cell Endocrinol, 418 Pt 3, 207-19. 
GHOSH, D. 2007. Human sulfatases: a structural perspective to catalysis. Cell Mol 
Life Sci, 64, 2013-22. 
  References 
211 
 
GILLESSEN, S., TEMPLETON, A., MARRA, G., KUO, Y. F., VALTORTA, E. & 
SHAHINIAN, V. B. 2010. Risk of colorectal cancer in men on long-term 
androgen deprivation therapy for prostate cancer. J Natl Cancer Inst, 102, 
1760-70. 
GILLIGAN, L. C., GONDAL, A., TANG, V., HUSSAIN, M. T., ARVANITI, A., 
HEWITT, A.-M. & FOSTER, P. A. 2017. Estrone Sulfate Transport and 
Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone 
Replacement Therapy. Frontiers in Pharmacology, 8. 
GILSING, A. M., SCHOUTEN, L. J., GOLDBOHM, R. A., DAGNELIE, P. C., VAN 
DEN BRANDT, P. A. & WEIJENBERG, M. P. 2015. Vegetarianism, low meat 
consumption and the risk of colorectal cancer in a population based cohort 
study. Sci Rep, 5, 13484. 
GIORGINO, F., LAVIOLA, L. & ERIKSSON, J. W. 2005. Regional differences of 
insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta 
Physiol Scand, 183, 13-30. 
GIOVANNUCCI, E., RIMM, E. B., ASCHERIO, A., STAMPFER, M. J., COLDITZ, G. 
A. & WILLETT, W. C. 1995. Alcohol, low-methionine--low-folate diets, and 
risk of colon cancer in men. J Natl Cancer Inst, 87, 265-73. 
GIOVANNUCCI, E., STAMPFER, M. J., COLDITZ, G. A., HUNTER, D. J., FUCHS, 
C., ROSNER, B. A., SPEIZER, F. E. & WILLETT, W. C. 1998. Multivitamin 
use, folate, and colon cancer in women in the Nurses' Health Study. Ann 
Intern Med, 129, 517-24. 
GIOVANNUCCI, E., STAMPFER, M. J., COLDITZ, G. A., RIMM, E. B., 
TRICHOPOULOS, D., ROSNER, B. A., SPEIZER, F. E. & WILLETT, W. C. 
1993. Folate, methionine, and alcohol intake and risk of colorectal adenoma. 
J Natl Cancer Inst, 85, 875-84. 
GIRGERT, R., EMONS, G. & GRUNDKER, C. 2014. Inhibition of GPR30 by estriol 
prevents growth stimulation of triple-negative breast cancer cells by 17beta-
estradiol. BMC Cancer, 14, 935. 
GONG, H., JARZYNKA, M. J., COLE, T. J., LEE, J. H., WADA, T., ZHANG, B., 
GAO, J., SONG, W. C., DEFRANCO, D. B., CHENG, S. Y. & XIE, W. 2008. 
Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated 
activation of estrogen sulfotransferase. Cancer Res, 68, 7386-93. 
GRAVALLESE, E. M. & KANTROWITZ, F. G. 1988. Arthritic manifestations of 
inflammatory bowel disease. Am J Gastroenterol, 83, 703-9. 
GU, S., PAPADOPOULOU, N., GEHRING, E. M., NASIR, O., DIMAS, K., 
BHAVSAR, S. K., FOLLER, M., ALEVIZOPOULOS, K., LANG, F. & 
STOURNARAS, C. 2009. Functional membrane androgen receptors in colon 
tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor 
incidence in vivo. Mol Cancer, 8, 114. 
GUINNEY, J., DIENSTMANN, R., WANG, X., DE REYNIES, A., SCHLICKER, A., 
SONESON, C., MARISA, L., ROEPMAN, P., NYAMUNDANDA, G., 
ANGELINO, P., BOT, B. M., MORRIS, J. S., SIMON, I. M., GERSTER, S., 
FESSLER, E., DE SOUSA, E. M. F., MISSIAGLIA, E., RAMAY, H., BARRAS, 
D., HOMICSKO, K., MARU, D., MANYAM, G. C., BROOM, B., BOIGE, V., 
PEREZ-VILLAMIL, B., LADERAS, T., SALAZAR, R., GRAY, J. W., 
HANAHAN, D., TABERNERO, J., BERNARDS, R., FRIEND, S. H., 
LAURENT-PUIG, P., MEDEMA, J. P., SADANANDAM, A., WESSELS, L., 
  References 
212 
 
DELORENZI, M., KOPETZ, S., VERMEULEN, L. & TEJPAR, S. 2015. The 
consensus molecular subtypes of colorectal cancer. Nat Med, 21, 1350-6. 
GULCAN, H. O. & DUFFEL, M. W. 2011. Substrate inhibition in human 
hydroxysteroid sulfotransferase SULT2A1: studies on the formation of 
catalytically non-productive enzyme complexes. Arch Biochem Biophys, 507, 
232-40. 
GUO, Y., XIAO, P., LEI, S., DENG, F., XIAO, G. G., LIU, Y., CHEN, X., LI, L., WU, 
S., CHEN, Y., JIANG, H., TAN, L., XIE, J., ZHU, X., LIANG, S. & DENG, H. 
2008. How is mRNA expression predictive for protein expression? A 
correlation study on human circulating monocytes. Acta Biochim Biophys Sin 
(Shanghai), 40, 426-36. 
HAMILTON, K. E., SIMMONS, J. G., DING, S., VAN LANDEGHEM, L. & LUND, P. 
K. 2011. Cytokine induction of tumor necrosis factor receptor 2 is mediated 
by STAT3 in colon cancer cells. Mol Cancer Res, 9, 1718-31. 
HANAHAN, D. & WEINBERG, R. A. 2000. The hallmarks of cancer. Cell, 100, 57-
70. 
HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. 
Cell, 144, 646-74. 
HANDELSMAN, D. J. & WARTOFSKY, L. 2013. Requirement for mass 
spectrometry sex steroid assays in the Journal of Clinical Endocrinology and 
Metabolism. J Clin Endocrinol Metab, 98, 3971-3. 
HARDY, R. S., DOIG, C. L., HUSSAIN, Z., O'LEARY, M., MORGAN, S. A., 
PEARSON, M. J., NAYLOR, A., JONES, S. W., FILER, A., STEWART, P. 
M., BUCKLEY, C. D., LAVERY, G. G., COOPER, M. S. & RAZA, K. 2016. 
11beta-Hydroxysteroid dehydrogenase type 1 within muscle protects against 
the adverse effects of local inflammation. J Pathol, 240, 472-483. 
HARJES, S., BAYER, P. & SCHEIDIG, A. J. 2005. The crystal structure of human 
PAPS synthetase 1 reveals asymmetry in substrate binding. J Mol Biol, 347, 
623-35. 
HE, Y. Q., SHENG, J. Q., LING, X. L., FU, L., JIN, P., YEN, L. & RAO, J. 2012. 
Estradiol regulates miR-135b and mismatch repair gene expressions via 
estrogen receptor-beta in colorectal cells. Exp Mol Med, 44, 723-32. 
HEINE, P. A., TAYLOR, J. A., IWAMOTO, G. A., LUBAHN, D. B. & COOKE, P. S. 
2000. Increased adipose tissue in male and female estrogen receptor-alpha 
knockout mice. Proc Natl Acad Sci U S A, 97, 12729-34. 
HEISKANEN, I., LUOSTARINEN, T. & JARVINEN, H. J. 2000. Impact of screening 
examinations on survival in familial adenomatous polyposis. Scand J 
Gastroenterol, 35, 1284-7. 
HEMSELL, D. L., GRODIN, J. M., BRENNER, P. F., SIITERI, P. K. & MACDONALD, 
P. C. 1974. Plasma Precursors of Estrogen. II. Correlation of the Extent of 
Conversion of Plasma Androstenedione to Estrone with Age. The Journal of 
Clinical Endocrinology & Metabolism, 38, 476-479. 
HENDIFAR, A., YANG, D., LENZ, F., LURJE, G., POHL, A., LENZ, C., NING, Y., 
ZHANG, W. & LENZ, H. J. 2009. Gender disparities in metastatic colorectal 
cancer survival. Clin Cancer Res, 15, 6391-7. 
HER, C., AKSOY, I. A., KIMURA, S., BRANDRIFF, B. F., WASMUTH, J. J. & 
WEINSHILBOUM, R. M. 1995. Human estrogen sulfotransferase gene 
  References 
213 
 
(STE): cloning, structure, and chromosomal localization. Genomics, 29, 16-
23. 
HERNANDEZ-GUZMAN, F. G., HIGASHIYAMA, T., PANGBORN, W., OSAWA, Y. 
& GHOSH, D. 2003. Structure of human estrone sulfatase suggests 
functional roles of membrane association. J Biol Chem, 278, 22989-97. 
HILDEBRAND, J. S., JACOBS, E. J., CAMPBELL, P. T., MCCULLOUGH, M. L., 
TERAS, L. R., THUN, M. J. & GAPSTUR, S. M. 2009. Colorectal cancer 
incidence and postmenopausal hormone use by type, recency, and duration 
in cancer prevention study II. Cancer Epidemiol Biomarkers Prev, 18, 2835-
41. 
HIRATA, H., HINODA, Y., OKAYAMA, N., SUEHIRO, Y., KAWAMOTO, K., 
KIKUNO, N., RABBAN, J. T., CHEN, L. M. & DAHIYA, R. 2008. CYP1A1, 
SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial 
cancer susceptibility. Cancer, 112, 1964-73. 
HODGIN, J. B., KREGE, J. H., REDDICK, R. L., KORACH, K. S., SMITHIES, O. & 
MAEDA, N. 2001. Estrogen receptor alpha is a major mediator of 17beta-
estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin 
Invest, 107, 333-40. 
HOFF, M. B., CHANG, W. W. & MAK, K. M. 1981. Effect of estrogen on cell 
proliferation in colonic mucosa of the mouse. Virchows Arch B Cell Pathol 
Incl Mol Pathol, 35, 263-73. 
HONMA, S., SHIMODAIRA, K., SHIMIZU, Y., TSUCHIYA, N., SAITO, H., 
YANAIHARA, T. & OKAI, T. 2002. The influence of inflammatory cytokines 
on estrogen production and cell proliferation in human breast cancer cells. 
Endocr J, 49, 371-7. 
HONOUR, J. W. 2011. Development and validation of a quantitative assay based 
on tandem mass spectrometry. Ann Clin Biochem, 48, 97-111. 
HOTAMISLIGIL, G. S., ARNER, P., CARO, J. F., ATKINSON, R. L. & 
SPIEGELMAN, B. M. 1995. Increased adipose tissue expression of tumor 
necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest, 
95, 2409-15. 
HOTAMISLIGIL, G. S., SHARGILL, N. S. & SPIEGELMAN, B. M. 1993. Adipose 
expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin 
resistance. Science, 259, 87-91. 
HOWELL, S. J., JOHNSTON, S. R. & HOWELL, A. 2004. The use of selective 
estrogen receptor modulators and selective estrogen receptor down-
regulators in breast cancer. Best Pract Res Clin Endocrinol Metab, 18, 47-
66. 
HSU, H.-H., KUO, W.-W., JU, D.-T., YEH, Y.-L., TU, C.-C., TSAI, Y.-L., SHEN, C.-
Y., CHANG, S.-H., CHUNG, L.-C. & HUANG, C.-Y. 2014. Estradiol agonists 
inhibit human LoVo colorectal-cancer cell proliferation and migration through 
p53. World Journal of Gastroenterology : WJG, 20, 16665-16673. 
HUHTANIEMI, I. T., TAJAR, A., LEE, D. M., O'NEILL, T. W., FINN, J. D., BARTFAI, 
G., BOONEN, S., CASANUEVA, F. F., GIWERCMAN, A., HAN, T. S., KULA, 
K., LABRIE, F., LEAN, M. E., PENDLETON, N., PUNAB, M., SILMAN, A. J., 
VANDERSCHUEREN, D., FORTI, G. & WU, F. C. 2012. Comparison of 
serum testosterone and estradiol measurements in 3174 European men 
  References 
214 
 
using platform immunoassay and mass spectrometry; relevance for the 
diagnostics in aging men. Eur J Endocrinol, 166, 983-91. 
IGNATOV, A., IGNATOV, T., WEISSENBORN, C., EGGEMANN, H., BISCHOFF, 
J., SEMCZUK, A., ROESSNER, A., COSTA, S. D. & KALINSKI, T. 2011. G-
protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast 
cancer. Breast Cancer Res Treat, 128, 457-66. 
IM, H.-J., PARK, N.-H., KWON, Y.-J., SHIN, S., KIM, D. & CHUN, Y.-J. 2012. 
Bacterial Lipopolysaccharides Induce Steroid Sulfatase Expression and Cell 
Migration through IL-6 Pathway in Human Prostate Cancer Cells. 
Biomolecules & Therapeutics, 20, 556-561. 
INSIGHT. 2016. International Society for Gastrointestinal Hereditary Tumours 
Guidelines, [Online]. Available: http://insight-group.org/pdf/FAP-
guidelines.pd [Accessed 25th April 2016]. 
JAMES, M. R., SKAAR, T. C., LEE, R. Y., MACPHERSON, A., ZWIEBEL, J. A., 
AHLUWALIA, B. S., AMPY, F. & CLARKE, R. 2001. Constitutive expression 
of the steroid sulfatase gene supports the growth of MCF-7 human breast 
cancer cells in vitro and in vivo. Endocrinology, 142, 1497-505. 
JANSSON, A. K., GUNNARSSON, C., COHEN, M., SIVIK, T. & STAL, O. 2006. 
17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast 
cancer cells and is a prognostic marker in estrogen receptor-positive breast 
cancer. Cancer Res, 66, 11471-7. 
JARVINEN, H. J., AARNIO, M., MUSTONEN, H., AKTAN-COLLAN, K., 
AALTONEN, L. A., PELTOMAKI, P., DE LA CHAPELLE, A. & MECKLIN, J. 
P. 2000. Controlled 15-year trial on screening for colorectal cancer in families 
with hereditary nonpolyposis colorectal cancer. Gastroenterology, 118, 829-
34. 
JIANG, M., HE, J., KUCERA, H., GAIKWAD, N. W., ZHANG, B., XU, M., 
O'DOHERTY, R. M., SELCER, K. W. & XIE, W. 2014. Hepatic 
overexpression of steroid sulfatase ameliorates mouse models of obesity 
and type 2 diabetes through sex-specific mechanisms. J Biol Chem, 289, 
8086-97. 
JIANG, M., KLEIN, M., ZANGER, U. M., MOHAMMAD, M. K., CAVE, M. C., 
GAIKWAD, N. W., DIAS, N. J., SELCER, K. W., GUO, Y., HE, J., ZHANG, 
X., SHEN, Q., QIN, W., LI, J., LI, S. & XIE, W. 2016. Inflammatory regulation 
of steroid sulfatase: A novel mechanism to control estrogen homeostasis and 
inflammation in chronic liver disease. J Hepatol, 64, 44-52. 
JOHNSON, J. R., LACEY, J. V., JR., LAZOVICH, D., GELLER, M. A., SCHAIRER, 
C., SCHATZKIN, A. & FLOOD, A. 2009. Menopausal hormone therapy and 
risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 18, 196-203. 
KAPIT, W. & ELSON, L. The Anatomy Coloring Book, Benjamin Cummings. 
KAPIT, W., MACEY, R. & MEISAMI, E. 2000. The Physiology Coloring Book, 
Addision Wesley Longman Inc. 
KAPOOR, V. 2013. Colon Anatomy [Online]. Medscape. Available: 
http://emedicine.medscape.com/article/1949039-overview [Accessed 8th 
May 2016]. 
KEFFER, J., PROBERT, L., CAZLARIS, H., GEORGOPOULOS, S., KASLARIS, E., 
KIOUSSIS, D. & KOLLIAS, G. 1991. Transgenic mice expressing human 
  References 
215 
 
tumour necrosis factor: a predictive genetic model of arthritis. EMBO J, 10, 
4025-31. 
KENDRICK, N. 2014. A gene's mRNA level does not usually predict its protein level. 
KENNELLY, R., KAVANAGH, D. O., HOGAN, A. M. & WINTER, D. C. 2008. 
Oestrogen and the colon: potential mechanisms for cancer prevention. 
Lancet Oncol, 9, 385-91. 
KESTER, M. H., BULDUK, S., VAN TOOR, H., TIBBOEL, D., MEINL, W., GLATT, 
H., FALANY, C. N., COUGHTRIE, M. W., SCHUUR, A. G., BROUWER, A. 
& VISSER, T. J. 2002. Potent inhibition of estrogen sulfotransferase by 
hydroxylated metabolites of polyhalogenated aromatic hydrocarbons reveals 
alternative mechanism for estrogenic activity of endocrine disrupters. J Clin 
Endocrinol Metab, 87, 1142-50. 
KOIVISTO, V. A., YKI-JARVINEN, H. & DEFRONZO, R. A. 1986. Physical training 
and insulin sensitivity. Diabetes Metab Rev, 1, 445-81. 
KONTOYIANNIS, D., PASPARAKIS, M., PIZARRO, T. T., COMINELLI, F. & 
KOLLIAS, G. 1999. Impaired on/off regulation of TNF biosynthesis in mice 
lacking TNF AU-rich elements: implications for joint and gut-associated 
immunopathologies. Immunity, 10, 387-98. 
KOZUKA, S., NOGAKI, M., OZEKI, T. & MASUMORI, S. 1975. Premalignancy of 
the mucosal polyp in the large intestine: II. Estimation of the periods required 
for malignant transformation of mucosal polyps. Dis Colon Rectum, 18, 494-
500. 
KRAMER, H. U., SCHOTTKER, B., RAUM, E. & BRENNER, H. 2012. Type 2 
diabetes mellitus and colorectal cancer: meta-analysis on sex-specific 
differences. Eur J Cancer, 48, 1269-82. 
KRASOWSKI, M. D., DREES, D., MORRIS, C. S., MAAKESTAD, J., BLAU, J. L. & 
EKINS, S. 2014. Cross-reactivity of steroid hormone immunoassays: clinical 
significance and two-dimensional molecular similarity prediction. BMC Clin 
Pathol, 14, 33. 
KRAZEISEN, A., BREITLING, R., IMAI, K., FRITZ, S., MOLLER, G. & ADAMSKI, 
J. 1999. Determination of cDNA, gene structure and chromosomal 
localization of the novel human 17beta-hydroxysteroid dehydrogenase type 
7(1). FEBS Lett, 460, 373-9. 
KROTKIEWSKI, M., BJORNTORP, P., SJOSTROM, L. & SMITH, U. 1983. Impact 
of obesity on metabolism in men and women. Importance of regional adipose 
tissue distribution. J Clin Invest, 72, 1150-62. 
KUSHNIR, M. M., ROCKWOOD, A. L., YUE, B. & MEIKLE, A. W. 2010. High 
sensitivity measurement of estrone and estradiol in serum and plasma using 
LC-MS/MS. Methods Mol Biol, 603, 219-28. 
LABRIE, F., LUU-THE, V., LIN, S. X., LABRIE, C., SIMARD, J., BRETON, R. & 
BELANGER, A. 1997. The key role of 17 beta-hydroxysteroid 
dehydrogenases in sex steroid biology. Steroids, 62, 148-58. 
LAFFERTY, A. R., TORPY, D. J., STOWASSER, M., TAYMANS, S. E., LIN, J. P., 
HUGGARD, P., GORDON, R. D. & STRATAKIS, C. A. 2000. A novel genetic 
locus for low renin hypertension: familial hyperaldosteronism type II maps to 
chromosome 7 (7p22). J Med Genet, 37, 831-5. 
LARSSON, S. C. & WOLK, A. 2006. Meat consumption and risk of colorectal 
cancer: a meta-analysis of prospective studies. Int J Cancer, 119, 2657-64. 
  References 
216 
 
LEE, J. S., ETTINGER, B., STANCZYK, F. Z., VITTINGHOFF, E., HANES, V., 
CAULEY, J. A., CHANDLER, W., SETTLAGE, J., BEATTIE, M. S., 
FOLKERD, E., DOWSETT, M., GRADY, D. & CUMMINGS, S. R. 2006. 
Comparison of methods to measure low serum estradiol levels in 
postmenopausal women. J Clin Endocrinol Metab, 91, 3791-7. 
LEOWARDI, C., SCHNEIDER, M. L., HINZ, U., HARNOSS, J. M., TARANTINO, I., 
LASITSCHKA, F., ULRICH, A., BUCHLER, M. W. & KADMON, M. 2016. 
Prognosis of Ulcerative Colitis-Associated Colorectal Carcinoma Compared 
to Sporadic Colorectal Carcinoma: A Matched Pair Analysis. Ann Surg 
Oncol, 23, 870-6. 
LI, Y., XU, J., JIANG, F., JIANG, Z., LIU, C., LI, L., LUO, Y., LU, R., MU, Y., LIU, Y. 
& XUE, B. 2015. G protein-coupled estrogen receptor is involved in 
modulating colonic motor function via nitric oxide release in C57BL/6 female 
mice. Neurogastroenterol Motil. 
LIN, J. H. & GIOVANNUCCI, E. 2010. Sex hormones and colorectal cancer: what 
have we learned so far? J Natl Cancer Inst, 102, 1746-7. 
LIN, J. H., ZHANG, S. M., REXRODE, K. M., MANSON, J. E., CHAN, A. T., WU, 
K., TWOROGER, S. S., HANKINSON, S. E., FUCHS, C., GAZIANO, J. M., 
BURING, J. E. & GIOVANNUCCI, E. 2013. Association between sex 
hormones and colorectal cancer risk in men and women. Clin Gastroenterol 
Hepatol, 11, 419-424 e1. 
LIU, H., YAN, Y., WEN, H., JIANG, X., CAO, X., ZHANG, G. & LIU, G. 2014. A novel 
estrogen receptor GPER mediates proliferation induced by 17beta-estradiol 
and selective GPER agonist G-1 in estrogen receptor alpha (ERalpha)-
negative ovarian cancer cells. Cell Biol Int, 38, 631-8. 
LUBAHN, D. B., MOYER, J. S., GOLDING, T. S., COUSE, J. F., KORACH, K. S. & 
SMITHIES, O. 1993. Alteration of reproductive function but not prenatal 
sexual development after insertional disruption of the mouse estrogen 
receptor gene. Proc Natl Acad Sci U S A, 90, 11162-6. 
LUKACIK, P., KAVANAGH, K. L. & OPPERMANN, U. 2006. Structure and function 
of human 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol, 248, 
61-71. 
LUKACIK, P., KELLER, B., BUNKOCZI, G., KAVANAGH, K. L., LEE, W. H., 
ADAMSKI, J. & OPPERMANN, U. 2007. Structural and biochemical 
characterization of human orphan DHRS10 reveals a novel cytosolic enzyme 
with steroid dehydrogenase activity. Biochem J, 402, 419-27. 
LUNDANES, E., REUBSAET, L. & GEEIBROKK, T. 2014. Chromatography: Basic 
Principles, Sample Preparations and Related Methods, Wiley. 
LUQUE-GARCÍA, J. L., MARTÍNEZ-TORRECUADRADA, J. L., EPIFANO, C., 
CAÑAMERO, M., BABEL, I. & CASAL, J. I. 2010. Differential protein 
expression on the cell surface of colorectal cancer cells associated to tumor 
metastasis. PROTEOMICS, 10, 940-952. 
LUU-THE, V., TREMBLAY, P. & LABRIE, F. 2006. Characterization of type 12 
17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-
hydroxysteroid dehydrogenase responsible for estradiol formation in women. 
Mol Endocrinol, 20, 437-43. 
MACAULAY, V. M., NICHOLLS, J. E., GLEDHILL, J., ROWLANDS, M. G., 
DOWSETT, M. & ASHWORTH, A. 1994. Biological effects of stable 
  References 
217 
 
overexpression of aromatase in human hormone-dependent breast cancer 
cells. Br J Cancer, 69, 77-83. 
MACDOUGALL, I. P. 1964. THE CANCER RISK IN ULCERATIVE COLITIS. 
Lancet, 2, 655-8. 
MAIER, T., GUELL, M. & SERRANO, L. 2009. Correlation of mRNA and protein in 
complex biological samples. FEBS Lett, 583, 3966-73. 
MAITI, K., PAUL, J. W., READ, M., CHAN, E. C., RILEY, S. C., NAHAR, P. & 
SMITH, R. 2011. G-1-activated membrane estrogen receptors mediate 
increased contractility of the human myometrium. Endocrinology, 152, 2448-
55. 
MALINI, B., PUROHIT, A., GANESHAPILLAI, D., WOO, L. W. L., POTTER, B. V. L. 
& REED, M. J. 2000. Inhibition of steroid sulphatase activity by tricyclic 
coumarin sulphamates. The Journal of Steroid Biochemistry and Molecular 
Biology, 75, 253-258. 
MALLET, A. I. & DOWN, S. 2010. Dictionary of Mass Spectrometry, Wiley. 
MARIJANOVIC, Z., LAUBNER, D., MOLLER, G., GEGE, C., HUSEN, B., 
ADAMSKI, J. & BREITLING, R. 2003. Closing the gap: identification of 
human 3-ketosteroid reductase, the last unknown enzyme of mammalian 
cholesterol biosynthesis. Mol Endocrinol, 17, 1715-25. 
MARJON, N. A., HU, C., HATHAWAY, H. J. & PROSSNITZ, E. R. 2014. G protein-
coupled estrogen receptor (GPER) regulates mammary tumorigenesis and 
metastasis. Molecular cancer research : MCR, 12, 1644-1654. 
MARTEL, C., RHEAUME, E., TAKAHASHI, M., TRUDEL, C., COUET, J., LUU-
THE, V., SIMARD, J. & LABRIE, F. 1992. Distribution of 17 beta-
hydroxysteroid dehydrogenase gene expression and activity in rat and 
human tissues. J Steroid Biochem Mol Biol, 41, 597-603. 
MARTENSSON, U. E., SALEHI, S. A., WINDAHL, S., GOMEZ, M. F., SWARD, K., 
DASZKIEWICZ-NILSSON, J., WENDT, A., ANDERSSON, N., 
HELLSTRAND, P., GRANDE, P. O., OWMAN, C., ROSEN, C. J., ADAMO, 
M. L., LUNDQUIST, I., RORSMAN, P., NILSSON, B. O., OHLSSON, C., 
OLDE, B. & LEEB-LUNDBERG, L. M. 2009. Deletion of the G protein-
coupled receptor 30 impairs glucose tolerance, reduces bone growth, 
increases blood pressure, and eliminates estradiol-stimulated insulin release 
in female mice. Endocrinology, 150, 687-98. 
MARUGO, M., ASTE, H., BERNASCONI, D., FAZZUOLI, L., CONIO, M., CUVA, A. 
& MEOZZI, M. 1992. Cytosolic and nuclear androgen receptors in colorectal 
adenomas. Anticancer Res, 12, 705-8. 
MATTAR, M. C., LOUGH, D., PISHVAIAN, M. J. & CHARABATY, A. 2011. Current 
Management of Inflammatory Bowel Disease and Colorectal Cancer. 
Gastrointestinal Cancer Research : GCR, 4, 53-61. 
MAYO CLINIC. 2015. Estrogens, E1+E2, fractionated, S [Online]. Available: 
http://www.mayomedicallaboratories.com/test-
catalog/setup.php?unit_code=84230&format=pdf [Accessed 17th April 
2015]. 
MCMILLAN, H. J., WORTHYLAKE, T., SCHWARTZENTRUBER, J., GOTTLIEB, C. 
C., LAWRENCE, S. E., MACKENZIE, A., BEAULIEU, C. L., MOOYER, P. A., 
WANDERS, R. J., MAJEWSKI, J., BULMAN, D. E., GERAGHTY, M. T., 
FERDINANDUSSE, S. & BOYCOTT, K. M. 2012. Specific combination of 
  References 
218 
 
compound heterozygous mutations in 17beta-hydroxysteroid 
dehydrogenase type 4 (HSD17B4) defines a new subtype of D-bifunctional 
protein deficiency. Orphanet J Rare Dis, 7, 90. 
MCNAMARA, K. M., NAKAMURA, Y., MIKI, Y. & SASANO, H. 2013. Phase two 
steroid metabolism and its roles in breast and prostate cancer patients. Front 
Endocrinol (Lausanne), 4, 116. 
MEDEIROS, R., FIGUEIREDO, C. P., PANDOLFO, P., DUARTE, F. S., 
PREDIGER, R. D., PASSOS, G. F. & CALIXTO, J. B. 2010. The role of TNF-
alpha signaling pathway on COX-2 upregulation and cognitive decline 
induced by beta-amyloid peptide. Behav Brain Res, 209, 165-73. 
MEINL, W. & GLATT, H. 2001. Structure and localization of the human SULT1B1 
gene: neighborhood to SULT1E1 and a SULT1D pseudogene. Biochem 
Biophys Res Commun, 288, 855-62. 
MIETTINEN, M., MUSTONEN, M., POUTANEN, M., ISOMAA, V., WICKMAN, M., 
SODERQVIST, G., VIHKO, R. & VIHKO, P. 1999. 17Beta-hydroxysteroid 
dehydrogenases in normal human mammary epithelial cells and breast 
tissue. Breast Cancer Res Treat, 57, 175-82. 
MIZOGUCHI, E., MIZOGUCHI, A., TAKEDATSU, H., CARIO, E., DE JONG, Y. P., 
OOI, C. J., XAVIER, R. J., TERHORST, C., PODOLSKY, D. K. & BHAN, A. 
K. 2002. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic 
epithelial hyperplasia and chronic intestinal inflammation in mice. 
Gastroenterology, 122, 134-44. 
MOLODECKY, N. A., SOON, I. S., RABI, D. M., GHALI, W. A., FERRIS, M., 
CHERNOFF, G., BENCHIMOL, E. I., PANACCIONE, R., GHOSH, S., 
BARKEMA, H. W. & KAPLAN, G. G. 2012. Increasing incidence and 
prevalence of the inflammatory bowel diseases with time, based on 
systematic review. Gastroenterology, 142, 46-54 e42; quiz e30. 
MUELLER, J. W., GILLIGAN, L. C., IDKOWIAK, J., ARLT, W. & FOSTER, P. A. 
2015. The Regulation of Steroid Action by Sulfation and Desulfation. Endocr 
Rev, 36, 526-63. 
MY CANCER GENOME. 2015. Molecular Profiling of Colorectal Cancer [Online]. 
Available: http://www.mycancergenome.org/content/disease/colorectal-
cancer/ [Accessed 4th jan 2016]. 
NARDI, A., POMARI, E., ZAMBON, D., BELVEDERE, P., COLOMBO, L. & DALLA 
VALLE, L. 2009. Transcriptional control of human steroid sulfatase. J Steroid 
Biochem Mol Biol, 115, 68-74. 
NATIONAL CANCER INSTITUTE. 2015. Tumor Markers [Online]. Available: 
http://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-
markers-fact-sheet [Accessed 4th Jan 2016]. 
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. 2009. Early and 
locally advanced breast cancer: diagnosis and treatment [Online]. Available: 
https://www.nice.org.uk/guidance/cg80/chapter/1-guidance [Accessed 8th 
June 2016]. 
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. 2011a. Clinical 
Guideline 
Colorectal cancer: the diagnosis and management of colorectal cancer [Online]. 
Available: https://www.nice.org.uk/guidance/cg131/evidence/full-guideline-
183509677 [Accessed 25th April 2016]. 
  References 
219 
 
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. 2011b. 
Colorectal cancer prevention: colonoscopic surveillance in adults with 
ulcerative colitis, Crohn's disease or adenomas [Online]. Available: 
https://www.nice.org.uk/guidance/cg118/chapter/1-Guidance#people-with-
inflammatory-bowel-disease [Accessed 18th Aigust 2017]. 
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. 2011c. 
Fulvestrant for the treatment of locally advanced or metastatic breast cancer 
[Online]. Available: https://www.nice.org.uk/guidance/ta239 [Accessed 14th 
Jan 2016]. 
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. 2014. 
Colorectal cancer: diagnosis and management [Online]. Available: 
https://www.nice.org.uk/guidance/cg131/chapter/Key-priorities-for-
implementation [Accessed 24th April 2016]. 
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. 2015a. Early 
and locally advanced breast cancer: diagnosis and treatment [Online]. 
Available: https://www.nice.org.uk/guidance/cg80 [Accessed 14th Jan 2016]. 
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. 2015b. 
Suspected cancer: recognition and referral NG12 [Online]. Available: 
https://www.nice.org.uk/guidance/ng12/chapter/1-Recommendations-
organised-by-site-of-cancer#lower-gastrointestinal-tract-cancers [Accessed 
21st March 2016]. 
NATIONAL INSTITUTE FOR HEALTH CARE AND EXCELLENCE. 2015. Staging 
Colorectal Cancer [Online]. Available: 
http://pathways.nice.org.uk/pathways/colorectal-cancer [Accessed 6th 
November 2015]. 
NATIONAL MEASUREMENT SYSTEM. 2014. Guide to achieving reliable 
quantitative LC-MS measurements [Online]. Available: 
http://www.rsc.org/images/AMC%20LCMS%20Guide_tcm18-240030.pdf 
[Accessed 5th Feb 2016]. 
NAUDE, P. J., DEN BOER, J. A., LUITEN, P. G. & EISEL, U. L. 2011. Tumor 
necrosis factor receptor cross-talk. Febs j, 278, 888-98. 
NEE, J. & FEUERSTEIN, J. D. 2015. Optimizing the Care and Health of Women 
with Inflammatory Bowel Disease. Gastroenterol Res Pract, 2015, 435820. 
NELSON, R. E., GREBE, S. K., DJ, O. K. & SINGH, R. J. 2004. Liquid 
chromatography-tandem mass spectrometry assay for simultaneous 
measurement of estradiol and estrone in human plasma. Clin Chem, 50, 373-
84. 
NEWCOMB, P. A., SOLOMON, C. & WHITE, E. 1999. Tamoxifen and risk of large 
bowel cancer in women with breast cancer. Breast Cancer Res Treat, 53, 
271-7. 
NEWMAN, S. P., PUROHIT, A., GHILCHIK, M. W., POTTER, B. V. & REED, M. J. 
2000. Regulation of steroid sulphatase expression and activity in breast 
cancer. J Steroid Biochem Mol Biol, 75, 259-64. 
NGO, S. T., STEYN, F. J. & MCCOMBE, P. A. 2014. Gender differences in 
autoimmune disease. Front Neuroendocrinol, 35, 347-69. 
NIV, Y. 2015. Estrogen receptor beta expression and colorectal cancer: a 
systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 27, 1438-
42. 
  References 
220 
 
NOKELAINEN, P., PELTOKETO, H., VIHKO, R. & VIHKO, P. 1998. Expression 
cloning of a novel estrogenic mouse 17 beta-hydroxysteroid 
dehydrogenase/17-ketosteroid reductase (m17HSD7), previously described 
as a prolactin receptor-associated protein (PRAP) in rat. Mol Endocrinol, 12, 
1048-59. 
NUSSBAUMER, P. & BILLICH, A. 2004. Steroid sulfatase inhibitors. Med Res Rev, 
24, 529-76. 
ODUWOLE, O. O., MAKINEN, M. J., ISOMAA, V. V., PULKKA, A., JERNVALL, P., 
KARTTUNEN, T. J. & VIHKO, P. T. 2003. 17Beta-hydroxysteroid 
dehydrogenase type 2: independent prognostic significance and evidence of 
estrogen protection in female patients with colon cancer. J Steroid Biochem 
Mol Biol, 87, 133-40. 
OFFICE FOR NATIONAL STATISTICS. 2016. Bowel cancer rates in England have 
risen since 1971 [Online]. Available: 
http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.
gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-
/no--41--2010/sty-bowel-cancer-rates-in-england.html [Accessed 17th 
March 2016]. 
OGAWA, S., ENG, V., TAYLOR, J., LUBAHN, D. B., KORACH, K. S. & PFAFF, D. 
W. 1998. Roles of estrogen receptor-alpha gene expression in reproduction-
related behaviors in female mice. Endocrinology, 139, 5070-81. 
OH, J.-E., KIM, Y.-W., PARK, S.-Y. & KIM, J.-Y. 2013. Estrogen Rather Than 
Progesterone Cause Constipation in Both Female and Male Mice. The 
Korean Journal of Physiology & Pharmacology : Official Journal of the 
Korean Physiological Society and the Korean Society of Pharmacology, 17, 
423-426. 
OHNESORG, T. & ADAMSKI, J. 2006. Analysis of the 5' flanking regions of human 
and murine HSD17B7: identification of a cholesterol dependent enhancer 
region. Mol Cell Endocrinol, 248, 164-7. 
OKADA, F., KAWAGUCHI, T., HABELHAH, H., KOBAYASHI, T., TAZAWA, H., 
TAKEICHI, N., KITAGAWA, T. & HOSOKAWA, M. 2000. Conversion of 
human colonic adenoma cells to adenocarcinoma cells through inflammation 
in nude mice. Lab Invest, 80, 1617-28. 
ORLICH, M. J., SINGH, P. N., SABATE, J., FAN, J., SVEEN, L., BENNETT, H., 
KNUTSEN, S. F., BEESON, W. L., JACELDO-SIEGL, K., BUTLER, T. L., 
HERRING, R. P. & FRASER, G. E. 2015. Vegetarian dietary patterns and 
the risk of colorectal cancers. JAMA Intern Med, 175, 767-76. 
OSHIMA, C. T., WONRAHT, D. R., CATARINO, R. M., MATTOS, D. & FORONES, 
N. M. 1999. Estrogen and progesterone receptors in gastric and colorectal 
cancer. Hepatogastroenterology, 46, 3155-8. 
OWEN, L. J., WU, F. C. & KEEVIL, B. G. 2014. A rapid direct assay for the routine 
measurement of oestradiol and oestrone by liquid chromatography tandem 
mass spectrometry. Ann Clin Biochem, 51, 360-7. 
PALMIERI, C., STEIN, R., LIU, X., HUDSON, E., REED, S., NICHOLAS, H., 
BARRETT, S., HOLCOMBE, C., LIM, A., HAYWARD, R., HOWELL, S. & 
COOMBES, C. 2016a. A Phase II study to assess the safety and efficacy of 
the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor 
  References 
221 
 
in ER positive locally advanced or metastatic breast cancer patients (IRIS) – 
Trial Results. J Clin Oncol, Abstract. 
PALMIERI, C., SZYDLO, R., MILLER, M., WOODLEY-BARKER, L., PATEL, N., 
BERWICK, T., TAM, H., HADJIMINAS, D., LEE, J., SHAABAN, A., REED, 
S., NICHOLAS, H., COOMBES, C. & LM., K. 2016b. The effects of the first 
in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in 
estrogen receptor positive early breast cancer: Results of the perioperative 
IPET study. J Clin Oncol. 
PANDEY, D. P., LAPPANO, R., ALBANITO, L., MADEO, A., MAGGIOLINI, M. & 
PICARD, D. 2009. Estrogenic GPR30 signalling induces proliferation and 
migration of breast cancer cells through CTGF. EMBO J, 28, 523-32. 
PASQUALINI, J. R. 2009. Estrogen sulfotransferases in breast and endometrial 
cancers. Ann N Y Acad Sci, 1155, 88-98. 
PASQUALINI, J. R., CHETRITE, G., BLACKER, C., FEINSTEIN, M. C., 
DELALONDE, L., TALBI, M. & MALOCHE, C. 1996. Concentrations of 
estrone, estradiol, and estrone sulfate and evaluation of sulfatase and 
aromatase activities in pre- and postmenopausal breast cancer patients. J 
Clin Endocrinol Metab, 81, 1460-4. 
PAUL, W. & STEINWEDEL, H. 1953. Ein neues Massenspektrometer ohne 
Magnetfeld. Zeitschrift Fur Naturforschung. 
PEDDAREDDIGARI, V. G., WANG, D. & DUBOIS, R. N. 2010. The tumor 
microenvironment in colorectal carcinogenesis. Cancer Microenviron, 3, 149-
66. 
PEDERSEN, L. C., PETROTCHENKO, E., SHEVTSOV, S. & NEGISHI, M. 2002. 
Crystal structure of the human estrogen sulfotransferase-PAPS complex: 
evidence for catalytic role of Ser137 in the sulfuryl transfer reaction. J Biol 
Chem, 277, 17928-32. 
PEETERS, P. J., BAZELIER, M. T., LEUFKENS, H. G., DE VRIES, F. & DE BRUIN, 
M. L. 2015. The risk of colorectal cancer in patients with type 2 diabetes: 
associations with treatment stage and obesity. Diabetes Care, 38, 495-502. 
PELTOKETO, H., ISOMAA, V., POUTANEN, M. & VIHKO, R. 1996. Expression and 
regulation of 17 beta-hydroxysteroid dehydrogenase type 1. J Endocrinol, 
150 Suppl, S21-30. 
PENG, C., ZHU, F., WEN, W., YAO, K., LI, S., ZYKOVA, T., LIU, K., LI, X., MA, W. 
Y., BODE, A. M. & DONG, Z. 2012. Tumor necrosis factor receptor-
associated factor family protein 2 is a key mediator of the epidermal growth 
factor-induced ribosomal S6 kinase 2/cAMP-responsive element-binding 
protein/Fos protein signaling pathway. J Biol Chem, 287, 25881-92. 
PHIPPS, A. I., BUCHANAN, D. D., MAKAR, K. W., WIN, A. K., BARON, J. A., 
LINDOR, N. M., POTTER, J. D. & NEWCOMB, P. A. 2013. KRAS-mutation 
status in relation to colorectal cancer survival: the joint impact of correlated 
tumour markers. Br J Cancer, 108, 1757-64. 
PIERCE, S. B., WALSH, T., CHISHOLM, K. M., LEE, M. K., THORNTON, A. M., 
FIUMARA, A., OPITZ, J. M., LEVY-LAHAD, E., KLEVIT, R. E. & KING, M. C. 
2010. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian 
dysgenesis, hearing loss, and ataxia of Perrault Syndrome. Am J Hum 
Genet, 87, 282-8. 
  References 
222 
 
PINO, M. S. & CHUNG, D. C. 2010. The chromosomal instability pathway in colon 
cancer. Gastroenterology, 138, 2059-72. 
PREMIER BIOSOFT. 2016. Mass Spectrometry [Online]. Available: 
http://www.premierbiosoft.com/tech_notes/mass-spectrometry.html 
[Accessed 5th Feb 2016]. 
PRENTICE, R. L., PETTINGER, M., BERESFORD, S. A., WACTAWSKI-WENDE, 
J., HUBBELL, F. A., STEFANICK, M. L. & CHLEBOWSKI, R. T. 2009. 
Colorectal cancer in relation to postmenopausal estrogen and estrogen plus 
progestin in the Women's Health Initiative clinical trial and observational 
study. Cancer Epidemiol Biomarkers Prev, 18, 1531-7. 
PREUSSER-KUNZE, A., MARIAPPAN, M., SCHMIDT, B., GANDE, S. L., 
MUTENDA, K., WENZEL, D., VON FIGURA, K. & DIERKS, T. 2005. 
Molecular characterization of the human Calpha-formylglycine-generating 
enzyme. J Biol Chem, 280, 14900-10. 
PROSSNITZ, E. R. & BARTON, M. 2014. Estrogen biology: new insights into GPER 
function and clinical opportunities. Mol Cell Endocrinol, 389, 71-83. 
PROSSNITZ, E. R. & HATHAWAY, H. J. 2015. What have we learned about GPER 
function in physiology and disease from knockout mice? J Steroid Biochem 
Mol Biol, 153, 114-26. 
PUBLIC HEALTH ENGLAND. 2015. Bowel Cancer Screening: programme 
overview [Online]. Available: https://www.gov.uk/guidance/bowel-cancer-
screening-programme-overview [Accessed 6th November 2015]. 
PURANEN, T. J., KURKELA, R. M., LAKKAKORPI, J. T., POUTANEN, M. H., 
ITARANTA, P. V., MELIS, J. P., GHOSH, D., VIHKO, R. K. & VIHKO, P. T. 
1999. Characterization of molecular and catalytic properties of intact and 
truncated human 17beta-hydroxysteroid dehydrogenase type 2 enzymes: 
intracellular localization of the wild-type enzyme in the endoplasmic 
reticulum. Endocrinology, 140, 3334-41. 
PUROHIT, DUNCAN, WANG,, COLDHAM, G. & REED, A. 1997. Paracrine control 
of oestrogen 
production in breast cancer. Endocrine-Related Cancer, 4, 323-330. 
PUROHIT, A., NEWMAN, S. P. & REED, M. J. 2002. The role of cytokines in 
regulating estrogen synthesis: implications for the etiology of breast cancer. 
Breast Cancer Res, 4, 65-9. 
PUROHIT, A., REED, M. J., MORRIS, N. C., WILLIAMS, G. J. & POTTER, B. V. 
1996. Regulation and inhibition of steroid sulfatase activity in breast cancer. 
Ann N Y Acad Sci, 784, 40-9. 
PUROHIT, A., WILLIAMS, G. J., ROBERTS, C. J., POTTER, B. V. & REED, M. J. 
1995. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone 
sulphatase by oestrone-3-O-sulphamate. Int J Cancer, 63, 106-11. 
PUROHIT, A., WOO, L. W. & POTTER, B. V. 2011. Steroid sulfatase: a pivotal 
player in estrogen synthesis and metabolism. Mol Cell Endocrinol, 340, 154-
60. 
QIN, T., DU, M., DU, H., SHU, Y., WANG, M. & ZHU, L. 2015. Folic acid 
supplements and colorectal cancer risk: meta-analysis of randomized 
controlled trials. Scientific Reports, 5, 12044. 
QIN, Y. M., POUTANEN, M. H., HELANDER, H. M., KVIST, A. P., SIIVARI, K. M., 
SCHMITZ, W., CONZELMANN, E., HELLMAN, U. & HILTUNEN, J. K. 1997. 
  References 
223 
 
Peroxisomal multifunctional enzyme of beta-oxidation metabolizing D-3-
hydroxyacyl-CoA esters in rat liver: molecular cloning, expression and 
characterization. Biochem J, 321 ( Pt 1), 21-8. 
QIU, Y., WATERS, C. E., LEWIS, A. E., LANGMAN, M. J. & EGGO, M. C. 2002. 
Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor 
beta. J Endocrinol, 174, 369-77. 
RANADIVE, G. N., MISTRY, J. S., DAMODARAN, K., KHOSRAVI, M. J., 
DIAMANDI, A., GIMPEL, T., CASTRACANE, V. D., PATEL, S. & 
STANCZYK, F. Z. 1998. Rapid, convenient radioimmunoassay of estrone 
sulfate. Clin Chem, 44, 244-9. 
RAO JN, W. J. 2010. Regulation of Gastrointestinal Mucosal Growth. 
RAWLUSZKO, A. A., HORBACKA, K., KROKOWICZ, P. & JAGODZINSKI, P. P. 
2011. Decreased expression of 17beta-hydroxysteroid dehydrogenase type 
1 is associated with DNA hypermethylation in colorectal cancer located in the 
proximal colon. BMC Cancer, 11, 522. 
REED, M. J. & PUROHIT, A. 1997. Breast cancer and the role of cytokines in 
regulating estrogen synthesis: an emerging hypothesis. Endocr Rev, 18, 
701-15. 
REED, M. J., PUROHIT, A., WOO, L. W., NEWMAN, S. P. & POTTER, B. V. 2005. 
Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev, 
26, 171-202. 
REGENSTEINER, J. G., MAYER, E. J., SHETTERLY, S. M., ECKEL, R. H., 
HASKELL, W. L., MARSHALL, J. A., BAXTER, J. & HAMMAN, R. F. 1991. 
Relationship between habitual physical activity and insulin levels among 
nondiabetic men and women. San Luis Valley Diabetes Study. Diabetes 
Care, 14, 1066-74. 
REN, X., WU, X., HILLIER, S. G., FEGAN, K. S., CRITCHLEY, H. O., MASON, J. 
I., SARVI, S. & HARLOW, C. R. 2015. Local estrogen metabolism in epithelial 
ovarian cancer suggests novel targets for therapy. J Steroid Biochem Mol 
Biol, 150, 54-63. 
RHODES, D. R., YU, J., SHANKER, K., DESHPANDE, N., VARAMBALLY, R., 
GHOSH, D., BARRETTE, T., PANDEY, A. & CHINNAIYAN, A. M. 2004. 
ONCOMINE: a cancer microarray database and integrated data-mining 
platform. Neoplasia, 6, 1-6. 
RICCARDI, G. & RIVELLESE, A. A. 1991. Effects of dietary fiber and carbohydrate 
on glucose and lipoprotein metabolism in diabetic patients. Diabetes Care, 
14, 1115-25. 
RICHES, Z., STANLEY, E. L., BLOOMER, J. C. & COUGHTRIE, M. W. 2009. 
Quantitative evaluation of the expression and activity of five major 
sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab 
Dispos, 37, 2255-61. 
RIGIRACCIOLO, D. C., SCARPELLI, A., LAPPANO, R., PISANO, A., SANTOLLA, 
M. F., AVINO, S., DE MARCO, P., BUSSOLATI, B., MAGGIOLINI, M. & DE 
FRANCESCO, E. M. 2016. GPER is involved in the stimulatory effects of 
aldosterone in breast cancer cells and breast tumor-derived endothelial cells. 
Oncotarget, 7, 94-111. 
RITENBAUGH, C., STANFORD, J. L., WU, L., SHIKANY, J. M., SCHOEN, R. E., 
STEFANICK, M. L., TAYLOR, V., GARLAND, C., FRANK, G., LANE, D., 
  References 
224 
 
MASON, E., MCNEELEY, S. G., ASCENSAO, J. & CHLEBOWSKI, R. T. 
2008. Conjugated equine estrogens and colorectal cancer incidence and 
survival: the Women's Health Initiative randomized clinical trial. Cancer 
Epidemiol Biomarkers Prev, 17, 2609-18. 
RIZNER, T. L., THALHAMMER, T. & OZVEGY-LACZKA, C. 2017. The Importance 
of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers. 
Front Pharmacol, 8, 346. 
ROEHM, E. 2015. A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: 
Long-Term Outcomes in Women 50-59 Years of Age. Obstet Gynecol Int, 
2015, 713295. 
ROSENQVIST, H., OHRLING, H., LAGERCRANTZ, R. & EDLING, N. 1959. 
Ulcerative colitis and carcinoma coli. Lancet, 1, 906-8. 
ROSHAN, M. H., TAMBO, A. & PACE, N. P. 2016. The role of testosterone in 
colorectal carcinoma: pathomechanisms and open questions. EPMA J, 7, 22. 
ROSSOUW, J. E., ANDERSON, G. L., PRENTICE, R. L., LACROIX, A. Z., 
KOOPERBERG, C., STEFANICK, M. L., JACKSON, R. D., BERESFORD, 
S. A., HOWARD, B. V., JOHNSON, K. C., KOTCHEN, J. M. & OCKENE, J. 
2002. Risks and benefits of estrogen plus progestin in healthy 
postmenopausal women: principal results From the Women's Health 
Initiative randomized controlled trial. JAMA, 288, 321-33. 
ROSSOUW, J. E., MANSON, J. E., KAUNITZ, A. M. & ANDERSON, G. L. 2013. 
Lessons learned from the Women's Health Initiative trials of menopausal 
hormone therapy. Obstet Gynecol, 121, 172-6. 
RUDER, H. J., LORIAUX, L. & LIPSETT, M. B. 1972. Estrone sulfate: production 
rate and metabolism in man. J Clin Invest, 51, 1020-33. 
SAKURAI, N., MIKI, Y., SUZUKI, T., WATANABE, K., NARITA, T., ANDO, K., 
YUNG, T. M., AOKI, D., SASANO, H. & HANDA, H. 2006. Systemic 
distribution and tissue localizations of human 17beta-hydroxysteroid 
dehydrogenase type 12. J Steroid Biochem Mol Biol, 99, 174-81. 
SALONIEMI, T., JÄRVENSIVU, P., KOSKIMIES, P., JOKELA, H., LAMMINEN, T., 
GHAEM-MAGHAMI, S., DINA, R., DAMDIMOPOULOU, P., MÄKELÄ, S., 
PERHEENTUPA, A., KUJARI, H., BROSENS, J. & POUTANEN, M. 2010. 
Novel Hydroxysteroid (17β) Dehydrogenase 1 Inhibitors Reverse Estrogen-
Induced Endometrial Hyperplasia in Transgenic Mice. The American Journal 
of Pathology, 176, 1443-1451. 
SAMARTZIS, E. P., NOSKE, A., MEISEL, A., VARGA, Z., FINK, D. & IMESCH, P. 
2014. The G protein-coupled estrogen receptor (GPER) is expressed in two 
different subcellular localizations reflecting distinct tumor properties in breast 
cancer. PLoS One, 9, e83296. 
SANTOLLA, M. F., AVINO, S., PELLEGRINO, M., DE FRANCESCO, E. M., DE 
MARCO, P., LAPPANO, R., VIVACQUA, A., CIRILLO, F., RIGIRACCIOLO, 
D. C., SCARPELLI, A., ABONANTE, S. & MAGGIOLINI, M. 2015. SIRT1 is 
involved in oncogenic signaling mediated by GPER in breast cancer. Cell 
Death Dis, 6, e1834. 
SANTOLLA, M. F., LAPPANO, R., DE MARCO, P., PUPO, M., VIVACQUA, A., 
SISCI, D., ABONANTE, S., IACOPETTA, D., CAPPELLO, A. R., DOLCE, V. 
& MAGGIOLINI, M. 2012. G protein-coupled estrogen receptor mediates the 
  References 
225 
 
up-regulation of fatty acid synthase induced by 17beta-estradiol in cancer 
cells and cancer-associated fibroblasts. J Biol Chem, 287, 43234-45. 
SATO, R., SUZUKI, T., KATAYOSE, Y., MIURA, K., SHIIBA, K., MIKI, Y., 
KAMOGAWA, Y., YAMAMOTO, K., TAKAYUKI, 2ND, EGAWA, S., UNNO, 
M. & SASANO, H. 2012. Aromatase in colon carcinoma. Anticancer Res, 32, 
3069-75. 
SATO, R., SUZUKI, T., KATAYOSE, Y., MIURA, K., SHIIBA, K., TATENO, H., MIKI, 
Y., AKAHIRA, J., KAMOGAWA, Y., NAGASAKI, S., YAMAMOTO, K., II, T., 
EGAWA, S., EVANS, D. B., UNNO, M. & SASANO, H. 2009. Steroid 
sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of 
intratumoral estrogen concentrations and potent prognostic factors. Cancer 
Res, 69, 914-22. 
SCHMIDT, B., SELMER, T., INGENDOH, A. & VON FIGURA, K. 1995. A novel 
amino acid modification in sulfatases that is defective in multiple sulfatase 
deficiency. Cell, 82, 271-8. 
SECKY, L., SVOBODA, M., KLAMETH, L., BAJNA, E., HAMILTON, G., 
ZEILLINGER, R., JAGER, W. & THALHAMMER, T. 2013. The sulfatase 
pathway for estrogen formation: targets for the treatment and diagnosis of 
hormone-associated tumors. J Drug Deliv, 2013, 957605. 
SETIAWAN, V. W., HANKINSON, S. E., COLDITZ, G. A., HUNTER, D. J. & DE 
VIVO, I. 2004. HSD17B1 gene polymorphisms and risk of endometrial and 
breast cancer. Cancer Epidemiol Biomarkers Prev, 13, 213-9. 
SHACKLETON, C. 2010. Clinical steroid mass spectrometry: a 45-year history 
culminating in HPLC-MS/MS becoming an essential tool for patient 
diagnosis. J Steroid Biochem Mol Biol, 121, 481-90. 
SHAH, S., NATHAN, L., SINGH, R., FU, Y. S. & CHAUDHURI, G. 2001. E2 and not 
P4 increases NO release from NANC nerves of the gastrointestinal tract: 
implications in pregnancy. Am J Physiol Regul Integr Comp Physiol, 280, 
R1546-54. 
SHEHU, A., ALBARRACIN, C., DEVI, Y. S., LUTHER, K., HALPERIN, J., LE, J., 
MAO, J., DUAN, R. W., FRASOR, J. & GIBORI, G. 2011. The stimulation of 
HSD17B7 expression by estradiol provides a powerful feed-forward 
mechanism for estradiol biosynthesis in breast cancer cells. Mol Endocrinol, 
25, 754-66. 
SHEHU, A., MAO, J., GIBORI, G. B., HALPERIN, J., LE, J., DEVI, Y. S., MERRILL, 
B., KIYOKAWA, H. & GIBORI, G. 2008. Prolactin receptor-associated 
protein/17beta-hydroxysteroid dehydrogenase type 7 gene (Hsd17b7) plays 
a crucial role in embryonic development and fetal survival. Mol Endocrinol, 
22, 2268-77. 
SHISHODIA, S., KOUL, D. & AGGARWAL, B. B. 2004. Cyclooxygenase (COX)-2 
inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through 
inhibition of activation of I kappa B alpha kinase and Akt in human non-small 
cell lung carcinoma: correlation with suppression of COX-2 synthesis. J 
Immunol, 173, 2011-22. 
SHOELSON, S. E., LEE, J. & YUAN, M. 2003. Inflammation and the IKK beta/I 
kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int 
J Obes Relat Metab Disord, 27 Suppl 3, S49-52. 
  References 
226 
 
SHORT, E., THOMAS, L. E., HURLEY, J., JOSE, S. & SAMPSON, J. R. 2015. 
Inherited predisposition to colorectal cancer: towards a more complete 
picture. J Med Genet. 
SIDLER, D., RENZULLI, P., SCHNOZ, C., BERGER, B., SCHNEIDER-JAKOB, S., 
FLUCK, C., INDERBITZIN, D., CORAZZA, N., CANDINAS, D. & BRUNNER, 
T. 2011. Colon cancer cells produce immunoregulatory glucocorticoids. 
Oncogene, 30, 2411-9. 
SIITERI, P. K. 1987. Adipose tissue as a source of hormones. Am J Clin Nutr, 45, 
277-82. 
SIMON, T. A., THOMPSON, A., GANDHI, K. K., HOCHBERG, M. C. & SUISSA, S. 
2015. Incidence of malignancy in adult patients with rheumatoid arthritis: a 
meta-analysis. Arthritis Res Ther, 17, 212. 
SIVIK, T., GUNNARSSON, C., FORNANDER, T., NORDENSKJOLD, B., SKOOG, 
L., STAL, O. & JANSSON, A. 2012. 17beta-Hydroxysteroid dehydrogenase 
type 14 is a predictive marker for tamoxifen response in oestrogen receptor 
positive breast cancer. PLoS One, 7, e40568. 
SKRZYPCZAK, M., SCHULER, S., LATTRICH, C., IGNATOV, A., ORTMANN, O. 
& TREECK, O. 2013. G protein-coupled estrogen receptor (GPER) 
expression in endometrial adenocarcinoma and effect of agonist G-1 on 
growth of endometrial adenocarcinoma cell lines. Steroids, 78, 1087-91. 
SLATTERY, M. L., LUNDGREEN, A., HERRICK, J. S., KADLUBAR, S., CAAN, B. 
J., POTTER, J. D. & WOLFF, R. K. 2011. Variation in the CYP19A1 gene 
and risk of colon and rectal cancer. Cancer Causes Control, 22, 955-63. 
SMALLEY, W. E. & DUBOIS, R. N. 1997. Colorectal cancer and nonsteroidal anti-
inflammatory drugs. Adv Pharmacol, 39, 1-20. 
SMITH, H. O., ARIAS-PULIDO, H., KUO, D. Y., HOWARD, T., QUALLS, C. R., LEE, 
S. J., VERSCHRAEGEN, C. F., HATHAWAY, H. J., JOSTE, N. E. & 
PROSSNITZ, E. R. 2009. GPR30 predicts poor survival for ovarian cancer. 
Gynecol Oncol, 114, 465-71. 
SOLDIN, S. J. & SOLDIN, O. P. 2009. Steroid hormone analysis by tandem mass 
spectrometry. Clin Chem, 55, 1061-6. 
SONG, D., LIU, G., LUU-THE, V., ZHAO, D., WANG, L., ZHANG, H., XUELING, G., 
LI, S., DESY, L., LABRIE, F. & PELLETIER, G. 2006. Expression of 
aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in 
breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol, 
101, 136-44. 
SORBY, L. A., ANDERSEN, S. N., BUKHOLM, I. R. & JACOBSEN, M. B. 2010. 
Evaluation of suitable reference genes for normalization of real-time reverse 
transcription PCR analysis in colon cancer. J Exp Clin Cancer Res, 29, 144. 
SPEIRS, V., ADAMS, E. F., RAFFERTY, B. & WHITE, M. C. 1993. Interactive 
effects of interleukin-6, 17β-estradiol and progesterone on growth and 17β-
hydroxysteroid dehydrogenase activity in human breast carcinoma cells. The 
Journal of Steroid Biochemistry and Molecular Biology, 46, 11-15. 
STANWAY, S. J., PUROHIT, A. & REED, M. J. 2007. Measurement of estrone 
sulfate in postmenopausal women: comparison of direct RIA and GC-MS/MS 
methods for monitoring response to endocrine therapy in women with breast 
cancer. Anticancer Res, 27, 2765-7. 
  References 
227 
 
STANWAY, S. J., PUROHIT, A., WOO, L. W., SUFI, S., VIGUSHIN, D., WARD, R., 
WILSON, R. H., STANCZYK, F. Z., DOBBS, N., KULINSKAYA, E., ELLIOTT, 
M., POTTER, B. V., REED, M. J. & COOMBES, R. C. 2006. Phase I study of 
STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid 
sulfatase inhibitor. Clin Cancer Res, 12, 1585-92. 
STAROS, A. G. S. A. E. B. 2015. Estradiol [Online]. Available: 
http://emedicine.medscape.com/article/2089003-overview [Accessed 17th 
April 2015]. 
STEBBINGS, W. S., FARTHING, M. J., PUDDEFOOT, J. R., ANDERSON, E., 
VINSON, G. P., NORTHOVER, J. M. & WOOD, R. F. 1988. Androgen 
receptors in colorectal adenomas. J Cancer Res Clin Oncol, 114, 208-11. 
STEIN, C., HILLE, A., SEIDEL, J., RIJNBOUT, S., WAHEED, A., SCHMIDT, B., 
GEUZE, H. & VON FIGURA, K. 1989. Cloning and expression of human 
steroid-sulfatase. Membrane topology, glycosylation, and subcellular 
distribution in BHK-21 cells. J Biol Chem, 264, 13865-72. 
STENGEL, C., NEWMAN, S. P., DAY, J. M., TUTILL, H. J., REED, M. J. & 
PUROHIT, A. 2008. Effects of mutations and glycosylations on STS activity: 
a site-directed mutagenesis study. Mol Cell Endocrinol, 283, 76-82. 
STRAUB, R. H. 2007. The complex role of estrogens in inflammation. Endocr Rev, 
28, 521-74. 
SU, E. J., CHENG, Y. H., CHATTERTON, R. T., LIN, Z. H., YIN, P., REIERSTAD, 
S., INNES, J. & BULUN, S. E. 2007. Regulation of 17-beta hydroxysteroid 
dehydrogenase type 2 in human placental endothelial cells. Biol Reprod, 77, 
517-25. 
SUH, B. Y., JUNG, J. J., PARK, N., SEONG, C. H., IM, H. J., KWON, Y., KIM, D. & 
CHUN, Y. J. 2011. Induction of steroid sulfatase expression by tumor 
necrosis factor-alpha through phosphatidylinositol 3-kinase/Akt signaling 
pathway in PC-3 human prostate cancer cells. Exp Mol Med, 43, 646-52. 
SUNG, C. H., IM, H. J., PARK, N., KWON, Y., SHIN, S., YE, D. J., CHO, N. H., 
PARK, Y. S., CHOI, H. K., KIM, D. & CHUN, Y. J. 2013. Induction of steroid 
sulfatase expression in PC-3 human prostate cancer cells by insulin-like 
growth factor II. Toxicol Lett, 223, 109-15. 
SUZUKI, T., MIKI, Y., NAKAMURA, Y., ITO, K. & SASANO, H. 2011. Steroid 
sulfatase and estrogen sulfotransferase in human carcinomas. Mol Cell 
Endocrinol, 340, 148-53. 
SVORONOS, N., PERALES-PUCHALT, A., ALLEGREZZA, M. J., RUTKOWSKI, 
M. R., PAYNE, K. K., TESONE, A. J., NGUYEN, J. M., CURIEL, T. J., 
CADUNGOG, M. G., SINGHAL, S., ERUSLANOV, E. B., ZHANG, P., 
TCHOU, J., ZHANG, R. & CONEJO-GARCIA, J. R. 2016. Tumor Cell-
Independent Estrogen Signaling Drives Disease Progression through 
Mobilization of Myeloid-Derived Supressor Cells. Cancer Discovery. 
TAYLOR, A. E., KEEVIL, B. & HUHTANIEMI, I. T. 2015. Mass spectrometry and 
immunoassay: how to measure steroid hormones today and tomorrow. Eur 
J Endocrinol, 173, D1-12. 
TAYLOR, P. J. 2005. Matrix effects: the Achilles heel of quantitative high-
performance liquid chromatography-electrospray-tandem mass 
spectrometry. Clin Biochem, 38, 328-34. 
  References 
228 
 
TAYLOR, T. Large Intestine [Online]. InnerBody,. Available: 
http://www.innerbody.com/anatomy/digestive/large-intestine#full-description 
[Accessed 8th May 2016]. 
THE ASSOCIATION OF COLPROCTOLOGY OF GREAT BRITAIN AND IRELAND. 
2007. Guidelines for the Management of Colorectal Cancer 3rd edition 
(2007) [Online]. Available: http://www.acpgbi.org.uk/content/uploads/2007-
CC-Management-Guidelines.pdf [Accessed 24th April 2016]. 
THERMO FISHER SCIENTIFIC 2005. Real-Time PCR Systems Chemistry Guide, 
PN 4348358. 
THOMAS, M. P. & POTTER, B. V. 2013. The structural biology of oestrogen 
metabolism. J Steroid Biochem Mol Biol, 137, 27-49. 
THOMAS, P., PANG, Y., FILARDO, E. J. & DONG, J. 2005. Identity of an estrogen 
membrane receptor coupled to a G protein in human breast cancer cells. 
Endocrinology, 146, 624-32. 
TOMASZEWSKA, A., ROSZAK, A., PAWLIK, P., SAJDAK, S. & JAGODZINSKI, P. 
P. 2015. Increased 17ss-hydroxysteroid dehydrogenase type 1 levels in 
primary cervical cancer. Biomed Pharmacother, 72, 179-83. 
TONG, M. H., JIANG, H., LIU, P., LAWSON, J. A., BRASS, L. F. & SONG, W. C. 
2005. Spontaneous fetal loss caused by placental thrombosis in estrogen 
sulfotransferase-deficient mice. Nat Med, 11, 153-9. 
TORN, S., NOKELAINEN, P., KURKELA, R., PULKKA, A., MENJIVAR, M., 
GHOSH, S., COCA-PRADOS, M., PELTOKETO, H., ISOMAA, V. & VIHKO, 
P. 2003. Production, purification, and functional analysis of recombinant 
human and mouse 17beta-hydroxysteroid dehydrogenase type 7. Biochem 
Biophys Res Commun, 305, 37-45. 
TOWLER, B., IRWIG, L., GLASZIOU, P., KEWENTER, J., WELLER, D. & SILAGY, 
C. 1998. A systematic review of the effects of screening for colorectal cancer 
using the faecal occult blood test, hemoccult. BMJ, 317, 559-65. 
TRIANTAFILLIDIS, J. K., NASIOULAS, G. & KOSMIDIS, P. A. 2009. Colorectal 
cancer and inflammatory bowel disease: epidemiology, risk factors, 
mechanisms of carcinogenesis and prevention strategies. Anticancer Res, 
29, 2727-37. 
TRUFELLI, H., PALMA, P., FAMIGLINI, G. & CAPPIELLO, A. 2011. An overview of 
matrix effects in liquid chromatography-mass spectrometry. Mass Spectrom 
Rev, 30, 491-509. 
TU, Z., MA, Y., TIAN, J., LI, H., AKERS, W., ACHILEFU, S. & GU, Y. 2012. Estrogen 
receptor beta potentiates the antiproliferative effect of raloxifene and affects 
the cell migration and invasion in HCT-116 colon cancer cells. J Cancer Res 
Clin Oncol, 138, 1091-103. 
TUTTON, P. J. & BARKLA, D. H. 1982. The influence of androgens, anti-androgens, 
and castration on cell proliferation in the jejunal and colonic crypt epithelia, 
and in dimethylhydrazine-induced adenocarcinoma of rat colon. Virchows 
Arch B Cell Pathol Incl Mol Pathol, 38, 351-5. 
VAN DEN BOOM, J., HEIDER, D., MARTIN, S. R., PASTORE, A. & MUELLER, J. 
W. 2012. 3'-Phosphoadenosine 5'-phosphosulfate (PAPS) synthases, 
naturally fragile enzymes specifically stabilized by nucleotide binding. J Biol 
Chem, 287, 17645-55. 
  References 
229 
 
VASEN, H. F., MOSLEIN, G., ALONSO, A., ARETZ, S., BERNSTEIN, I., 
BERTARIO, L., BLANCO, I., BULOW, S., BURN, J., CAPELLA, G., COLAS, 
C., ENGEL, C., FRAYLING, I., FRIEDL, W., HES, F. J., HODGSON, S., 
JARVINEN, H., MECKLIN, J. P., MOLLER, P., MYRHOI, T., NAGENGAST, 
F. M., PARC, Y., PHILLIPS, R., CLARK, S. K., DE LEON, M. P., 
RENKONEN-SINISALO, L., SAMPSON, J. R., STORMORKEN, A., 
TEJPAR, S., THOMAS, H. J. & WIJNEN, J. 2008. Guidelines for the clinical 
management of familial adenomatous polyposis (FAP). Gut, 57, 704-13. 
VENKATACHALAM, K. V. 2003. Human 3'-phosphoadenosine 5'-phosphosulfate 
(PAPS) synthase: biochemistry, molecular biology and genetic deficiency. 
IUBMB Life, 55, 1-11. 
VIANT, M., HE, S., DUNN, W., GENTA-JOUVE, G., BRADBURY, J., KNOWLES, J. 
& GOODACRE, R. MUSCLE for LC-MS Optimisation [Online]. Available: 
http://www.muscleproject.org/ [Accessed 17th April 2015]. 
VIDAL, O., LINDBERG, M., SAVENDAHL, L., LUBAHN, D. B., RITZEN, E. M., 
GUSTAFSSON, J. A. & OHLSSON, C. 1999. Disproportional body growth in 
female estrogen receptor-alpha-inactivated mice. Biochem Biophys Res 
Commun, 265, 569-71. 
VIDAL, O., LINDBERG, M. K., HOLLBERG, K., BAYLINK, D. J., ANDERSSON, G., 
LUBAHN, D. B., MOHAN, S., GUSTAFSSON, J. A. & OHLSSON, C. 2000. 
Estrogen receptor specificity in the regulation of skeletal growth and 
maturation in male mice. Proc Natl Acad Sci U S A, 97, 5474-9. 
VIVACQUA, A., BONOFIGLIO, D., ALBANITO, L., MADEO, A., RAGO, V., 
CARPINO, A., MUSTI, A. M., PICARD, D., ANDO, S. & MAGGIOLINI, M. 
2006a. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the 
proliferation of thyroid cancer cells through the g protein-coupled receptor 
GPR30. Mol Pharmacol, 70, 1414-23. 
VIVACQUA, A., BONOFIGLIO, D., RECCHIA, A. G., MUSTI, A. M., PICARD, D., 
ANDO, S. & MAGGIOLINI, M. 2006b. The G protein-coupled receptor 
GPR30 mediates the proliferative effects induced by 17beta-estradiol and 
hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol, 20, 631-46. 
VIVACQUA, A., ROMEO, E., DE MARCO, P., DE FRANCESCO, E. M., 
ABONANTE, S. & MAGGIOLINI, M. 2012. GPER mediates the Egr-1 
expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and 
endometrial cancer cells. Breast Cancer Research and Treatment, 133, 
1025-1035. 
VON FIGURA, K., SCHMIDT, B., SELMER, T. & DIERKS, T. 1998. A novel protein 
modification generating an aldehyde group in sulfatases: its role in catalysis 
and disease. Bioessays, 20, 505-10. 
WANG, L. Q. & JAMES, M. O. 2006. Inhibition of sulfotransferases by xenobiotics. 
Curr Drug Metab, 7, 83-104. 
WANG, X., GERARD, C., THERIAULT, J. F., POIRIER, D., DOILLON, C. J. & LIN, 
S. X. 2015. Synergistic control of sex hormones by 17beta-HSD type 7: a 
novel target for estrogen-dependent breast cancer. J Mol Cell Biol, 7, 568-
79. 
WANG, X. & LIN, Y. 2008. Tumor necrosis factor and cancer, buddies or foes? Acta 
pharmacologica Sinica, 29, 1275-1288. 
  References 
230 
 
WARREN, J. C. & FRENCH, A. P. 1965. DISTRIBUTION OF STEROID 
SULFATASE IN HUMAN TISSUES. J Clin Endocrinol Metab, 25, 278-82. 
WINAWER, S. J., ZAUBER, A. G., GERDES, H., O'BRIEN, M. J., GOTTLIEB, L. S., 
STERNBERG, S. S., BOND, J. H., WAYE, J. D., SCHAPIRO, M., PANISH, 
J. F. & ET AL. 1996. Risk of colorectal cancer in the families of patients with 
adenomatous polyps. National Polyp Study Workgroup. N Engl J Med, 334, 
82-7. 
WISE, J. 2015. Bowel cancer categorisation into four subtypes could help to guide 
treatment, doctors say. BMJ, 351, h5433. 
WITTE, D., CHIRALA, M., YOUNES, A., LI, Y. & YOUNES, M. 2001. Estrogen 
receptor beta is expressed in human colorectal adenocarcinoma. Hum 
Pathol, 32, 940-4. 
XIE, J. & ITZKOWITZ, S. H. 2008. Cancer in inflammatory bowel disease. World J 
Gastroenterol, 14, 378-89. 
XU, X. & THOMAS, M. L. 1994. Estrogen receptor-mediated direct stimulation of 
colon cancer cell growth in vitro. Mol Cell Endocrinol, 105, 197-201. 
XU, Y., LIU, X., GUO, F., NING, Y., ZHI, X., WANG, X., CHEN, S., YIN, L. & LI, X. 
2012. Effect of estrogen sulfation by SULT1E1 and PAPSS on the 
development of estrogen-dependent cancers. Cancer Sci, 103, 1000-9. 
YANG, S., FANG, Z., GURATES, B., TAMURA, M., MILLER, J., FERRER, K. & 
BULUN, S. E. 2001. Stromal PRs Mediate Induction of 17β-Hydroxysteroid 
Dehydrogenase Type 2 Expression in Human Endometrial Epithelium: A 
Paracrine Mechanism for Inactivation Of E2. Molecular Endocrinology, 15, 
2093-2105. 
YEN, P. H., MARSH, B., ALLEN, E., TSAI, S. P., ELLISON, J., CONNOLLY, L., 
NEISWANGER, K. & SHAPIRO, L. J. 1988. The human X-linked steroid 
sulfatase gene and a Y-encoded pseudogene: evidence for an inversion of 
the Y chromosome during primate evolution. Cell, 55, 1123-35. 
ZAICHUK, T., IVANCIC, D., SCHOLTENS, D., SCHILLER, C. & KHAN, S. A. 2007. 
Tissue-specific transcripts of human steroid sulfatase are under control of 
estrogen signaling pathways in breast carcinoma. J Steroid Biochem Mol 
Biol, 105, 76-84. 
ZERVOUDAKIS, A., STRICKLER, H. D., PARK, Y., XUE, X., HOLLENBECK, A., 
SCHATZKIN, A. & GUNTER, M. J. 2011. Reproductive history and risk of 
colorectal cancer in postmenopausal women. J Natl Cancer Inst, 103, 826-
34. 
ZHA, S., FERDINANDUSSE, S., HICKS, J. L., DENIS, S., DUNN, T. A., WANDERS, 
R. J., LUO, J., DE MARZO, A. M. & ISAACS, W. B. 2005. Peroxisomal 
branched chain fatty acid beta-oxidation pathway is upregulated in prostate 
cancer. Prostate, 63, 316-23. 
ZHANG, H., VARLAMOVA, O., VARGAS, F. M., FALANY, C. N. & LEYH, T. S. 
1998. Sulfuryl transfer: the catalytic mechanism of human estrogen 
sulfotransferase. J Biol Chem, 273, 10888-92. 
ZHOU, D. J., POMPON, D. & CHEN, S. A. 1990. Stable expression of human 
aromatase complementary DNA in mammalian cells: a useful system for 
aromatase inhibitor screening. Cancer Res, 50, 6949-54. 
ZHU, B. T., HAN, G. Z., SHIM, J. Y., WEN, Y. & JIANG, X. R. 2006. Quantitative 
structure-activity relationship of various endogenous estrogen metabolites 
  References 
231 
 
for human estrogen receptor alpha and beta subtypes: Insights into the 
structural determinants favoring a differential subtype binding. 
Endocrinology, 147, 4132-50. 
ZHU, M., ZHU, Y. & LANCE, P. 2013. TNFalpha-activated stromal COX-2 signalling 
promotes proliferative and invasive potential of colon cancer epithelial cells. 
Cell Prolif, 46, 374-81. 
ZISMAN, A. L., NICKOLOV, A., BRAND, R. E., GORCHOW, A. & ROY, H. K. 2006. 
Associations between the age at diagnosis and location of colorectal cancer 
and the use of alcohol and tobacco: implications for screening. Arch Intern 
Med, 166, 629-34. 
ZITO, E., BUONO, M., PEPE, S., SETTEMBRE, C., ANNUNZIATA, I., SURACE, E. 
M., DIERKS, T., MONTI, M., COZZOLINO, M., PUCCI, P., BALLABIO, A. & 
COSMA, M. P. 2007. Sulfatase modifying factor 1 trafficking through the 
cells: from endoplasmic reticulum to the endoplasmic reticulum. EMBO J, 26, 
2443-53. 
ZITO, E., FRALDI, A., PEPE, S., ANNUNZIATA, I., KOBINGER, G., DI NATALE, 
P., BALLABIO, A. & COSMA, M. P. 2005. Sulphatase activities are regulated 
by the interaction of sulphatase-modifying factor 1 with SUMF2. EMBO Rep, 
6, 655-60. 
 
